WO2005048945A2 - Hydroxylamine substituted imidazo ring compounds - Google Patents

Hydroxylamine substituted imidazo ring compounds Download PDF

Info

Publication number
WO2005048945A2
WO2005048945A2 PCT/US2004/038033 US2004038033W WO2005048945A2 WO 2005048945 A2 WO2005048945 A2 WO 2005048945A2 US 2004038033 W US2004038033 W US 2004038033W WO 2005048945 A2 WO2005048945 A2 WO 2005048945A2
Authority
WO
WIPO (PCT)
Prior art keywords
group
alkyl
aryl
alkylene
alkenyl
Prior art date
Application number
PCT/US2004/038033
Other languages
English (en)
French (fr)
Other versions
WO2005048945A3 (en
Inventor
Tushar A. Kshirsagar
Gregory D. Lundquist, Jr.
David T. Amos
Joseph F. Dellaria, Jr.
Bernhard M. Zimmermann
Philip D. Heppner
Original Assignee
3M Innovative Properties Company
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 3M Innovative Properties Company filed Critical 3M Innovative Properties Company
Priority to CA002545825A priority Critical patent/CA2545825A1/en
Priority to US10/595,790 priority patent/US8598192B2/en
Priority to AU2004291122A priority patent/AU2004291122A1/en
Priority to EP04810969A priority patent/EP1682544A4/en
Priority to JP2006539957A priority patent/JP2007511535A/ja
Publication of WO2005048945A2 publication Critical patent/WO2005048945A2/en
Publication of WO2005048945A3 publication Critical patent/WO2005048945A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/14—Ortho-condensed systems

Definitions

  • Certain lH-imidazo[4,5-c]quinolin-4-amines and 1- and 2-substituted derivatives thereof were later found to be useful as antiviral agents, bronchodilators and immunomodulators. Subsequently, certain substituted lH-imidazo[4,5-c]pyridin-4-amine, quinolin-4-amine, tetrahydroquinolin-4-amine, naphthyridin-4-amine, and tetrahydronaphthyridin-4-amine compounds as well as certain analogous thiazolo and oxazolo compounds were synthesized and found to be useful as immune response modifiers (IRMs), rendering them useful in the treatment of a variety of disorders.
  • IRMs immune response modifiers
  • the present invention provides a new class of compounds that are useful in inducing cytokine biosynthesis in animals.
  • Such compounds are of the following Formula
  • R', RA, RB, RAI, RBI, RI, R2, R2a, X, and Y' are as defined below.
  • the compounds of Formulas I and II are useful as immune response modifiers (IRMs) due to their ability to induce cytokine biosynthesis (e.g., induce the biosynthesis or production of one or more cytokines) and otherwise modulate the immune response when administered to animals.
  • IRMs immune response modifiers
  • the present invention provides pharmaceutical compositions containing the immune response modifier compounds, and methods of inducing cytokine biosynthesis in an animal, treating a viral disease in an animal, and treating a neoplastic disease in an animal, by administering an effective amount of one or more compounds of Formula I and/or Formula II and/or pharmaceutically acceptable salts thereof to the animal.
  • the invention provides methods of synthesizing compounds of
  • R, R', R' R A , RB, RAI, RBI, RA2, B2, RI, R2, R2a, R3, n, m, p, X, and Y' are as defined below.
  • X is C ⁇ -1 0 alkylene or C 2 . 10 alkenylene
  • R A and R B are each independently selected from the group consisting of: hydrogen, halogen, alkyl, aikenyl, alkoxy, alkylthio, and -N(R 9 ) 2 ; or when taken together, R A and R B form a fused aryl ring or heteroaryl ring containing one heteroatom selected from the group consisting of N and S, wherein the aryl or heteroaryl ring is unsubstituted or substituted by one or more R'" groups; or when taken together, RA and R B form a fused 5 to 7 membered saturated ring, optionally containing one heteroatom selected from the group consisting of N and S, and unsubstituted or substituted by one or more R groups; R. is selected from the group consisting of: halogen, hydroxy, alkyl, alkenyl, haloalkyl, alkoxy, alkylthio, and
  • Y " ' is selected from the group consisting of: a bond, -C(O)-, -C(S)-,
  • R 2 and R 2a are independently selected from the group consisting of: hydrogen, alkyl, alkenyl, aryl, arylalkylenyl, heteroaryl, heteroarylalkylenyl, heterocyclyl, heterocyclylalkylenyl, and alkyl, alkenyl, aryl, arylalkylenyl, heteroaryl, heteroarylalkylenyl, heterocyclyl, or heterocyclylalkylenyl, substituted by one or more substituents selected from the group consisting of: hydroxy, alkyl, halo alkyl, hydroxyalkyl, alkoxy, dialkylamino, -S(O)o-2-alkyl,
  • -S(O)o- 2 -aryl -NH-S(O) 2 -alkyl, -NH-S(O) 2 -aryl, haloalkoxy, halogen, cyano, nitro, aryl, heteroaryl, heterocyclyl, aryloxy, arylalkyleneoxy, -C(O)-O-alkyl, -C(O)-N(R 8 ) 2 , -N(R 8 )-C(O)-alkyl, -O-(CO)-alkyl, and
  • R and R 2a together with the nitrogen atom and Y' to which they are bonded can join to form a ring selected from the group consisting of: -N- C(R 6 ) -N- S(0) 2
  • R' is hydrogen or a non-interfering substituent
  • R' is a non-interfering substituent
  • R is C 2 - 7 alkylene
  • R 8 is selected from the group consisting of hydrogen, CMQ alkyl, C 2 . 10 alkenyl, C O alkoxy- -io al ylenyl, and aryl-d-io alkylenyl;
  • R 9 is selected from the group consisting of hydrogen and alkyl
  • R 10 is C 3-8 alkylene; or a pharmaceutically acceptable salt thereof.
  • X is C ⁇ -10 alkylene or C 2 - 10 alkenylene
  • R A1 and R B1 are each independently selected from the group consisting of: hydrogen, halogen, alkyl, alkenyl, alkoxy, alkylthio, and
  • R A ⁇ and R ⁇ i form a fused aryl ring or heteroaryl ring containing one heteroatom selected from the group consisting of N and S, wherein the aryl or heteroaryl ring is unsubstituted or substituted by one or more R groups, or substituted by one R 3 group, or substituted by one R 3 group and one R group; or when taken together, R A ⁇ and R B ⁇ form a fused 5 to 7 membered saturated ring, optionally containing one heteroatom selected from the group consisting of N and S, and unsubstituted or substituted by one or more R groups;
  • R is selected from the group consisting of: halogen, hydroxy, alkyl, alkenyl, haloalkyl, alkoxy, alkylthio, and -N(R 9 ) 2 ;
  • R 3 is selected from the group consisting of: -Z-R 4 , -Z-X'-R ⁇
  • Y' is selected from the group consisting of: a bond
  • Ri is selected from the group consisting of:
  • R-2, and R 2a are independently selected from the group consisting of: hydrogen, alkyl, alkenyl, aryl, arylalkylenyl, heteroaryl, heteroarylalkylenyl, heterocyclyl, heterocyclylalkylenyl, and alkyl.
  • R la and R ⁇ and/or R 2 and R 2a together with the nitrogen atom and Y' to which they are bonded can join to form a ring selected from the group consisting of:
  • K ⁇ and R ⁇ ' can join together to form a ring system selected from the group consisting of:
  • R e and R are independently selected from the group consisting of hydrogen, halogen, hydroxy, alkyl, alkenyl, aryl, haloalkyl, alkoxy, alkylthio, and -N(R 9 ) 2 ; or R e and can join to form a fused aryl ring or fused 5-10 membered heteroaryl ring containing one to four heteroatoms;
  • X' is selected from the group consisting of alkylene, alkenylene, alkynylene, arylene, heteroarylene, and heterocyclylene wherein the alkylene, alkenylene, and alkynylene groups can be optionally interrupted or terminated by arylene, heteroarylene or heterocyclylene and optionally interrupted by one or more -O- groups;
  • X" is -CH(R 13 )-alkylene- or -CH(R 13 )-alkenylene-, wherein the alkylene and alkenylene are optionally interrupted by one or more -O- groups;
  • Y is selected from the group consisting of: -S(O)o-2-,
  • Z is a bond or -O-;
  • R is selected from the group consisting of hydrogen, alkyl, alkenyl, alkynyl, aryl, arylalkylenyl, aryloxyalkylenyl, alkylarylenyl, heteroaryl, heteroarylalkylenyl, heteroaryloxyalkylenyl, alkylheteroarylenyl, and heterocyclyl wherein the alkyl, alkenyl, alkynyl, aryl, arylalkylenyl, aryloxyalkylenyl, alkylarylenyl, heteroaryl, heteroarylalkylenyl, heteroaryloxyalkylenyl, alkylheteroarylenyl, and heterocyclyl groups can be unsubstituted or substituted by one or more substituents independently selected from the group consisting of allcyl, alkoxy, hydroxyalkyl, haloalky
  • R 5 is selected from the group consisting of:
  • R 7 is C 2 _ 7 alkylene
  • R 8 is selected from the group consisting of hydrogen, C ⁇ io alkyl, C 2-10 alkenyl, C 1-10 alkoxy-C o alkylenyl, and aryl-Ci.-i.o alkylenyl;
  • R 9 is selected from the group consisting of hydrogen and alkyl;
  • R 10 is C -8 alkylene
  • R ⁇ is C 1-6 alkylene or C 2-6 alkenylene, wherein the alkylene or alkenylene is optionally interrupted by one heteroatom;
  • R 12 is selected from the group consisting of a bond, C 1-5 alkylene, and C 2-5 alkenylene, wherein the alkylene or alkenylene is optionally interrupted by one heteroatom;
  • R 13 is selected from the group consisting of hydrogen and alkyl which may be optionally interrupted by one or more -O- groups;
  • A is selected from the group consisting of-CH -, -O-, -C(O)-, -S(O) 0-2 -, and -NOE )-;
  • A' is selected from the group consisting of -O-, -S(O)o- 2 -, -N(-Q-R 4 )-, and -CH 2 -;
  • Q is selected from the group consisting of a bond, -C(R 6 )-, -C(R 6 )-C(R 6 )-, -S(O) 2 -, -C(R 6 )-N(R 8 )- -, -S(0) 2 -N(R 8 )-, -C(R 6 )-O-, and -C(R 6 )-N(OR 9 )-;
  • V is selected from the group consisting of -C(R 6 )-, -O-C(R 6 )-, -N(R 8 )-C(R 6 )-, and -S(O) 2 -;
  • W is selected from the group consisting of a bond, -C(O)-, and -S(O) 2 -; and a and b are independently integers from 1 to 6 with the proviso that a + b is ⁇ 7; or a pharmaceutically acceptable salt thereof.
  • X is C O alkylene or C 2-10 alkenylene; Y' is selected from the group consisting of: a bond,
  • R 2 and R 2a are independently selected from the group consisting of: hydrogen, alkyl, alkenyl, aryl, arylalkylenyl, heteroaryl, heteroarylalkylenyl, heterocyclyl, heterocyclylalkylenyl, and alkyl, alkenyl, aryl, arylalkylenyl, heteroaryl, heteroarylalkylenyl, heterocyclyl, or heterocyclylalkylenyl, substituted by one or more substituents selected from the group consisting of: hydroxy, alkyl, haloalkyl, hydroxyalkyl, alkoxy, dialkylamino, -S(O)o- 2 -alkyl, -S(O)o- 2 -aryl,
  • R 8 is selected from the group consisting of hydrogen, C 1-10 alkyl, C 2 -io alkenyl, C MO alkoxy-Ci-io alkylenyl, and aryl-C 1 . 1 o alkylenyl;
  • R 10 is C 3-8 alkylene;
  • n is an integer from 0 to 4;
  • R'" is a non-interfering substituent;
  • R' is hydrogen or a non-interfering substituent; or a pharmaceutically acceptable salt thereof.
  • X is Ci-io alkylene or C 2-10 alkenylene;
  • Y' is selected from the group consisting of: a bond, -C(O)-, -C(S)-, -S(O) 2 -, -S(O) 2 -N(R 8 )-,
  • R is selected from the group consisting of: halogen, hydroxy, alkyl, alkenyl, haloalkyl, alkoxy, alkylthio, and
  • R ⁇ is selected from the group consisting of:
  • Ria, Rib, Ri', Ri", R_, and R a are independently selected from the group consisting of: hydrogen, alkyl, alkenyl, aryl, arylalkylenyl, heteroaryl, heteroarylalkylenyl, heterocyclyl, heterocyclylalkylenyl, and alkyl, alkenyl, aryl, arylalkylenyl, heteroaryl, heteroarylalkylenyl, heterocyclyl, or heterocyclylalkylenyl, substituted by one or more substituents selected from the group consisting of: hydroxy, alkyl, haloalkyl, hydroxyalkyl, alkoxy, dialkylamino, -S(O)o -2 -alkyl, -S(O)o -2 -aryl
  • R la and R lb and/or R 2 and R 2a together with the nitrogen atom and Y' to which they are bonded can join to form a ring selected from the group consisting of: -N- C(R 6 ) -N- S(0) 2
  • Ri' and Ri" can join together to form a ring system selected from the group consisting of:
  • the total number of atoms in the ring is 4 to 9
  • R e and R d are independently selected from the group consisting of hydrogen, halogen, hydroxy, alkyl, alkenyl, aryl, haloalkyl, alkoxy, alkylthio, and -N(R 9 ) 2 ; or R e and R d can join to form a fused aryl ring or fused 5-10 membered heteroaryl ring containing one to four heteroatoms;
  • R 3 is selected from the group consisting of:
  • n is an integer from 0 to 4; m is 0 or 1 ; with the proviso that when m is 1, then n is 0 or 1 ;
  • X' is selected from the group consisting of alkylene, alkenylene, alkynylene, arylene, heteroarylene, and heterocyclylene wherein the alkylene, alkenylene, and alkynylene groups can be optionally interrupted or terminated by arylene, heteroarylene or heterocyclylene and optionally interrupted by one or more -O- groups;
  • X" is -CH(R 13 )-alkylene- or -CH(R 13 )-alkenylene-, wherein the alkylene and alkenylene are optionally interrupted by one or more -O- groups;
  • Y is selected from the group consisting of:
  • Z is a bond or -O-; is selected from the group consisting of hydrogen, alkyl, alkenyl, alkynyl, aryl, arylalkylenyl, aryloxyalkylenyl, alkylarylenyl, heteroaryl, heteroarylalkylenyl, heteroaryloxyalkylenyl, alkylheteroarylenyl, and heterocyclyl wherein the alkyl, alkenyl, alkynyl, aryl, arylalkylenyl, aryloxyalkylenyl, alkylarylenyl, heteroaryl, heteroarylalkylenyl, heteroaryloxyalkylenyl, alkylheteroarylenyl, and heterocyclyl groups can be unsubstituted or substituted by one or more substituents independently selected from the group consisting of alkyl, alkoxy, hydroxyalkyl, haloalkyl, hal
  • R 5 is selected from the group consisting of:
  • R 7 is C 2 _ 7 alkylene
  • R 8 is selected from the group consisting of hydrogen, Ci.in alkyl, C 2 - l0 alkenyl, C ⁇ - ⁇ o alkoxy-d- K ) alkylenyl, and aryl-C M o alkylenyl;
  • R 9 is selected from the group consisting of hydrogen and alkyl;
  • R ⁇ is C ⁇ -6 alkylene or C 2 . 6 alkenylene, wherein the alkylene or alkenylene is optionally interrupted by one heteroatom;
  • R 12 is selected from the group consisting of a bond, C 1 . 5 alkylene, and C 2-5 alkenylene, wherein the alkylene or alkenylene is optionally interrupted by one heteroatom;
  • R 13 is selected from the group consisting of hydrogen and alkyl which may be optionally interrupted by one or more -O- groups;
  • A is selected from the group consisting of-CH 2 -, -O-, -C(O)-, -S(O)o -2 -, and
  • A' is selected from the group consisting of -O-, -S(O)o- 2 -, -N ⁇ Q-R ⁇ -, and -CH -;
  • Q is selected from the group consisting of a bond, -C(R 6 )-, -C(R 6 )-C(R ⁇ )-, -S(O) 2 -, -C(R 6 )-N(R 8 )-W-, -S(O) 2 -N(R 8 )-, -C(R ⁇ s)-O-, and -C(R 6 )-N(OR 9 )-;
  • V is selected from the group consisting of -C(R 6 )-, -0-C(R 6 )-, -N(R 8 )-C(R 6 )-, and -S(O) 2 -;
  • W is selected from the group consisting of a bond, -C(O)-, and -S(O) 2 -; and a and b are independently integers from 1 to 6 with the proviso that a + b is ⁇ 7; or a pharmaceutically acceptable salt thereof.
  • X is Ci-io alkylene or C 2 - ⁇ o alkenylene; Y' is selected from the group consisting of: a bond, -C(O)-, -C(S)-,
  • R 2 and R 2a are independently selected from the group consisting of: hydrogen, alkyl, alkenyl, aryl, arylalkylenyl, heteroaryl, heteroarylalkylenyl, heterocyclyl, heterocyclylalkylenyl, and alkyl, alkenyl, aryl, arylalkylenyl, heteroaryl, heteroarylalkylenyl, heterocyclyl, or heterocyclylalkylenyl, substituted by one or more substituents selected from the group consisting of: hydroxy, alkyl, haloalkyl, hydroxyalkyl, alkoxy, dialkylamino, -S(O) 0 - 2 -alkyl, -S(O)o- 2 -aryl,
  • R is selected from the group consisting of: halogen, hydroxy, alkyl, alkenyl, haloalkyl, alkoxy, alkylthio, and -N(R 9 ) 2 ;
  • Ri is selected from the group consisting of: -X'-R 4 , -X-Y-R ⁇ -X'-Y-X'-Y-R ⁇
  • R 3 is selected from the group consisting of: -Z-R 4 ,
  • n is an integer from 0 to 4; m is 0 or 1 ; with the proviso that when m is 1 , then n is 0 or 1 ;
  • X' is selected from the group consisting of alkylene, alkenylene, alkynylene, arylene, heteroarylene, and heterocyclylene wherein the alkylene, alkenylene, and alkynylene groups can be optionally interrupted or terminated by arylene, heteroarylene or heterocyclylene and optionally interrupted by one or more -O- groups;
  • X" is -CH(R )-alkylene- or -CH(R ⁇ 3 )-alkenylene-;
  • Y is selected from the group consisting of: -S(O) 0 . 2 -, -S(O) 2 -N(R 8 )-, -C(R 6 )-, -C(R 6 )-O-,
  • Z is a bond or -O-
  • R is selected from the group consisting of hydrogen, alkyl, alkenyl, alkynyl, aryl, arylalkylenyl, aryloxyalkylenyl, alkylarylenyl, heteroaryl, heteroarylalkylenyl, heteroaryloxyalkylenyl, alkylheteroarylenyl, and heterocyclyl wherein the alkyl, alkenyl, alkynyl, aryl, arylalkylenyl, aryloxyalkylenyl, alkylarylenyl, heteroaryl, heteroarylalkylenyl, heteroaryloxyalkylenyl, alkylheteroarylenyl, and heterocyclyl groups can be unsubstituted or substituted by one or more substituents independently selected from the group consisting of alkyl, alkoxy, hydroxyalkyl, haloalkyl, haloalkoxy, halogen,
  • R 5 is selected from the group consisting of:
  • Ri' and R ⁇ " axe independently the same as R , or Ri' and R ⁇ " can join together to form a ring system selected from the group consisting of:
  • the total number of atoms in the ring is 4 to 9
  • R e and R are independently selected from the group consisting of hydrogen, halogen, hydroxy, alkyl, alkenyl, aryl, haloalkyl, alkoxy, alkylthio, and -N(R 9 ) 2 ; or R e and R d can join to form a fused aryl ring or fused 5-10 membered heteroaryl ring containing one to four heteroatoms;
  • R 7 is C2- 7 alkylene
  • R 8 is selected from the group consisting of hydrogen, C ⁇ - 10 alkyl, C 2 - 10 alkenyl, C ⁇ -10 alkoxy-Ci-io alkylenyl, and aryl-C 1-10 alkylenyl; R is selected from the group consisting of hydrogen and alkyl;
  • R11 is C ⁇ -6 alkylene or C 2-6 alkenylene, wherein the alkylene or alkenylene is optionally interrupted by one heteroatom;
  • R 12 is selected from the group consisting of a bond, C ⁇ -5 alkylene, and C -5 alkenylene, wherein the alkylene or alkenylene is optionally interrupted by one heteroatom;
  • R ⁇ 3 is selected from the group consisting of hydrogen and alkyl which may be optionally interrupted by one or more -O- groups;
  • A is selected from the group consisting of-CH 2 -, -O-, -C(O)-, -S(O)o- 2 -, and -NOR 4 )-;
  • A' is selected from the group consisting of -O-, -S(O)o -2 -, -N(-Q-R 4 )-, and -CH 2 -;
  • Q is selected from the group consisting of a bond, -C(R 6 )-, -C(R 6 )-C(R 6 )-, -S(O) 2 -, -C(R 6 )-N(R 8 )- -, -S(O) 2 -N(R 8 )-, -C(R 6 )-O-, and -C(R 6 )-N(OR 9 )-;
  • V is selected from the group consisting of -C(R($)-, -O-C(R 6 )-, -N(R 8 )-C(R 6 )-, and -S(O) 2 -;
  • W is selected from the group consisting of a bond, -C(O)-, and -S(O) 2 -; and a and b are independently integers from 1 to 6 with the proviso that a + b is ⁇ 7; or a pharmaceutically acceptable salt thereof.
  • X is Ci-io alkylene or C 2 . 1 o alkenylene; Y' is selected from the group consisting of: a bond,
  • R is selected from the group consisting of: halogen, hydroxy, alkyl, alkenyl, haloalkyl, alkoxy, alkylthio, and
  • n is an integer from 0 to 4.
  • R 2 and R 2a are independently selected from the group consisting of: hydrogen, alkyl, alkenyl, aryl, arylalkylenyl, heteroaryl, heteroarylalkylenyl, heterocyclyl, heterocyclylalkylenyl, and alkyl, alkenyl, aryl, arylalkylenyl, heteroaryl, heteroarylalkylenyl, heterocyclyl, or heterocyclylalkylenyl, substituted by one or more substituents selected from the group consisting of: hydroxy, alkyl, haloalkyl, hydroxyalkyl, alkoxy, dialkylamino,
  • R 8 is selected from the group consisting of hydrogen, Ci-io alkyl, C - ⁇ 0 alkenyl, C ⁇ - ⁇ 0 alkoxy-Ci-io alkylenyl, and aryl-Q-io alkylenyl;
  • R 9 is selected from the group consisting of hydrogen and alkyl;
  • Rio is C 3 . 8 alkylene; and R' is hydrogen or a non-interfering substituent; or a pharmaceutically acceptable salt thereof.
  • Y' is selected from the group consisting of: a bond, -C(O)-, -C(S)-, -S(O) 2 -,
  • R is selected from the group consisting of: halogen, hydroxy, alkyl, alkenyl, haloalkyl, alkoxy, alkylthio, and -N(R 9 ) 2 ;
  • Ri is selected from the group consisting of:
  • Ria, Rib, Ri', Ri", R2, and R 2a are independently selected from the group consisting of: hydrogen, alkyl, alkenyl, aryl, arylalkylenyl, heteroaryl, heteroarylalkylenyl, heterocyclyl, heterocyclylalkylenyl, and alkyl, alkenyl, aryl, arylalkylenyl, heteroaryl, heteroarylalkylenyl, heterocyclyl, or heterocyclylalkylenyl, substituted by one or more substituents selected from the group consisting of: hydroxy, alkyl, haloalkyl, hydroxyalkyl, alkoxy, dialkylamino,
  • R la and R ⁇ b and/or R 2 and R 2a together with the nitrogen atom and Y' to which they are bonded can join to form a ring selected from the group consisting of: -N- C(R 6 ) -N- S(0) 2 V and ; or Ri' and Ri" can join together to form a ring system selected from the group consisting of:
  • Re and Rd are independently selected from the group consisting of hydrogen, halogen, hydroxy, alkyl, alkenyl, aryl, haloalkyl, alkoxy, alkylthio, and -N(R 9 ) 2 ; or R ⁇ and
  • R d can join to form a fused aryl ring or fused 5-10 membered heteroaryl ring containing one to four heteroatoms;
  • n is an integer from 0 to 4;
  • X' is selected from the group consisting of alkylene, alkenylene, alkynylene, arylene, heteroarylene, and heterocyclylene wherein the alkylene, alkenylene, and alkynylene groups can be optionally interrupted or terminated by arylene, heteroarylene or heterocyclylene and optionally interrupted by one or more -O- groups;
  • X" is -CH(R 13 )-alkylene- or -CH(R ⁇ 3 )-alkenylene-, wherein the alkylene and alkenylene are optionally interrupted by one or more -O- groups;
  • Y is selected from the group consisting of: -S(O) 0 -2-, -S(O) 2 -N(R 8 )-, -C(R 6 )-, -C(R 6 )-O-, -O-C(R 6 )-,
  • R ⁇ is selected from the group consisting of hydrogen, alkyl, alkenyl, alkynyl, aryl, arylalkylenyl, aryloxyalkylenyl, alkylarylenyl, heteroaryl, heteroarylalkylenyl, heteroaryloxyalkylenyl, alkylheteroarylenyl, and heterocyclyl wherein the alkyl, alkenyl, alkynyl, aryl, arylalkylenyl, aryloxyalkylenyl, alkylarylenyl, heteroaryl, heteroarylalkylenyl, heteroaryloxyalkylenyl, alkylheteroarylenyl, and heterocyclyl groups can be unsubstituted or substituted by one or more substituents independently selected from the group consisting of alkyl, alkoxy, hydroxyalkyl, haloalkyl, haloalkoxy, halogen,
  • R 5 is selected from the group consisting of:
  • R 7 is C - 7 alkylene
  • R 8 is selected from the group consisting of hydrogen, C ⁇ - 10 alkyl, C - ⁇ 0 alkenyl,
  • R 9 is selected from the group consisting of hydrogen and alkyl; Rw is C 3 . 8 alkylene;
  • R ⁇ is C ⁇ -6 alkylene or C 2-6 alkenylene, wherein the alkylene or alkenylene is optionally interrupted by one heteroatom;
  • R ⁇ 2 is selected from the group consisting of a bond, C ⁇ -5 alkylene, and
  • R ⁇ 3 is selected from the group consisting of hydrogen and alkyl which may be optionally interrupted by one or more -O- groups;
  • A is selected from the group consisting of-CH 2 -, -O-, -C(O)-, -S(O)o- -, and
  • A' is selected from the group consisting of -O-, -S(O)o- 2 -, and -CH 2 -;
  • Q is selected from the group consisting of a bond, -C(R 6 )-, -C(R 6 )-C(R 6 )-,
  • V is selected from the group consisting of -C(R 6 )-, -O-C(R 6 )-, -N(R 8 )-C(R 6 )-, and
  • X is Ci-io alkylene or C 2- ⁇ o alkenylene
  • Y' is selected from the group consisting of: a bond, -C(O)-, -C(S)-,
  • R 2 and R a are independently selected from the group consisting of: hydrogen, alkyl, alkenyl, aryl, arylalkylenyl, heteroaryl, heteroarylalkylenyl, heterocyclyl, heterocyclylalkylenyl, and alkyl, alkenyl, aryl, arylalkylenyl, heteroaryl, heteroarylalkylenyl, heterocyclyl, or heterocyclylalkylenyl, substituted by one or more substituents selected from the group consisting of: hydroxy, alkyl, haloalkyl, hydroxyalkyl, alkoxy, dialkylamino, -S(O)o -2 -alkyl, -S(O)o- 2 -aryl,
  • R is selected from the group consisting of: halogen, hydroxy, alkyl, alkenyl, haloalkyl, alkoxy, alkylthio, and -N(R 9 ) 2 ; n is an integer from 0 to 4;
  • R ⁇ is selected from the group consisting of:
  • X' is selected from the group consisting of alkylene, alkenylene, alkynylene, arylene, heteroarylene, and heterocyclylene wherein the alkylene, alkenylene, and alkynylene groups can be optionally interrupted or terminated by arylene, heteroarylene or heterocyclylene and optionally interrupted by one or more -O- groups;
  • X" is -CH(R 13 )-alkylene- or -CH(R 13 )-alkenylene-;
  • Y is selected from the group consisting of: -S(O)o_2-,
  • R 4 is selected from the group consisting of hydrogen, alkyl, alkenyl, alkynyl, aryl, arylalkylenyl, aryloxyalkylenyl, alkylarylenyl, heteroaryl, heteroarylalkylenyl, heteroaryloxyalkylenyl, alkylheteroarylenyl, and heterocyclyl wherein the alkyl, alkenyl, alkynyl, aryl, arylalkylenyl, aryloxyalkylenyl, alkylarylenyl, heteroaryl, heteroarylalkylenyl, heteroaryloxyalkylenyl, alkylheteroarylenyl, and heterocyclyl groups can be unsubstituted or substituted by one or more substituents independently selected from the group consisting of alkyl, alkoxy, hydroxyalkyl, haloalkyl, haloalkoxy, halogen,
  • Ri' and Ri are independently R 2 , or Ri' and Ri" can join together to form a ring system selected from the group consisting of:
  • R e and Ra are independently selected from the group consisting of hydrogen, halogen, hydroxy, alkyl, alkenyl, aryl, haloalkyl, alkoxy, alkylthio, and -N(R 9 ) 2 ; or R e and R d can join to form a fused aryl ring or fused 5-10 membered heteroaryl ring containing one to four heteroatoms;
  • R 7 is C 2 - 7 alkylene;
  • R 8 is selected from the group consisting of hydrogen, C ⁇ - 10 alkyl, C 2 . 1 o alkenyl, Ci-io alkoxy-Ci-io alkylenyl, and aryl-Ci-io alkylenyl; R is selected from the group consisting of hydrogen and alkyl;
  • Rn is Ci. 6 alkylene or C 2 . 6 alkenylene, wherein the alkylene or alkenylene is optionally interrupted by one heteroatom;
  • R ⁇ 2 is selected from the group consisting of a bond, C ⁇ _ 5 alkylene, and C _ 5 alkenylene, wherein the alkylene or alkenylene is optionally interrupted by one heteroatom;
  • R 13 is selected from the group consisting of hydrogen and alkyl which may be optionally interrupted by one or more -O- groups;
  • A is selected from the group consisting of-CH 2 -, -O-, -C(O)-, -S(O) 0 - 2 -, and -N(R4)-;
  • A' is selected from the group consisting of -O-, -S(O)o-2-, and -CH 2 -;
  • Q is selected from the group consisting of a bond, -C(R 6 )-, -C(R 6 )-C(R 6 )-, -S(O) 2 -, -C(R 6 )-N(R 8 )-W-, -S(O) 2 -N(R 8 )-, -C(R 6 )-O-, and -C(R 6 )-N(OR 9 )-;
  • V is selected from the group consisting of -C(R 6 )-, -O-C(R 6 )-, -N(R 8 )-C(R 6 )-, and -S(O) 2 -;
  • W is selected from the group consisting of a bond, -C(O)-, and -S(O) -; and a and b are independently integers from 1 to 6 with the proviso that a + b is ⁇ 7; or a pharmaceutically acceptable salt thereof.
  • R is selected from the group consisting of: halogen, hydroxy, alkyl, alkenyl, haloalkyl, alkoxy, aikylthio, and -N(R 9 ) 2 ;
  • Ri is selected from the group consisting of:
  • R ⁇ b , Ri', Ri", R 2 , and R 2a are independently selected from the group consisting of: hydrogen, alkyl, alkenyl, aryl, arylalkylenyl, heteroaryl, heteroarylalkylenyl, heterocyclyl, heterocyclylalkylenyl, and alkyl, alkenyl, aryl, arylalkylenyl, heteroaryl, heteroarylalkylenyl, heterocyclyl, or heterocyclylalkylenyl, substituted by one or more substituents selected from the group consisting of: hydroxy, alkyl, haloalkyl, hydroxyalkyl, alkoxy, dialkylamino, -S(O)o -2 -alkyl, -S(O)o -2 -aryl,
  • R la and R Jb and/or R 2 and R 2a together with the nitrogen atom and Y' to which they are bonded can join to form a ring selected from the group consisting of:
  • Ri' and R n together to form a ring system selected from the group consisting of:
  • the total number of atoms in the ring is 4 to 9
  • R e and d are independently selected from the group consisting of hydrogen, halogen, hydroxy, alkyl, alkenyl, aryl, haloalkyl, alkoxy, alkylthio, and -N(R 9 ) 2 ; or R e and R d can join to form a fused aryl ring or fused 5-10 membered heteroaryl ring containing one to four heteroatoms;
  • R 3 is selected from the group consisting of:
  • X" is -CH(R ⁇ 3 )-alkylene- or -CH(R ⁇ 3 )-alkenylene-, wherein the alkylene and alkenylene are optionally interrupted by one or more -O- groups;
  • Y is selected from the group consisting of: -S(O)o-2",
  • Z is a bond or -O-
  • R A is selected from the group consisting of hydrogen, alkyl, alkenyl, alkynyl, aryl, arylalkylenyl, aryloxyalkylenyl, alkylarylenyl, heteroaryl, heteroarylalkylenyl, heteroaryloxyalkylenyl, alkylheteroarylenyl, and heterocyclyl wherein the alkyl, alkenyl, alkynyl, aryl, arylalkylenyl, aryloxyalkylenyl, alkylarylenyl, heteroaryl, heteroarylalkylenyl, heteroaryloxyalkylenyl, alkylheteroarylenyl, and heterocyclyl groups can be unsubstituted or substituted by one or more substituents independently selected from the group consisting of alkyl, alkoxy, hydroxyalkyl, haloalkyl, haloalkoxy, halogen,
  • R 5 is selected from the group consisting of:
  • R 8 is selected from the group consisting of hydrogen, Ci-io alkyl, C 2 - ⁇ o alkenyl, Ci-io alkoxy-Ci-io alkylenyl, and aryl-Ci-io alkylenyl;
  • R 9 is selected from the group consisting of hydrogen and alkyl;
  • Rii is C ⁇ - 6 alkylene or C 2-6 alkenylene, wherein the alkylene or alkenylene is optionally interrupted by one heteroatom;
  • R ⁇ is selected from the group consisting of a bond, C 1-5 alkylene, and C -5 alkenylene, wherein the alkylene or alkenylene is optionally interrupted by one heteroatom;
  • R 13 is selected from the group consisting of hydrogen and alkyl which may be optionally interrupted by one or more -O- groups;
  • A is selected from the group consisting of-CH 2 -, -O-, -C(O)-, -S(O)o -2 -, and
  • A' is selected from the group consisting of -O-, -S(O)o -2 -, -N ⁇ Q-R*)-, and -CH 2 -;
  • Q is selected from the group consisting of a bond, -C(Re)-, -C(R 6 )-C(R 6 )-, -S(O) 2 -, -C(R 6 )-N(R 8 )-W-, -S(O) 2 -N(R 8 )-, -C(R 6 )-O-, and -C(R 6 )-N(OR 9 )-;
  • V is selected from the group consisting of -C(R 6 )-, -O-C(R 6 )-, -N(R 8 )-C(R 6 )-, and -S(O) 2 -;
  • W is selected from the group consisting of a bond, -C(O)-, and -S(O) 2 -; and a and b are independently integers from 1 to 6 with the proviso that a + b is ⁇ 7; or a pharmaceutically acceptable salt thereof.
  • compounds are provided that are of the following Formula VI:
  • X is C i-io alkylene or C 2- ⁇ o alkenylene
  • a 2 and R ⁇ 2 are each independently selected from the group consisting of: hydrogen, halogen, alkyl, alkenyl, alkoxy, alkylthio, and -N(R 9 ) 2
  • Y' is selected from the group consisting of: a bond, -C(O)-, -C(S)-, -S(O) 2 -, -S(O) 2 -N(R 8 )-,
  • Ri is selected from the group consisting of:
  • Ri a , R ⁇ , Ri', Ri", R 2 , and R 2a are independently selected from the group consisting of: hydrogen, alkyl, alkenyl, aryl, arylalkylenyl, heteroaryl, heteroarylalkylenyl, heterocyclyl, heterocyclylalkylenyl, and alkyl, alkenyl, aryl, arylalkylenyl, heteroaryl, heteroarylalkylenyl, heterocyclyl, or heterocyclylalkylenyl, substituted by one or more substituents selected from the group consisting of: hydroxy, alkyl, haloalkyl, hydroxyalkyl, alkoxy, dialkylamino,
  • R la and R lb and/or R 2 and R 2a together with the nitrogen atom and Y' to which they are bonded can join to form a ring selected from the group consisting of: -N- C(R 6 ) -N- S(O) 2
  • Ri' and Ri" can join together to form a ring system selected from the group consisting of: R 11 ⁇
  • R e and R d are independently selected from the group consisting of hydrogen, halogen, hydroxy, alkyl, alkenyl, aryl, haloalkyl, alkoxy, alkylthio, and -N(R 9 ) 2 ; or e and R d can join to form a fused aryl ring or fused 5-10 membered heteroaryl ring containing one to four heteroatoms;
  • X' is selected from the group consisting of alkylene, alkenylene, alkynylene, arylene, heteroarylene, and heterocyclylene wherein the alkylene, alkenylene, and alkynylene groups can be optionally interrupted or terminated by arylene, heteroarylene or heterocyclylene and optionally interrupted by one or more -O- groups;
  • X" is -CH(R ⁇ 3 )-alkylene- or -CH(R ⁇ 3 )-alkenylene-, wherein the alkylene and alkenylene are optionally interrupted by one or more -O- groups;
  • Y is selected from the group consisting of:
  • R 4 is selected from the group consisting of hydrogen, alkyl, alkenyl, alkynyl, aryl, arylalkylenyl, aryloxyalkylenyl, alkylarylenyl, heteroaryl, heteroarylalkylenyl, heteroaryloxyalkylenyl, alkylheteroarylenyl, and heterocyclyl wherein the alkyl, alkenyl, alkynyl, aryl, arylalkylenyl, aryloxyalkylenyl, alkylarylenyl, heteroaryl, heteroarylalkylenyl, heteroaryloxyalkylenyl, alkylheteroarylenyl, and heterocyclyl groups can be unsubstituted or substituted by one or more substituents independently selected from the group consisting of alkyl, alkoxy, hydroxyalkyl, haloalkyl, haloalkoxy, halogen,
  • R 5 is selected from the group consisting of:
  • R 7 is C _ 7 alkylene;
  • R 8 is selected from the group consisting of hydrogen, C ⁇ - 10 alkyl, C _ ⁇ o alkenyl,
  • R is selected from the group consisting of hydrogen and alkyl; Rio is C 3 - 8 alkylene; Rii is C ⁇ - 6 alkylene or C 2 . 6 alkenylene, wherein the alkylene or alkenylene is optionally interrupted by one heteroatom;
  • R ⁇ 2 is selected from the group consisting of a bond, C ⁇ -5 alkylene, and C 2-5 alkenylene, wherein the alkylene or alkenylene is optionally interrupted by one heteroatom;
  • R ⁇ is selected from the group consisting of hydrogen and alkyl which may be optionally interrupted by one or more -O- groups;
  • A is selected from the group consisting of-CH 2 -, -O-, -C(O)-, -S(O)o- -, and
  • A' is selected from the group consisting of -O-, -S(O)o -2 -, -N(-Q-R 4 )-, and -CH 2 -;
  • Q is selected from the group consisting of a bond, -C(R ⁇ )-, -C(R 6 )-C(R 6 )-, -S(O) 2 -, -C(R 6 )-N(R 8 )-W-, -S(O) 2 -N(R 8 )-, -C(R 6 )-O-, and -C(R 6 )-N(OR 9 )-;
  • V is selected from the group consisting of -C(R 6 )-, -O-C(R 6 )-, -N(R 8 )-C(R 6 )-, and -S(O) 2 -;
  • W is selected from the group consisting of a bond, -C(O)-, and -S(O) 2 -; and a and b are independently integers from 1 to 6 with the proviso that a + b is ⁇ 7; or a pharmaceutically acceptable salt thereof.
  • R' is hydrogen or a non-interfering substitutent
  • R'" is a non-interfering substituent
  • non-interfering means that the ability of the compound or salt, which includes a non-interfering substituent, to modulate (e.g., induce or inhibit) the biosynthesis of one or more cytokines is not destroyed by the non-interfering substitutent.
  • Illustrative non-interfering R' groups include those described herein for Ri.
  • Illustrative non- interfering R'" groups include those described herein for R and R .
  • alkyl As used herein, the terms “alkyl”, “alkenyl”, “alkynyl” and the prefix “alk-” are inclusive of both straight chain and branched chain groups and of cyclic groups, i.e. cycloalkyl and cycloalkenyl. Unless otherwise specified, these groups contain from 1 to 20 carbon atoms, with alkenyl groups containing from 2 to 20 carbon atoms, and alkynyl groups containing from 2 to 20 carbon atoms, hi some embodiments, these groups have a total of up to 10 carbon atoms, up to 8 carbon atoms, up to 6 carbon atoms, or up to 4 carbon atoms.
  • Cyclic groups can be monocyclic or polycyclic and preferably have from 3 to 10 ring carbon atoms.
  • Exemplary cyclic groups include cyclopropyl, cyclopropylmethyl, cyclopentyl, cyclohexyl, adamantyl, and substituted and unsubstituted bornyl, norbornyl, and norbornenyl.
  • alkylene alkenylene
  • alkynylene are the divalent forms of the “alkyl”, “alkenyl”, and “alkynyl” groups defined above.
  • alkylenyl alkenylenyl
  • alkynylenyl use when “alkylene”, “alkenylene”, and “alkynylene”, respectively, are substituted.
  • an arylalkylenyl group comprises an alkylene moiety to which an aryl group is attached.
  • haloalkyl is inclusive of groups that are substituted by one or more halogen atoms, including perfluorinated groups. This is also true of other groups that include the prefix "halo-”. Examples of suitable haloalkyl groups are chloromethyl, trifluoromethyl, and the like.
  • aryl as used herein includes carbocyclic aromatic rings or ring systems.
  • aryl groups include phenyl, naphthyl, biphenyl, fiuorenyl and indenyl.
  • heteroatom refers to the atoms O, S, or N.
  • heteroaryl includes aromatic rings or ring systems that contain at least one ring heteroatom (e.g., O, S, N).
  • Suitable heteroaryl groups include furyl, thienyl, pyridyl, quinolinyl, isoquinolinyl, indolyl, isoindolyl, triazolyl, pyrrolyl, tetrazolyl, imidazolyl, pyrazolyl, oxazolyl, thiazolyl, benzofuranyl, benzothiophenyl, carbazolyl, benzoxazolyl, pyrimidiiiyl, benzimidazolyl, quinoxalinyl, benzothiazolyl, naphthyridinyl, isoxazolyl, isothiazolyl, purinyl, quinazolinyl, pyrazinyl, 1-oxidopyridyl, pyridazinyl, triazinyl, tetrazinyl, oxadiazolyl, thiadiazolyl, and so on.
  • heterocyclyl includes non-aromatic rings or ring systems that contain at least one ring heteroatom (e.g., O, S, N) and includes all of the fully saturated and partially unsaturated derivatives of the above mentioned heteroaryl groups.
  • heterocyclic groups include pyrrolidinyl, tefrahydrofuranyl, morpholinyl, thiomorpholinyl, piperidinyl, piperazinyl, thiazolidinyl, imidazolidinyl, isothiazolidinyl, tetrahydropyranyl, quinuclidinyl, homopiperidinyl (azepanyl), homopiperazinyl (diazepanyl), 1,3-dioxolanyl, aziridinyl, dihydroisoquinolin-(lH)-yl, octahydroisoquinolin-(lH)-yl, dihydroquinolin- (2H)-yl, octahydroquinolin-(2H)-yl, dihydro-lH-imidazolyl, and the like.
  • heterocyclyl contains a nitrogen atom, the point of attachment of the heterocyclyl
  • arylene "heteroarylene,” and “heterocyclylene” are the divalent forms of the "aryl,” “heteroaryl,” and “heterocyclyl” groups defined above.
  • arylenyl “heteroarylenyl”, and “heterocyclylenyl” are used when “arylene,” “heteroarylene,” and “heterocyclylene”, respectively, are substituted.
  • an alkylarylenyl group comprises an arylene moiety to which an alkyl group is attached.
  • each group is independently selected, whether explicitly stated or not.
  • each R 8 group is independently selected, hi another example, when an Ri and an R 3 group both contain an R 4 group, each R group is independently selected.
  • more than one Y group is present (i.e., Ri and R both contain a Y group) and each Y group contains one or more R 7 groups, then each Y group is independently selected, and each R 7 group is independently selected.
  • the invention is inclusive of the compounds described herein in any of their pharmaceutically acceptable forms, including isomers (e.g., diastereomers and enantiomers), salts, solvates, polymorphs, and the like.
  • isomers e.g., diastereomers and enantiomers
  • salts e.g., sodium tartrate
  • solvates e.g., sodium metabisulfite
  • polymorphs e.g., sodium metabisulfite, sodium metabisulfite, sodium metabisulfite, sodium metabisulfite, sodium metabisulfite, sodium metabisulfite, sodium metabisulfite, sodium metabisulfite, sodium metabisulfite, sodium metabisulfite, sodium metabisulfite, sodium metabisulfite, sodium metabisulfite, sodium metabisulfite, sodium metabisulfite, sodium metabisulfite, sodium metabisulfite, sodium metabisulfite, sodium metabisulfite, sodium
  • each one of the following variables e.g., R, R', R'", R A , R B , R A ⁇ , R B I, RI, R2, R 2a , R3, n, X, Y, Y', Z and so on
  • each one of the following variables e.g., R, R', R'", R A , R B , R A ⁇ , R B I, RI, R2, R 2a , R3, n, X, Y, Y', Z and so on
  • each of the resulting combinations of variables is an embodiment of the present invention.
  • R is selected from the group consisting of halogen, hydroxy, alkyl, alkenyl, haloalkyl, alkoxy, alkylthio, and -N(R 9 ) 2 .
  • R is selected from the group consisting of halogen and hydroxy.
  • RA and R B are each independently selected from the group consisting of hydrogen, halogen, alkyl, alkenyl, alkoxy, alkylthio, and -N(R 9 ) 2 .
  • R A and R B when taken together, form a fused aryl ring or heteroaryl ring containing one heteroatom selected from the group consisting of N and S, wherein the aryl or heteroaryl ring is unsubstituted or substituted by one or more R'" groups.
  • R A and R B when taken together, form a fused 5 to 7 membered saturated ring, optionally containing one heteroatom selected from the group consisting of N and S, and unsubstituted or substituted by one or more R groups.
  • R A and R B are each independently selected from the group consisting of hydrogen, halogen, alkyl, alkenyl, alkoxy, alkylthio, and -N(R 9 ) 2 .
  • R A and R B form a fused aryl or heteroaryl ring.
  • h some embodiments, particularly embodiments of Formula I, RA and R B form a fused 5 to 7 membered saturated ring.
  • R A ⁇ and R BI are each independently selected from the group consisting of hydrogen, halogen, alkyl, alkenyl, alkoxy, alkylthio, and -N(R 9 ) 2 .
  • R AI. and R B1 form a fused aryl ring or heteroaryl ring containing one heteroatom selected from the group consisting of N and S, wherein the aryl or heteroaryl ring is unsubstituted or substituted by one or more R groups, or substituted by one R 3 group, or substituted by one R 3 group and one R group.
  • R AI and R BI form a fused 5 to 7 membered saturated ring, optionally containing one heteroatom selected from the group consisting of N and S, and unsubstituted or substituted by one or more R groups.
  • R AI and R B ⁇ form a fused benzene ring which is unsubstituted.
  • R AI and R B ⁇ fonn a fused pyridine ring which is unsubstituted.
  • R AI and R BI form a fused 5 to 7 membered saturated ring, optionally containing one heteroatom selected from the group consisting of N and S, wherein the ring is unsubstituted.
  • R 2 and B2 are each independently selected from the group consisting of hydrogen, halogen, alkyl, alkenyl, alkoxy, alkylthio, and -N(R 9 )2. hi certain of these embodiments, R A2 and R ⁇ 2 are each independently alkyl. In some embodiments, R A2 and R B2 are each methyl.
  • R e and R d are independently selected from the group consisting of hydrogen, halogen, hydroxy, alkyl, alkenyl, aryl, haloalkyl, alkoxy, alkylthio, and -N(R 9 ) 2 ; or R e and R d can j oin to form a fused aryl ring or fused 5-10 membered heteroaryl ring containing one to four heteroatoms. In certain embodiments, at least one of R e or R d is aryl.
  • Ri is selected from the group consisting of -R , -X'-R4, -X'-Y-Ri,
  • Ri is selected from the group consisting of alkyl, arylalkylenyl, aryloxyalkylenyl, hydroxyalkyl, alkylsulfonylalkylenyl, -X'-Y-Ri, and -X'-R 5 .
  • Ri is 2-methylpropyl, 2-hydroxy-2-methylpropyl, or -X'-Y-R
  • Ri is 2-methylpropyl or -X'-Y-R ⁇
  • Ri is 2-methylpropyl or 2-hydroxy-2-methylpropyl.
  • Ri is 2-methyl-2-[(methylsulfonyl)amino]propyl or 4-[(methylsulfonyl)amino]butyl.
  • R' is hydrogen or a non-interfering substituent.
  • Ri' and Ri" are independently the same as R 2 .
  • R ⁇ and Ri" are independently selected from the group consisting of hydrogen, alkyl, alkenyl, aryl, arylalkylenyl, heteroaryl, heteroarylalkylenyl, heterocyclyl, heterocyclylalkylenyl, as well as alkyl, alkenyl, aryl, arylalkylenyl, heteroaryl, heteroarylalkylenyl, heterocyclyl, or heterocyclylalkylenyl, substituted by one or more substituents selected from the group consisting of hydroxy, alkyl, haloalkyl, hydroxyalkyl, alkoxy, dialkylamino, -S(O) 0-2 -alkyl, -S(O) 0-2 -aryl, -NH-S(O) 2 -alkyl, -NH-S(O) 2 -aryl, haloalkoxy, halogen, cyano, nitro,
  • Ri' and Ri" can join together to form a ring system selected from the group consisting of:
  • Ri' and Ri" can join together to form a ring system selected from the group consisting of:
  • R ⁇ a and R ⁇ b are independently selected from the group consisting of hydrogen, alkyl, alkenyl, aryl, arylalkylenyl, heteroaryl, heteroarylalkylenyl, heterocyclyl, heterocyclylalkylenyl, as well as alkyl, alkenyl, aryl, arylalkylenyl, heteroaryl, heteroarylalkylenyl, heterocyclyl, or heterocyclylalkylenyl, substituted by one or more substituents selected from the group consisting of hydroxy, alkyl, haloalkyl, hydroxyalkyl, alkoxy, dialkylamino, -S(O) 0-2 -alkyl, -S(O) 0 - 2 -aryl, -NH-S(O) 2 -alkyl, -NH-S(O) 2 -aryl, haloalkoxy, halogen, cyano
  • R ⁇ a and R ⁇ b together with the nitrogen atom and Y' to which they are bonded can join to form a ring selected from the group consisting of -N- C(R 6 ) -N- S(0) 2 R R /
  • R ⁇ a is hydrogen.
  • R 2 and R 2a are independently selected from the group consisting of hydrogen, alkyl, alkenyl, aryl, arylalkylenyl, heteroaryl, heteroarylalkylenyl, heterocyclyl, heterocyclylalkylenyl, as well as alkyl, alkenyl, aryl, arylalkylenyl, heteroaryl, heteroarylalkylenyl, heterocyclyl, or heterocyclylalkylenyl, substituted by one or more substituents selected from the group consisting of hydroxy (i.e., hydroxyl), alkyl, haloalkyl, hydroxyalkyl, alkoxy, dialkylamino, -S(O) 0 - 2 -alkyl, -S(O)o- 2 -aryl,
  • R and R a together with the nitrogen atom and Y' to which they are bonded can join to form a ring selected from the group consisting of
  • R 2a are independently selected from the group consisting of hydrogen, alkyl, alkenyl, aryl, heteroaryl, wherein the alkyl, alkenyl, aryl, and heteroaryl are each optionally substituted with one or more substitutents selected from the group consisting of Ci-io alkyl, aryl, heteroaryl, Ci-io alkoxy, -O-C(O)-Ci-io alkyl, -C(O)-O-Ci-io alkyl, halogen, and cyano (i.e., nitrile).
  • R 2 is alkyl or substituted alkyl. In some embodiments, R 2 is methyl or cyclopropyl.
  • R 2 is alkenyl or substituted alkenyl. In some embodiments, R 2 is aryl, arylalkylenyl, substituted aryl, or substituted arylalkylenyl. hi some embodiments, R 2 is heteroaryl , heteroarylalkylenyl, substituted heteroaryl, or substituted heteroarylalkylenyl. In some embodiments, R is heterocyclyl, heterocyclylalkylenyl, substituted heterocyclyl, or substituted heterocyclylalkylenyl.
  • R 2 is selected from the group consisting of methyl, (ethoxycarbonyl)methyl, ethyl, cyclopropyl, cyclopropylmethyl, 2- (ethoxycarbonyl)cyclopropylmethyl, propyl, butyl, 2-methylpropyl, tert-butyl, 3- methylbutyl, 2,2-dimethylpropyl, cyclopentyl, 2-cyclopentylethyl, furyl, fur-3-ylmethyl, furfuryl, furfurylmethyl, cyclohexyl, tetrahydrofuranyl, tetrahydrofuran-3 -ylmethyl, 2- (methylthio)ethyl, 3-(methylthio)propyl, phenyl, 2-methylphenyl, 3-methylphenyl, 4- methylphenyl, 2-methoxyphenyl, 3-methoxyphenyl, 4-methoxyphenyl, 2,6- dimethoxyphenyl, 2-
  • R 2 is selected from the group consisting of methyl, (ethoxycarbonyl)methyl, ethyl, cyclopropyl, cyclopropylmethyl, 2- (ethoxycarbonyl)cyclopropylmethyl, propyl, butyl, 2-methylpropyl, tert-butyl, 3- methylbutyl, 2,2-dimethylpropyl, cyclopentyl, 2-cyclopentylethyl, furyl, fur-3-ylmethyl, furfuryl, furfurylmethyl, cyclohexyl, tefrahydrofuranyl, tetrahydrofuran-3-ylmethyl, 2- (methylthio)ethyl, 3-(methylthio)propyl, phenyl, 2-methylphenyl, 3-methylphenyl, 4- methylphenyl, 2-methoxyphenyl, 3-methoxyphenyl, 4-methoxyphenyl, 2,6- dimethoxyphenyl,
  • R'" is a non-interfering substituent. In some embodiments, R'" is R 3 . In some embodiments, particularly embodiments of Formula , R'" is R or R 3 when n is 1 , R or one R and one R 3 when n is 2, or R when n is 3 to 4.
  • R 3 is selected from the group consisting of -Z-R 4 , -Z-X'-R 4 , -Z-X'-Y-Ri, -Z-X'-Y-X'-Y-R ⁇ and -Z-X'-R 5 .
  • R 3 is selected from the group consisting of -Z-R 4 and -Z-X'-Y-R
  • R 4 is selected from the group consisting of hydrogen, alkyl, alkenyl, alkynyl, aryl, arylalkylenyl, aryloxyalkylenyl, alkylarylenyl, heteroaryl, heteroarylalkylenyl, heteroaryloxyalkylenyl, alkylheteroarylenyl, and heterocyclyl wherein the alkyl, alkenyl, alkynyl, aryl, arylalkylenyl, aryloxyalkylenyl, alkylarylenyl, heteroaryl, heteroarylalkylenyl, heteroaryloxyalkylenyl, alkylheteroarylenyl, and heterocyclyl groups can be unsubstituted or substituted by one or more substituents independently selected from the group consisting of alkyl, alkoxy, hydroxyalkyl, haloalkyl, haloalkoxy,
  • R 4 is hydrogen, alkyl, alkenyl, aryl, or heteroaryl.
  • R 4 is hydrogen, alkyl, alkenyl, aryl, or heteroaryl, wherein alkyl and alkenyl are optionally substituted by aryl or aryloxy and wherein aryl is optionally substituted by one or more substituents selected from the group consisting of alkyl, alkoxy, cyano, haloalkyl, and halogen.
  • * is selected from the group consisting of aryl or heteroaryl, each of which may be unsubstituted or substituted by one or more substituents selected from the group consisting of alkyl, hydroxy, cyano, hydroxyalkyl, dialkylamino, and alkoxy.
  • R 5 is selected from the group consisting of
  • R 5 is
  • R 7 is C 2-7 alkylene. In some embodiments, R 7 is ethylene. i some embodiments, R 7 is propylene. In some embodiments, R 8 is selected from the group consisting of hydrogen,
  • R 8 is hydrogen or methyl. In some embodiments, R 8 is hydrogen.
  • R is selected from the group consisting of hydrogen and alkyl.
  • Rio is C 3 . 8 alkylene.
  • Rio is pentylene.
  • Rn is C 3 . 9 alkylene or C 3 . 9 alkenylene, optionally interrupted by one hetero atom.
  • Rn is d- ⁇ alkylene or C 2-6 alkenylene, wherein the alkylene or alkenylene is optionally interrupted by one heteroatom.
  • R ⁇ is methylene; in some embodiments, R ⁇ is ethylene.
  • R 12 is C 2-7 alkylene or C2- 7 alkenylene, optionally interrupted by one hetero atom.
  • R ⁇ 2 is selected from the group consisting of a bond, C ⁇ -5 alkylene, and C 2-5 alkenylene, wherein the alkylene or alkenylene is optionally interrupted by one heteroatom.
  • R 12 is ethylene.
  • R ⁇ 3 is selected from the group consisting of hydrogen and alkyl which may be optionally interrupted by one or more -O- -groups, h some embodiments, R ⁇ 3 is hydrogen.
  • A is selected from the group consisting of -CH 2 -, -O-, -C(O)-, -S(O)o -2 -, and -NCR4)-. In some embodiments, A is selected from the group consisting of-CH 2 - and -O-. hi some embodiments, A' is selected from the group consisting of -O-, -S(O)o- 2 -, -N(-Q-R 4 )-, and -CH 2 -. hi some embodiments, A' is -CH 2 -, -O-, or -N(-Q-R 4 )-.
  • Q is selected from the group consisting of a bond, -C(R 6 )-, -C(R 6 )-C(R 6 )-, -S(O) 2 -, -C(R 6 )-N(R 8 )-W-, -S(O) 2 -N(R 8 )-, -C(R 6 )-O-, and -C(R 6 )-N(OR 9 )-.
  • Q is selected from the group consisting of -C(O)-, -S(O) 2 -, and -C(O)-N(R 8 )-W-.
  • V is selected from the group consisting of -C(R 6 )-,
  • V is -N(R 8 )-C(O)-.
  • W is selected from the group consisting of a bond, -C(O)-, and -S(O) 2 -.
  • W is selected from the group consisting of a bond and -C(O)-.
  • X is C 1 - 10 alkylene or C 2- ⁇ o alkenylene.
  • X is
  • Ci-io alkylene or C 3-1 o alkenylene In some embodiments, particularly embodiments of Formulas a and IVa, X is C ⁇ -4 alkylene. In some embodiments, X is methylene.
  • X' is selected from the group consisting of alkylene, alkenylene, alkynylene, arylene, heteroarylene, and heterocyclylene wherein the alkylene, alkenylene, and alkynylene groups can be optionally interrupted or terminated by arylene, heteroarylene or heterocyclylene and optionally interrupted by one or more -O- groups, hi some embodiments, X' is alkylene. i some embodiments, X' is ethylene, propylene, or butylene (including isobutylene).
  • X" is -CH(R ⁇ 3 )-alkylene- or -CH(R ⁇ 3 )-alkenylene-, wherein the alkylene and alkenylene are optionally interrupted by one or more -O- groups.
  • X" is -CH(R ⁇ 3 )-alkylene- or -CH(R ⁇ 3 )-alkenylene-.
  • Y is selected from the group consisting of -S(O)o -2 -, -S(O) 2 -N(R 8 )-, -C(R 6 )-, -C(R 6 )-O-, -O-C(R 6 )-, -O-C(O)-O-, -N(R 8 )-Q-, -C(R 6 )-N(R 8 )-, -O-C(R 6 )-N(R 8 )-, -C(R 6 )-N(OR 9 )-,
  • Y is selected from the group consisting of -S(O)o -2 -, -S(O) 2 -N(R 8 >, -C(R 6 )-, -C(R 6 )-O-, -O-C(R 6 )-, -O-C(O)-O-, -N(R 8 )-Q-, -C(R 6 )-N(R 8 )-, -O-C(R 6 )-N(R 8 )-, -C(R 6 )-N(OR 9 )-,
  • Y is -N(R 8 )-C(O)-, -N(R 8 )-S(O) 2 -, -N(R 8 )-S(O) 2 -N(R 8 )-, -N(R 8 )-C(O)-N(R 8 )-, -N(R 8 )-C(O)-N(R 8 )-C(O)-,
  • Y is -NH-C(O)-, -NH-S(O) 2 -, -NH-S(O) 2 -N(R 8 )-, -NH-C(O)-N(R 8 )-, -NH-C(O)-NH-C(O)-, or — H- C(O)-N
  • Y' is selected from the group consisting of a bond, -C(O)-, -C(S)-, -S(O) 2 -, -S(O) 2 -N(R 8 )-,
  • Y' is selected from the group consisting of a bond, -C(O)-, -C(O)-O-, -S(O) 2 -, -S(O) 2 -N(R 8 )-, -C(O)-N(R 8 )-, -C(S)-N(R 8 )-, -C(O)-N(R 8 )-C(O)-, and
  • Y' is selected from the group consisting of a bond, -C(O)-, -C(O)-O-, -S(O) 2 -, -S(O) 2 -N(R 8 )-, -C(O)-N(R 8 )-, -C(O)-N(R 8 )-C(O)-, and
  • Y' is selected from the group consisting of -C(O)-, -S(O) 2 -, and -C(O)-N(R 8 )-.
  • Z is a bond or -O-.
  • Z is a bond.
  • Z is -O-.
  • a and b are independently integers from 1 to 6 with the proviso that a + b is ⁇ 7.
  • a and b are each 2.
  • n is an integer from 0 to 4.
  • n is 0 or 1.
  • n is 0.
  • m is 0 or 1.
  • m is 1.
  • m is 0.
  • h some embodiments, m is 0 or 1 ; with the proviso that when m is 1, then n is 0 or 1.
  • particularly embodiments of Formula ma m and n are 0. hi some embodiments, n is 0 or m is 0.
  • p is an integer from 0 to 3. In some embodiments, p is 0 or 1. In some embodiments, p is 0.
  • m is 0 or 1, with the proviso that when m is 1, p is 0 or 1. In some embodiments, p and m are 0.
  • R' is selected from the group consisting of:
  • R'" is R or R 3 when n is 1 , R or one R and one R 3 when n is 2, or R when n is 3 to 4; wherein:
  • R is selected from the group consisting of: halogen, hydroxy, alkyl, alkenyl, haloalkyl, alkoxy, alkylthio, and -N(R 9 ) 2 ;
  • R 3 is selected from the group consisting of: -Z-R4, -Z-X'-R 4 , -Z-X'-Y-R4,
  • n is an integer from 0 to 4;
  • Z is a bond or -O-; and
  • X', Y, R 4 , R 5 , and R 9 are as defined above.
  • R 2 is alkyl or substituted alkyl, and R 2a is hydrogen.
  • R 2 is methyl or cyclopropyl, and R 2a is hydrogen.
  • R 2 is alkenyl or substituted alkenyl, and R2a is hydrogen.
  • R 2 is aryl, arylalkylenyl, substituted aryl, or substituted arylalkylenyl, and R 2a is hydrogen.
  • R 2 is heteroaryl, heteroarylalkylenyl, substituted heteroaryl, or substituted heteroarylalkylenyl, and R 2a is hydrogen.
  • R 2 is heterocyclyl, heterocyclylalkylenyl, substituted heterocyclyl, or substituted heterocyclylalkylenyl
  • R 2a is hydrogen.
  • R 2 is selected from the group consisting of methyl, (ethoxycarbonyl)methyl, ethyl, cyclopropyl, cyclopropylmethyl, 2-
  • R 2 is selected from the group consisting of methyl, (ethoxycarbonyl)methyl, ethyl, cyclopropyl, cyclopropylmethyl, 2-(ethoxycarbonyl)cyclopropylmethyl, propyl, butyl, 2-methylpropyl, tert-butyl, 3 -methylbutyl, 2,2-dimethylpropyl, cyclopentyl, 2-cyclopentylethyl, furyl, fur-3- ylmethyl, furfuryl, furfurylmethyl, cyclohexyl, tetrahydrofuranyl, tetrahydrofuran-3- ylmethyl, 2-(methylthio)ethyl, 2-(methylthio)propyl, phenyl, 2-methylphenyl, 3- methylphenyl, 4-methylphenyl, 2-methoxyphenyl, 3-methoxyphenyl, 4-methoxyphenyl, 4-methoxyphenyl, 4-methoxypheny
  • Ri is selected from the group consisting of alkyl, arylalkylenyl, aryloxyalkylenyl, hydroxyalkyl, alkylsulfonylalkylenyl, -X'-Y-R ⁇ and -X*-R 5 ; wherein X' is alkylene; Y is -N(R 8 )-C(O)-, -N(R 8 )-S(O) 2 -, -N(R 8 )-S(O) 2 -N(R 8 )-, -N(R 8 )-C(O)-N(R 8 )-, -N(R 8 )-C(O)-N(R 8 )-C(O)-N(R 8 )-, -N(R 8 )-C(O)-N(R 8 )-C(O)-,
  • R 4 is hydrogen, alkyl, alkenyl, aryl, or heteroaryl; and R 5 is
  • Ri is 2-methylpropyl or -X'-Y-Ri;
  • X' is ethylene, propylene, or butylene;
  • Y is -NH-C(O)-, -NH-S(O) 2 -, -NH-S(O) 2 -N(R 8 )-, -NH-C(O)-N(R 8 )-, -NH-C(O)-NH-C(O)-, or
  • R 8 is hydrogen or methyl.
  • R ⁇ is 2-methylpropyl, 2-hydroxy-2-methylpropyl, or
  • X' is ethylene, propylene, or butylene (including isobutylene);
  • Y is -NH-C(O)-,
  • Ri is selected from the group consisting of alkyl, arylalkylenyl, aryloxyalkylenyl, hydroxyalkyl, alkylsulfonylalkylenyl, -X'-Y-R-t, and -X'-R 5 ; wherein X' is alkylene; Y is -N(R 8 )-C(O)-, -N(R 8 )-S(O) 2 -, -N(R 8 )-S(O) 2 -N(R 8 )- -N(R 8 )-C(O)-N(R 8 )-, -N(R 8 )-C(O)-N(R 8 )-C(O)-N(R 8 )-, -N(R 8 )-C(O)-N(R 8 )-C(O)-,
  • R 4 is hydrogen, alkyl, alkenyl, aryl, or heteroaryl, wherein alkyl and alkenyl are optionally substituted by aryl or aryloxy and wherein aryl is optionally substituted by one or more substituents selected from the group consisting of alkyl, alkoxy, cyano, haloalkyl, and halogen; and R 5 is
  • Ri' and Ri" can join together to form a ring system selected from the group consisting of:
  • A' is selected from the group consisting of
  • R ⁇ is C 3-9 alkylene or C 3-9 alkenylene, optionally interrupted by one hetero atom
  • R 1 2 is C2- 7 alkylene or C2- 7 alkenylene, optionally interrupted by one heteroatom
  • R e and R d are independently selected from the group consisting of hydrogen, halogen, hydroxy, alkyl, alkenyl, aryl, haloalkyl, alkoxy, alkylthio, and -N(R 9 ) 2 ; or R e and R d can join to fonn a fused aryl ring or fused 5-10 membered heteroaryl ring containing one to four heteroatoms.
  • Ri' and Ri" can join together to form a ring system selected from the group consisting of:
  • R e and R d are independently selected from the group consisting of hydrogen, halogen, hydroxy, alkyl, alkenyl, aryl, haloalkyl, alkoxy, alkylthio, and -N(R 9 ) 2 ; or R e and R d can join to form a fused aryl ring or fused 5-10 membered hetero
  • Step (1) of Reaction Scheme I a quinoline-3,4-diamine of Formula X is reacted with a carboxylic acid or an equivalent thereof to provide a lH-imidazo[4,5-c]quinoline of Formula XI.
  • Suitable equivalents to a carboxylic acid include orthoesters, and 1,1-dialkoxyalkyl alkanoates.
  • the carboxylic acid or equivalent is selected such that it will provide the desired -X-Hal substituent in a compound of Formula XI.
  • Hal-X-CO 2 H or Hal-X-C(O-alkyl) will provide a compound with the desired -X-Hal substitutent at the 2-position.
  • the reaction can be run in the absence of solvent or in an inert solvent such as toluene.
  • the reaction is run with sufficient heating to drive off any alcohol or water formed as a byproduct of the reaction.
  • a catalyst such as pyridine hydrochloride can be included.
  • step (1) can be carried out by (i) reacting a compound of Formula X with an acyl halide of formula Hal-X-C(O)Cl or Hal-X-C(O)Br and then (ii) cyclizing.
  • the acyl halide is added to a solution of a compound of Formula X in an inert solvent such as acetonitrile, pyridine or dichloromethane.
  • the reaction can be carried out at ambient temperature.
  • a catalyst such as pyridine hydrochloride can be included.
  • the reaction can be carried out in the presence of triethylamine.
  • the product of part (i) is heated in pyridine.
  • step (2) of Reaction Scheme I a lH-imidazo[4,5-c]quinoline of Formula XI is oxidized to provide an N-oxide of Formula XII using a conventional oxidizing agent that is capable of forming N-oxides.
  • the reaction can be carried out by treating a solution of a compound of Formula XI in a suitable solvent such as chloroform or dichloromethane with
  • step (3) of Reaction Scheme I an N-oxide of Formula XII is animated to provide a lH-imidazo[4,5-c]quinoline-4-amine of Formula Xm.
  • the reaction is carried out in two parts.
  • a compound of Formula XII is reacted with an acylating agent.
  • Suitable acylating agents include alkyl- or arylsulfonyl chorides (e.g., benzenesulfonyl choride, methanesulfonyl choride, or/?-toluenesulfonyl chloride).
  • the product of part (i) is reacted with an excess of an aminating agent.
  • Suitable aminating agents include ammonia (e.g. in the form of ammonium hydroxide) and ammonium salts (e.g., ammonium carbonate, ammonium bicarbonate, ammonium phosphate).
  • ammonia e.g. in the form of ammonium hydroxide
  • ammonium salts e.g., ammonium carbonate, ammonium bicarbonate, ammonium phosphate.
  • the reaction can be carried out by dissolving a compound of Formula XE in a suitable solvent such as dichloromethane or chloroform, adding ammonium hydroxide to the solution, and then adding >-toluenesulfonyl chloride.
  • the product or a pharmaceutically acceptable salt thereof can be isolated using conventional methods.
  • a lH-imidazo[4,5-c]quinoline-4-amine of Formula Xm is treated with N-hydroxyphthalimide to provide an N-phthalimide-protected lH-imidazo[4,5-c]quinolin-2-yl hydroxylamine of Formula XIV.
  • the reaction is conveniently carried out by adding a base, such as triethylamine, to a solution of N- hydroxyphthalimide in a suitable solvent such as N,N-dimethylformamide (DMF); and then adding the lH-imidazo[4,5-c]quinoline-4-amine of Formula XUI in a suitable solvent (for example, DMF) to the resulting mixture.
  • a suitable solvent for example, DMF
  • the reaction can be carried out at ambient temperature.
  • the product or a pharmaceutically acceptable salt thereof can be isolated using conventional methods.
  • step (5) of Reaction Scheme I an N-phthalimide-protected lH-imidazo[4,5- c]quinolin-2-yl hydroxylamine of Formula XIV is converted to a lH-imidazo[4,5- c]quinolin-2-yl hydroxylamine of Formula XV.
  • Removal of the N-phthalimide protecting group is conveniently carried out by adding hydrazine to a suspension of anN- phthalimide-protected lH-imidazo[4,5-c]quinolin-2-yl hydroxylamine of Formula XIV in a suitable solvent such as ethanol.
  • the reaction can be carried out at ambient temperature.
  • the product or a pharmaceutically acceptable salt thereof can be isolated using conventional methods .
  • step (6) of Reaction Scheme I a lH-imidazo[4,5-c]quinolin-2-yl hydroxylamine of Formula XV is reacted with an aldehyde or ketone of formula R 2 'C(O)R 2 " to provide a lH-imidazo[4,5-c]quinolin-2-yl oxime of Formula XVI.
  • aldehydes and ketones of formula R 2 'C(O)R 2 " are commercially available; others can be readily prepared using known synthetic methods.
  • reaction can be conveniently carried out by adding the aldehyde or ketone of formula R 2 'C(O)R 2 " to a lH-imidazo[4,5-c]quinolin-4-amine of Formula XV in a suitable solvent such as methanol.
  • a suitable solvent such as methanol.
  • the reaction can be carried out at ambient temperature.
  • the product or a pharmaceutically acceptable salt thereof can be isolated using conventional methods.
  • step (7) of Reaction Scheme I a lH-imidazo[4,5-c]quinolin-2-yl oxime of
  • Formula XVI is reduced to provide a lH-imidazo[4,5-c]quinolin-2-yl hydroxylamine of Formula XVII, which is a subgenus of Formulas I, II, m, and ma.
  • the reduction is conveniently carried out by treating a lH-imidazo[4,5-c]quinolin-2-yl oxime of Fonnula XVI with excess sodium cyanoborohydride in a suitable solvent or solvent mixture such as methanol/acetic acid.
  • the reaction can be carried out at ambient temperature.
  • the product or a pharmaceutically acceptable salt thereof can be isolated using conventional methods.
  • step (1) of Reaction Scheme II a lH-imidazo[4,5-c]quinolin-l-yl tert-butylcarbamate of Formula XVm is treated with N-hydroxyphthalimide to provide an N-phthalimide-protected 1H- imidazo[4,5-c]quinolin-2-yl hydroxylamine of Formula XIX.
  • the reaction is conveniently carried out by adding a base, such as triethylamine, to N-hydroxyphthalimide dissolved in a suitable solvent such as DMF; and then adding the lH-imidazo[4,5-c]quinolin-l-yl tgrt- butylcarbamate of Formula XV in a suitable solvent (for example, DMF) to the resulting mixture.
  • a suitable solvent for example, DMF
  • the reaction can be carried out at ambient temperature.
  • the product or a pharmaceutically acceptable salt thereof can be isolated using conventional methods.
  • Compounds of Formula XVLU can be readily prepared using known synthetic routes; see for example, U.S. Patent No.
  • Removal of the N-phthalimide protecting group is conveniently carried out by adding hydrazine to a suspension of an N- phthalimide-protected lH-imidazo[4,5-c]quinolin-2-yl hydroxylamine of Formula XIX in a suitable solvent such as ethanol.
  • the reaction can be carried out at ambient temperature.
  • the product or a pharmaceutically acceptable salt thereof can be isolated using conventional methods.
  • step (3) of Reaction Scheme II a lH-imidazo[4,5-c]quinolin-2-yl hydroxylamine of Formula XX is reacted with an aldehyde or ketone of formula R 2 'C(O)R 2 " to provide a lH-imidazo[4,5-c]quinolin-2-yl oxime of Formula XXI.
  • aldehydes and ketones of formula R 2 'C(O)R 2 " are commercially available; others can be readily prepared using known synthetic methods.
  • the reaction can be conveniently carried out by adding the aldehyde or ketone of formula R 2 'C(O)R 2 " to a solution of the lH-imidazp[4,5-c]quinolin- 4-amine of Formula XX in a suitable solvent such as methanol.
  • a suitable solvent such as methanol.
  • the reaction can be carried out at ambient temperature.
  • the product or a pharmaceutically acceptable salt thereof can be isolated using conventional methods.
  • step (4) of Reaction Scheme II a lH-imidazo[4,5-c]quinolin-2-yl oxime of Formula XXI is deprotected to provide an amino group at the 1 -position of a 1H- imidazo[4,5-c]quinolin-2-yl oxime of Formula XXII.
  • the reaction can be conveniently carried out by dissolving a compound of Formula XXI in a mixture of trifluoroacetic acid and a suitable solvent such as dichloromethane. The reaction can be carried out at ambient temperature.
  • the product or a pharmaceutically acceptable salt thereof, including the trifluoro acetate salt can be isolated using conventional methods.
  • a lH-imidazo[4,5-c]quinolin-2-yl oxime of Formula XXLI is converted to a lH-imidazo[4,5-c]quinolin-2-yl oxime of Formula XXm or XXIV, using conventional methods.
  • Formula XXTH (Q is -S(O) 2 -) can be prepared by reacting a compound of Formula XXII with a sulfonyl chloride of formula R 4 S(O) 2 Cl.
  • the reaction can be carried out at ambient temperature in an inert solvent such as chloroform or dichloromethane by adding the sulfonyl chloride to a compound of Formula XXLI in the presence of a base such as N,N- diisopropylethylamine, triethylamine, or pyridine.
  • Sulfamides of Fonnula XXTfl (Q is, for example, -S(O) 2 - ⁇ (R 8 )-) can be prepared by reacting a compound of Formula XXJT with a sulfamoyl chloride of formula R 4 (R 8 )NS(O) 2 Cl or by reacting a compound of Formula XX ⁇ with sulfuryl chloride to generate a sulfamoyl chloride in situ, and then reacting the resulting sulfamoyl chloride with an amine of formula ⁇ N(R 8 )R 4 .
  • the product or a pharmaceutically acceptable salt thereof can be isolated using conventional methods.
  • Some sulfamoyl chlorides of formula R 4 (R 8 )NS(O) 2 ⁇ and many sulfonyl chlorides of formula 4 S(O) 2 Cl and amines of formula HN(R 8 )R 4 are commercially available; others can be prepared using known synthetic methods.
  • step (5a) of Reaction Scheme II a lH-imidazo[4,5- c]quinolin-2-yl oxime of Formula XXII is reacted with a chloroalkanesulfonyl chloride of formula Cl-R 7 -S(O) 2 Cl to provide a compound of Formula XXIV, wherein R 5a is a ring having the structure
  • the reaction is preferably carried out by adding the chloroalkanesulfonyl chloride to a solution of a compound of Formula XXII in a suitable solvent such as dichloromethane in the presence of a base such as triethylamine.
  • a suitable solvent such as dichloromethane
  • the intermediate chloroalkanesulfonamide may optionally be isolated before treatment with a stronger base such as 1,8- diazabicyclo[5.4.0]undec-7-ene (DBU) at ambient temperature. If the intermediate chloroalkanesulfonamide is isolated, the reaction with DBU can be carried out in a suitable solvent such as DMF.
  • the product or a pharmaceutically acceptable salt thereof can be isolated using conventional methods.
  • Amides of Formulas XXm (Q is, for example, -C(O)-) and XXIV can be prepared from lH-imidazo[4,5-c]quinolin-2-yl oxime of Formula XXII using conventional methods.
  • a compound of Formula XXLI can be reacted with an acid chloride of formula 4 C(O)Cl to provide a compound of Formula XXHI.
  • the reaction can be carried out by adding the acid chloride to a solution of a compound of Formula XXLI in a suitable solvent such as chloroform, optionally in the presence of a base such as N,N- diisopropylethylamine, triethylamine, or pyridine, at ambient temperature.
  • a base such as N,N- diisopropylethylamine, triethylamine, or pyridine
  • step (5a) a lH-imidazo[4,5-c]quinolin-2-yl oxime of Formula XXII is reacted with a chloroalkanoyl chloride compound of formula Cl-R 7 -C(O)Cl to provide a compound of Formula XXIV, wherein R 5a is a ring having the structure
  • the reaction is preferably carried out by adding the chloroalkanoyl chloride compound to a compound of Formula XXII in a suitable solvent such as dichloromethane in the presence of a base such as N,N-diisopropylethylamine.
  • a suitable solvent such as dichloromethane
  • the intermediate chloroalkanamide may optionally be isolated before treatment with a stronger base such as DBU at ambient temperature. If the intermediate chloroalkanamide is isolated, the reaction with DBU can be carried out in a suitable solvent such as DMF.
  • the product or a pharmaceutically acceptable salt thereof can be isolated using conventional methods.
  • Ureas and thioureas of Formula XXHI (Q is, for example, -C(O)- ⁇ (R 8 )- or -C(S)-N(R 8 )-) and XXIV can be prepared from lH-imidazo[4,5-c]quinolin-2-yl oximes of Formula XXII using conventional methods.
  • the reaction can be carried out by adding the isocyanate to a solution of a compound of Formula XXII in a suitable solvent such as chloroform, optionally in the presence of a base such as N,N- diisopropylethylamine, or triethylamine, at ambient temperature.
  • the product or a pharmaceutically acceptable salt thereof can be isolated using conventional methods.
  • a lH-imidazo[4,5-c]quinolin-2-yl oxime of Formula XXTH or Formula XXIV is reduced to provide a lH-imidazo[4,5- c]quinolin-2-yl hydroxylamine of Formula XXV or Formula XXVI, each of which is a subgenus of Formulas I, ⁇ , HI, and ma.
  • the reduction is conveniently carried out by treating a li ⁇ -imidazo[4,5-c]quinolin-2-yl oxime of Fonnula XXHI or Formula XXIV with excess sodium cyanoborohydride in a suitable solvent or solvent mixture such as methanol/acetic acid.
  • the reaction can be carried out at ambient temperature.
  • the product or a pharmaceutically acceptable salt thereof can be isolated using conventional methods.
  • each R B is independently selected from the group consisting of hydroxy, alkyl, alkoxy, -N(R 9 ) 2 ;
  • X c is C O alkylene;
  • P is a removable protecting group, such as an alkanoyloxy group (e.g., acetoxy) or an aroyloxy group (e.g., benzoyloxy);
  • R 2 ' and R 2 " are the same as Ri' and Ri" as defined above; and
  • R lc is a subset of Ri as defined above, which does not include those groups that one skilled in the art would recognize as being susceptible to reduction in step (5).
  • These groups include, for example, alkenyl, alkynyl, and aryl groups, and groups bearing nitro and -S- substitutents.
  • Reaction Scheme HI a quinoline-3,4-diamine of Formula Xa is reacted with a carboxylic acid of the formula, HO-X-CO 2 H, with a trialkyl orthoester of the formula HO-X-C(O-Ci_ alkyl) 3 , or with a combination thereof (wherein "alkyl” is a straight or branched chain) to provide a lH-imidazo[4,5-c]quinolin-2-yl alcohol of Formula XXVII.
  • the reaction is run with sufficient heating to drive off any alcohol or water formed as a byproduct of the reaction.
  • a catalyst such as pyridine hydrochloride can be included.
  • Compounds of Formula Xa are a subset of compounds of Formula X, which are shown in Reaction Scheme I.
  • step (2) of Reaction Scheme HI the hydroxyl group of a lH-imidazo[4,5- c] quinoline of Formula XXVII is protected with a removable protecting group such as an alkanoyloxy group (e.g., acetoxy) or aroyloxy group (e.g., benzoyloxy) to provide a 1H- imidazo[4,5-c]quinoline of Formula XXVHI.
  • Suitable protecting groups and reactions for their placement and removal are well known to those skilled in the art. See, for example, U.S. Patent No. 4,689,338 (Gerster), Examples 115 and 120 and 5,389,640 (Gerster et al), Examples 2 and 3.
  • step (1) it is possible to combine steps (1) and (2) when an acid chloride of the Formula PO-X-CO 2 Cl is used under the conditions of step (1).
  • Some acid chlorides of this type for example, acetoxyacetyl chloride, are commercially available
  • hi step (3) of Reaction Scheme HI a lH-imidazo[4,5-c]quinoline of Formula XXVi ⁇ is oxidized to provide an N-oxide of Formula XXIX using a conventional oxidizing agent that is capable of forming N-oxides.
  • the reaction can be carried out by treating a solution of a compound of Formula XXVLTI in a suitable solvent such as chloroform or dichloromethane with 3-chloroperoxybenzoic acid at ambient temperature.
  • step (4) of Reaction Scheme HI an N-oxide of Formula XXIX is aminated and the protecting group removed to provide a lH-imidazo[4,5-c]quinoline-4-amine of
  • Formula XXX The animation reaction is carried out in two parts, hi part (i) a compound of Formula XXTX is reacted with an acylating agent.
  • Suitable acylating agents include alkyl- or arylsulfonyl chorides (e.g., benzenesulfonyl choride, methanesulfonyl choride, or j9-toluenesulfonyl chloride).
  • Suitable aminating agents include ammonia (e.g.
  • ammonium hydroxide in the form of ammonium hydroxide
  • ammonium salts e.g., ammonium carbonate, ammonium bicarbonate, ammonium phosphate
  • the reaction can be carried out by dissolving a compound of Formula XXIX in a suitable solvent such as dichloromethane or chloroform, adding ammonium hydroxide to the solution, and then adding -toluenesulfonyl chloride.
  • the protecting group is removed using well-known methods.
  • the product or a pharmaceutically acceptable salt thereof can be isolated using conventional methods.
  • step (5) of Reaction Scheme HI a lH-imidazo[4,5-c]quinoline-4-amine of Formula XXX is reduced to provide a 6,7,8,9-tetrahydro-lH-imidazo[4,5-c]quinoline-4- amine of Formula XXXI.
  • the reaction can be conveniently carried out by suspending or dissolving a compound of Formula XXX in ethanol, adding a catalytic amount of rhodium on carbon, and hydrogenating.
  • the reaction can be carried out by suspending or dissolving a compound of Formula XXXX in trifluoroacetic acid, and adding platinum(lV) oxide, and hydrogenating.
  • the reaction can be carried out in a Pan apparatus.
  • a 6,7,8,9-tetrahydro-lH-imidazo[4,5- c]quinoline-4-amine of Formula XXXI is treated with N-hydroxyphthalimide under Mitsunobu reaction conditions to provide an N-phthalimide-protected 6,7,8,9-tetrahydro- lH-imidazo[4,5-c]quinolin-2-yl hydroxylamine of Formula XXXII.
  • step (6) may be carried out in two parts by (i) converting the hydroxy group in a compound of Formula XXXI to a leaving group and (ii) displacing the leaving group with N-hydroxyphthalimide in the presence of a base.
  • Part (i) of step (6) is conveniently carried out by treating the hydroxy-substituted 6,7,8,9-tetrahydiO-lH- imidazo[4,5-c]quinoline-4-amine of Formula XXXI with thionyl chloride in a suitable solvent such as 1,2-dichloroethane.
  • the reaction may be carried out at ambient temperature, and the product can be isolated by conventional methods.
  • Part (ii) of step (6) may be carried out under the conditions described in step (4) of Reaction Scheme I, and the product of Formula XXXII or phannaceutically acceptable salt thereof can be isolated using conventional methods.
  • step (7) of Reaction Scheme m an N-phthalimide-protected 6,7,8,9-tetrahydro- lH-imidazo[4,5-c]quinolin-2-yl hydroxylamine of Formula XXX ⁇ is converted to a
  • step (8) of Reaction Scheme m a 6,7,8,9-tetrahydro-lH-imidazo[4,5-c]quinolin- 2-yl hydroxylamine of Formula XXXL ⁇ is reacted with an aldehyde or ketone of formula R 2 'C(O)R 2 " to provide a 6,7,8,9-tetrahydro-lH-imidazo[4,5-c]quinolin-2-yl oxime of Formula XXXIV as in step (3) of Reaction Scheme ⁇ .
  • the product or phannaceutically acceptable salt thereof can be isolated using conventional methods.
  • step (9) of Reaction Scheme HI a lH-imidazo[4,5-c]quinolin-2-yl oxime of Formula XXXIV is reduced to provide a lH-imidazo[4,5-e]quinolin-2-yl hydroxylamine of Formula XXXV, which is a subgenus of Formulas I, H, IV and IVa.
  • the reduction is carried out as described in step (7) of Reaction Scheme I.
  • the product or pharmaceutically acceptable salt thereof can be isolated using conventional methods.
  • a compound of Formula XXXVI is combined with a boronic acid of the fomiula R 3a -B(O ⁇ ) 2 in the presence of palladium (LT) acetate, triphenylphosphine and a base such as aqueous sodium carbonate in a suitable solvent such as n-propanol or «-propanol and water.
  • the reaction can be canied out at an elevated temperature (e.g., 80 °C-100 °C).
  • Halogen substituted lH-imidazo[4,5-c]quinolin-2-yl oximes of Formula XXXVI can be prepared as described above in steps (l)-(6) of Reaction Scheme I or steps (1) - (5) or (5a) or Reaction Scheme ⁇ , wherein one of the R groups is Hal.
  • Numerous boronic acids of Formula R 3a -B(OH)2, anhydrides thereof, and boronic acid esters of Formula R 3a -B(O-alkyl) are commercially available; others can be readily prepared using known synthetic methods.
  • a lH-imidazo[4,5-c]quinolin-2-yl oxime of Formula XXXV ⁇ is reduced to provide a lH-imidazo[4,5-c]quinolin-2-yl hydroxylamine of Formula XXXVm, which is a subgenus of Formulas I, ⁇ , , and ma.
  • the reduction is carried out as described in step (7) of Reaction Scheme I.
  • the product or a phannaceutically acceptable salt thereof can be isolated using conventional methods.
  • Step (1) of Reaction Scheme V a lH-imidazo[4,5-c]quinolin-2-yl hydroxylamine of Formula XV is converted to a lH-imidazo[4,5-c]quinolin-2-yl hydroxylamine of Formula XXXLX, a subgenus of Formulas I, ⁇ , m, and a, using conventional methods.
  • sulfonamides of Formula XXXLX (Y a ' is -S(O) 2 -) can be prepared by reacting a compound of Formula XV with a sulfonyl chloride of formula R 2 S(O) 2 ⁇ .
  • the reaction can be carried out at ambient temperature in an inert solvent such as chloroform or dichloromethane by adding the sulfonyl chloride to a compound of Formula XV in the presence of a base such as iV,N-diisopropylethylamine, triethylamine, or pyridine.
  • Sulfamides of Formula XXXLX (Y a ' is -S(O) 2 - ⁇ (R 8 )- or ⁇ • R 1 i 0 , ) can be prepared by reacting a compound of Formula XV with sulfuryl chloride to generate a sulfamoyl chloride in situ, and then reacting the sulfamoyl chloride with an amine of
  • R sulfamoyl chloride of formula R 2 (R 8 )NS(O) 2 ⁇ or 10 The product or a pharmaceutically acceptable salt thereof can be isolated using conventional methods. Many sulfonyl chlorides of formula R 2 S(O) 2 Cl, amines of formulas HN(R 8 )R 2 , and
  • Amides of Formula XXXIX (Y a ' is -C(O)-) can be prepared from lH-imidazo[4,5- c]quinolin-2-yl hydroxylamines of Formula XV using conventional methods.
  • a compound of Formula XV can be reacted with an acid chloride of formula
  • R 2 C(O)Cl to provide a compound of Formula XXXLX.
  • the reaction can be carried out by adding the acid chloride to a solution of a compound of Formula XV in a suitable solvent such as chloroform, optionally in the presence of a base such as NJV- diisopropylethylamine, triethylamine, or pyridine, at ambient temperature.
  • a base such as NJV- diisopropylethylamine, triethylamine, or pyridine, at ambient temperature.
  • the product or a pharmaceutically acceptable salt thereof can be isolated using conventional methods.
  • the reaction can be carried out by adding the isocyanate to a solution of a compound of Formula XV in a suitable solvent such as chloroform, optionally in the presence of a base such as N,N- diisopropylethylamine, or triethylamine, at ambient temperature.
  • R 2a is other than hydrogen
  • Reaction Scheme VI where R, R ls R 2 , X, Y', and n are as defined above, hi step (1) of Reaction Scheme VI, a lH-imidazo[4,5-c]quinolin-2-yl hydroxylamine of Formula XL, a subgenus of Formulas I, II, HI, and a, is prepared by reductive alkylation of a lH-imidazo[4,5-cjquinolin-2-yl hydroxylamine of Formula XV.
  • reaction is carried out in two steps, (i) reacting a compound of Formula XV with the appropriate aldehyde to provide an oxime and (ii) reducing the oxime, using the methods of steps (6) and (7), respectively, of Reaction Scheme I.
  • step (2) of Reaction Scheme VI a lH-imidazo[4,5-c]quinolin-2-yl hydroxylamine of Formula XL is converted to a lH-imidazo[4,5-c]quinolin-2-yl hydroxylamine of Formula XLI, a subgenus of Formulas I, ⁇ , and Id.
  • Compounds of Formula XLI wherein Y' is a bond are prepared by subjecting the compound of Formula
  • tetrahydroquinolines of the invention can be prepared according to Reaction Scheme VII, wherein RB, RI C , XC, Y a ', R2, and n are as defined above.
  • the reaction in Reaction Scheme VH can be carried out according to one of the methods described in Reaction Scheme V to provide a tetrahydroquinoline of Formula XLE, a subgenus of Formulas I, U, TV, and IVa.
  • the product or pharmaceutically acceptable salt thereof can be isolated by conventional methods.
  • Tetrahydroquinolines of Formula XXXm can also be treated according to the methods described in Reaction Scheme V to provide compounds of the invention.
  • R, R 1? R 2 , R2', R2", R2a, X, Y', and Hal are as defined above;
  • E is carbon (imidazoquinoline ring) or nitrogen (imidazonaphthyridine ring); n is an integer from 0 to 4 (imidazoquinoline ring) or 0 to 3 (imidazonaphthyridine ring) with the proviso that when m is 1, then n is 0 or 1; and D is -Br, -I, or -OCH2PI1; wherein Ph is phenyl.
  • an aniline or aminopyridine of Formula XLILL is treated with the condensation product generated from 2,2-dimethyl-l,3-dioxane-4,6-dione (Meldrum's acid) and triethyl orthoformate to provide an imine of Formula XLTV.
  • the reaction is conveniently carried out by adding a solution of an aniline or aminopyridine of Formula XLi ⁇ to a heated mixture of Meldrum's acid and triethyl orthoformate and heating the reaction at an elevated temperature.
  • the product can be isolated using conventional methods.
  • Many anilines and aminopyridines of Formula XLIH are commercially available; others can be prepared by known synthetic methods.
  • benzyloxypyridines of Formula XLIH can be prepared using the method of Holladay et al., Biorg. Med. Chem. Lett, 8, pp. 2797-2802, (1998).
  • step (2) of Reaction Scheme Vm an imine of Formula XLTV undergoes thermolysis and cyclization to provide a compound of Formula XLV.
  • the reaction is conveniently carried out in a medium such as DOWTHERM A heat transfer fluid at a temperature of 200 °C to 250 °C.
  • the product can be isolated using conventional methods. Isomers of the compound of Formula XLIH or Formula XLV, wherein E is nitrogen, can also be synthesized and can be used to prepare compounds of the invention.
  • step (3) of Reaction Scheme Vm a compound of Formula XLV is nitrated under conventional nitration conditions to provide a compound of Formula XLVI.
  • the reaction is conveniently carried out by adding nitric acid to the compound of Formula XLV in a suitable solvent such as propionic acid and heating the mixture at an elevated temperature.
  • the product can be isolated using conventional methods.
  • step (4) of Reaction Scheme VHL a 3-nitro[l,5]naphthyridin-4-ol or 3- nitroquinolin-4-ol of Formula XLVI is chlorinated using conventional chlorination chemistry to provide a 4-chloro-3-nitro[l,5]naphthyridine or 4-chloro-3-mtroquinoline of Formula XLVH
  • the reaction is conveniently carried out by treating the compound of Formula XLVI with phosphorous oxychloride in a suitable solvent such as DMF.
  • the reaction can be carried out at ambient temperature or at an elevated temperature such as
  • step (5) of Reaction Scheme VILL a 4-chloro-3 -nitro [l,5]naphthyridine or 4- chloro-3-nitroquinoline of Formula XLVH is treated with an amine of Formula R 1 -NH 2 to provide a compound of Formula XX Vm.
  • amines of Formula R ⁇ -NH 2 are commercially available; others can be prepared by known synthetic methods.
  • the reaction is conveniently carried out by adding the amine of Formula R ⁇ -NH 2 to a solution of the 4- chloro-3-nitro[l,5]naphthyridine or 4-chloro-3-nitroquinoline of Formula XLVII in a suitable solvent such as dichloromethane in the presence of a tertiary amine such as triethylamine.
  • a suitable solvent such as dichloromethane
  • the reaction can be carried out at ambient temperature or at a sub-ambient temperature such as, for example, 0 °C.
  • the reaction product can be isolated using conventional methods.
  • a compound of Formula XLVm is reduced to provide a diamine of Formula XLEX.
  • the reaction can be carried out by hydrogenation using a heterogeneous hydrogenation catalyst such as palladium on carbon or platinum on carbon.
  • the hydrogenation is conveniently carried out in a Parr apparatus in a suitable solvent such as toluene, methanol, acetonitrile, or ethyl acetate.
  • the prefened catalyst is platinum on carbon.
  • the reaction can be carried out at ambient temperature, and the product can be isolated using conventional methods.
  • the reduction in step (6) can be carried out using nickel boride, prepared in situ from sodium borohydride and nickel(II) chloride.
  • the reduction is conveniently carried out by adding a solution of a compound of Formula XLVm in a suitable solvent or solvent mixture such as dichloromethane/methanol to a mixture of excess sodium borohydride and catalytic nickel(H) chloride in methanol.
  • the reaction can be carried out at ambient temperature.
  • the product can be isolated using conventional methods.
  • step (7) of Reaction Scheme VflT a diamine of Formula XLLX, is reacted with a carboxylic acid equivalent to provide a lH-imidazo[4,5-c][l,5]naphthyridine or 1H- imidazo[4,5-c]quinoline of Formula L.
  • the carboxylic acid or equivalent is selected such that it will provide the desired -X-Hal substituent in a compound of Formula L and the reaction can be carried out as described in step (1) of Reaction Scheme I.
  • an acid chloride for example chloroacetyl chloride
  • the reaction can be carried out in two steps.
  • Part (i) of step (7) is conveniently carried out by adding the acid chloride to a solution of a diamine of Formula XLIX in a suitable solvent such as dichloromethane, chloroform, or acetonitrile.
  • a tertiary amine such as triethylamine, pyridine, or 4-dimethylaminopyridine can be added.
  • the reaction can be carried out at ambient temperature.
  • the amide product or the salt thereof can be isolated and optionally purified using conventional techniques.
  • Part (ii) of step (7) involves heating the amide prepared in part (i) in the presence of base to provide a lH-imidazo[4,5- c][l,5]naphthyridine or lH-imidazo[4,5-c]quinoline of Formula L.
  • the reaction is conveniently carried out in a suitable solvent such as ethanol in the presence of a base such aqueous sodium hydroxide, aqueous potassium carbonate, or triethylamine at elevated temperature, hi some instances, the product of Formula L may be obtained directly from Part (i).
  • a diamine of Formula XLIX can be treated with ethyl chloroacetimidate hydrochloride as the carboxylic acid equivalent to provide a compound wherein X is methylene.
  • the reaction is carried out in a suitable solvent such as chloroform at ambient temperature and the product of Formula L can be isolated using conventional methods.
  • Ethyl chloroacetimidate hydrochloride is a known compound that can be prepared according to the literature procedure: Stillings, M. R. et al., J. Med.
  • a halogen-substituted lH-imidazo[4,5- c][l,5]naphthyridine or lH-imidazo [4, 5 -c] quinoline of Formula L can be converted into phthalimide-substituted lH-imidazo[4,5-c][l,5]naphthyridin-4-amine or lH-imidazo[4,5- c]quinolin-4-amine of Formula Lm using the chemistry described in steps (2) - (4) of
  • Steps (8) and (9) can alternatively be combined and carried out as a one-pot procedure by adding 3-chloroperoxybenzoic acid to a solution of a compound of Formula L in a solvent such as dichloromethane or chloroform and then adding ammomum hydroxide and j-toluenesulfonyl chloride without isolating the N-oxide of Formula LL
  • a solvent such as dichloromethane or chloroform
  • a phthalimide-substituted ⁇ H- imidazo[4,5-c][l,5]naphthyridin-4-amine or lH-imidazo[4,5-c]quinolin-4-amine of Formula Lm is converted to a hydroxylamine-subsitituted lH-imidazo[4,5- c][l,5]naphthyridin-4-amine or lH-imidazo[4,5-c]quinolm-4-amine of Formula LIV which is condensed with an aldehyde or ketone to form an oxime of Formula LV, sequentially using the chemistry described in steps (5) and (6) of Reaction Scheme I.
  • an oxime of Formula LV is reduced to provide a hydroxylamine of Formula LVI, a subgenus of Formulas I and II.
  • the reduction is conveniently carried out by treating the oxime of Formula LV with excess sodium cyanoborohydride in a suitable solvent or solvent mixture such as methanol/acetic acid.
  • a suitable solvent or solvent mixture such as methanol/acetic acid.
  • hydrochloric acid may be added.
  • the reaction can be carried out at ambient temperature or at elevated temperature.
  • the product or pharmaceutically acceptable salt thereof can be isolated using conventional methods.
  • step (14) of Reaction Scheme VAX a hydroxylamine of Formula LVI is converted to a compound of Formula LVH, a subgenus of Formulas I and H
  • the reaction is carried out using one of the methods described in Reaction Scheme V or step (2) of Reaction Scheme VI.
  • the product or pharmaceutically acceptable salt thereof can be isolated using conventional methods.
  • a compound of Formula LIV can be converted to a compound of Formula LVLH, a subgenus of Formulas I and H, as shown in step (12a) of Reaction Scheme VIH.
  • the transformation is conveniently carried out by using the conditions described in Reaction Scheme V and step (2) of Reaction Scheme VI.
  • the product or pharmaceutically acceptable salt thereof can be isolated using conventional methods.
  • a compound of Formula LVm is alkylated to provide a compound of Formula LVH.
  • the reaction can be carried out with an alkylating agent that is generated in situ from an alcohol of Formula R 2a -OH under Mitsunobu reaction conditions (described in step (6) of Reaction Scheme HT) or an alkylating agent of Formula R 2a -Br or ⁇ -I in the presence of a base such as cesium carbonate in a suitable solvent such as DMF.
  • the latter reaction may be carried out at ambient temperature for reactive alkylating agents such as, for example, methyl iodide, benzyl bromide, and substituted benzyl bromides, or at an elevated temperature.
  • catalytic tetrabutylammonium hydrogensulfate can be added.
  • the product or pharmaceutically acceptable salt thereof can be isolated by conventional methods.
  • One skilled in the art would recognize that the reactions described for the alkylation step would probably not be successful for R 2a groups that are difficult to introduce via bimolecular nucleophihc substitution reactions. These groups include, for example, sterically hindered alkyl groups.
  • a reagent of the Formula P-0-R. 7 C(O)Cl, wherein P is a protecting group may react with a compound of Formula LIV to generate an isolable intermediate that can then be deprotected to yield a hydroxyalkanamide.
  • the isolable hydroxyalkanamide is cyclized under Mitsunobu conditions, described in step (6) of Reaction Scheme HI.
  • the product or phannaceutically acceptable salt thereof can be isolated using conventional methods.
  • R 1 -NH2, used in step (5) of Reaction Scheme VIH may contain a protected functional group, such as a tert-butoxycarbonyl-protected amino group.
  • the protecting group maybe removed after step (14) of Reaction Scheme V to reveal an amine on the Ri group.
  • An amino group introduced in this manner may be further functionalized using the chemistry described in steps (5) and (5a) of Reaction Scheme H to provide compounds of the
  • the amine of Formula R 1 -NH2 used in step (5) of Reaction Scheme Vm may contain an appropriately-protected hydroxyl group, for example, a tert- butyldimethylsilyl-protected hydroxyl group.
  • the protecting group may be removed after step (14) in Reaction Scheme VIH to provide an alcohol on the Ri group.
  • An alcohol introduced in this manner into a compound of Formula LVH may be converted into a hydroxylamine upon treatment with N-hydroxyphthalimide using the Mitsunobu reaction conditions described in step (6) of Reaction Scheme HI, followed by deprotection of the resulting phthalimide-protected hydroxylamine with hydrazine in ethanol.
  • a hydroxylamine on the Ri group can undergo reaction with a ketone or aldehyde of Fonnula R ⁇ 'C(O)R ⁇ " to form an oxime using the reaction conditions described in step (6) of
  • a hydroxylamine on the Ri group of a compound of Formula LVH, prepared as described above, can also be further functionalized to a compound of the Formula LVH in which Ri is -X"-O-NR ⁇ a -Y'-R ⁇ b wherein Y' is -C(O)-, -S(O) 2 -, -C(O)-N(R 8 >,
  • R ia is hydrogen
  • R ⁇ b is as defined above using, respectively, an acid chloride, a sulfonyl chloride or a sulfonic anhydride; an isocyanate; an acyl isocyanate, an isothiocyanate, a sulfonyl isocyanate, a carbamoyl chloride, or a sulfamoyl chloride.
  • the reaction can be carried out using the conditions described in step (5) of Reaction Scheme H.
  • a large number of the reagents listed above are commercially available; others can be readily prepared using known synthetic methods.
  • a compound of Formula LVH in which Ri is -X"-O-NR ⁇ a -Y'-R ⁇ b wherein Y' is a bond, -C(O)-, -C(S)-, -S(O) 2 -, or -C(O)-C(O)-; R l is defined above, and R is hydrogen, can be derivatized further upon treatment with an alkylating agent that is generated in situ from an alcohol of Formula R ⁇ a -OH under Mitsunobu reaction conditions or an alkylating agent of Formula R ⁇ a -Br or R ⁇ a -I as described in step (13a) above.
  • R 7 or 7 can be prepared in a two-step procedure from a compound of Formula LVH in which Ri is -X"-0-NH 2 , using one of the methods described in step 5a of Reaction Scheme H or step 13a above.
  • Reaction Scheme LX wherein D, E, R, Ri, R 2 , R 2a , X, and Y'are as defined above, m is 1, n is 0 or 1, and R 3b and R 3c are as defined below.
  • step (1) is used to react a lH-imidazo[4,5-c]quinoline-4-amine or lH-imidazo[4,5-c][l,5]naphthyridine-4- amine of Formula LV ⁇ using known palladium-catalyzed coupling reactions such as the Suzuki coupling and the ⁇ eck reaction.
  • a bromo or iodo-substituted compound of Fonnula LV ⁇ undergoes Suzuki coupling with a boronic acid of Formula
  • R 3a -B(O ⁇ ) 2 an anhydride thereof, or a boronic acid ester of Formula R 3a -B(O-alkyl) 2 , wherein R a is as defined above, according to the method described in Reaction Scheme IV.
  • the product of Formula LIX, a subgenus of Formulas I and H wherein R 3b is the same as R a , or a pharmaceutically acceptable salt thereof, can be isolated by conventional methods.
  • the Heck reaction can also be used in step (1) of Reaction Scheme IX to provide compounds of Formula LLX, wherein R 3 is -X R ⁇ and -XVY-R 4 , wherein X' a , Y, R 4 , and ⁇ are as defined above.
  • the reaction is conveniently carried out by combining the compound of Formula LVH and the vinyl-substituted compound in the presence of palladium (TT) acetate, triphenylphosphine or tri-ortAo-tolylphosphine, and a base such as triethylamine in a suitable solvent such as acetonitrile or toluene.
  • TT palladium
  • triphenylphosphine or tri-ortAo-tolylphosphine a base
  • a base such as triethylamine
  • a suitable solvent such as acetonitrile or toluene
  • the reduction can be carried out by hydrogenation using a conventional heterogeneous hydrogenation catalyst such as palladium on carbon.
  • a conventional heterogeneous hydrogenation catalyst such as palladium on carbon.
  • the reaction can conveniently be carried out on a Pan apparatus in a suitable solvent such as ethanol, methanol, or mixtures thereof.
  • the product or pharmaceutically acceptable salt thereof can be isolated using conventional methods.
  • Compounds of Formula LVH wherein D is -OCH 2 Ph can be converted in Reaction
  • step (la) of Reaction Scheme DC the benzyl group in a lH-imidazo[4,5-c]quinoline-4-amine or 1H- imidazo[4,5-c][l,5]naphthyridine-4-amine of Formula LV ⁇ , wherein D is -OC ⁇ 2 Ph, is cleaved to provide a hydroxy group.
  • the cleavage is conveniently carried out on a Pan apparatus under hydrogenolysis conditions using a suitable heterogeneous catalyst such as palladium or platinum on carbon in a solvent such as ethanol.
  • the reaction can be carried out by transfer hydrogenation in the presence of a suitable hydrogenation catalyst.
  • the transfer hydrogenation is conveniently carried out by adding ammomum formate to a solution of a compound of Formula LVH in a suitable solvent such as ethanol in the presence of a catalyst such as palladium on carbon.
  • the reaction is carried out at an elevated temperature, for example, the refluxing temperature of the solvent.
  • the product of Formula LX, a subgenus of Formulas I and H, or pharmaceutically acceptable salt thereof can be isolated using conventional methods.
  • step (2) of Reaction Scheme IX a hydroxy-substituted lH-imidazo[4,5- c]quinoline-4-amine or lH-imidazo[4,5-c][l,5]naphthyridine-4-amine of Formula LX is converted to a compound of Formula LXI, a subgenus of Formula I and ⁇ wherein R 3c is -O-Rft, -O-X'-R/j, -O-X'-Y-Ri, or -O-X'-R 5 , using a Williamson-type ether synthesis.
  • the reaction is effected by treating a hydroxy-substituted lH-imidazo[4,5-c]quinoline-4-amine or lH-imidazo[4,5-c][l,5]naphthyridine-4-amine of Formula LX with an aryl, alkyl, or arylalkylenyl halide of Formula Halide-Rn,, Halide-alkylene-R ⁇ , Halide-alkylene-Y-R 4 , or Halide-alkylene-R 5 in the presence of a base.
  • alkyl, arylalkylenyl, and aryl halides of these formulas are commercially available, including substituted benzyl bromides and chlorides, substituted or unsubstituted alkyl or arylalkylenyl bromides and chlorides, and substituted fluorobenzenes.
  • Other halides of these formulas can be prepared using conventional synthetic methods. The reaction is conveniently carried out by combining an alkyl, arylalkylenyl, or aryl halide with the hydroxy-substituted compound of Fonnula LX in a solvent such as DMF in the presence of a suitable base such as cesium carbonate.
  • step (2) may be carried out using the Ullmann ether synthesis, in which an alkali metal aryloxide prepared from the hydroxy-substituted compound of Formula LX reacts with an aryl halide in the presence of copper salts, to provide a compound of Formula LXI, where R 3c is -O-R ⁇ , -O-XVR 4 , or -O-X Y-R4 5 wherein X' f is an arylene or heteroarylene.
  • Numerous substituted and unsubstituted aryl halides are commercially available; others can be prepared using conventional methods.
  • the product of Formula LXI, prepared by either of these methods, or pharmaceutically acceptable salt thereof can be isolated using conventional methods.
  • compounds of the invention are prepared according to Reaction Scheme X, where R ls R 2 , R 2 ', R 2 ", R 2a , X, Y' , R A2 , R B2 , and Hal are as defined above, and Ph is phenyl.
  • step (1) of Reaction Scheme X a 2,4-dichloro-3-nitropyridine of Formula LXH is reacted with an amine of the Formula to form a 2-chloro-3- nitropyridine of Formula LXH
  • the reaction is conveniently carried out by combining an amine of Fonnula ⁇ N-Ri and a 2,4-dichloro-3-nitropyridine of Formula LXH in the presence of a base such as triethylamine in an inert solvent such as DMF.
  • the reaction can be carried out at ambient temperature, and the product can be isolated from the reaction mixture using conventional methods.
  • Many amines of Formula are commercially available; others can be prepared by known synthetic methods.
  • a 2-chloro-3-nitropyridine of Formula LXTH is reacted with an alkali metal azide to provide an 8-nitrotetrazolo[l,5- ⁇ ]pyridin-7-amine of Formula LXTV.
  • the reaction can be carried out by combining the compound of Formula LXTH with an alkali metal azide, for example, sodium azide, in a suitable solvent such as acetonixrile/water, preferably 90/10 acetonitrile ⁇ vater, in the presence of cerium(m) chloride, preferably cerium(IH) chloride heptahydrate.
  • the reaction can be carried out with heating, for example, at the reflux temperature.
  • the reaction can be carried out by combining the compound of Formula LXTH with an alkali metal azide, for example, sodium azide, in a suitable solvent such as DMF and heating, for example to about 50 °C -60 °C, optionally in the presence of ammonium chloride.
  • an alkali metal azide for example, sodium azide
  • DMF a suitable solvent
  • heating for example to about 50 °C -60 °C, optionally in the presence of ammonium chloride.
  • the product can be isolated from the reaction mixture using conventional methods.
  • step (3) of Reaction Scheme X an 8-nitrotetrazolo[l,5- ⁇ ]pyridin-7-amine of Fomiula LXTV is reduced to provide a compound of Formula LXV.
  • the reaction can be carried out by hydrogenation using a heterogeneous hydrogenation catalyst such as palladium on carbon or platinum on carbon.
  • the hydrogenation is conveniently carried out in a Pan apparatus in a suitable solvent such as toluene, methanol, acetonitrile, or ethyl acetate.
  • the reaction can be carried out at ambient temperature, and the product can be isolated using conventional methods.
  • step (4) of Reaction Scheme X a tetrazolo[l,5-a]pyridine-7,8-diamine of Formula LXV, is reacted with a carboxylic acid or an equivalent thereof to provide a 7H- imidazo[4,5-c]tetrazolo[l,5- ⁇ ]pyridine of Formula LXVI.
  • the carboxylic acid or equivalent is selected such that it will provide the desired -X- ⁇ al substituent in a compound of Formula LXVI.
  • the reaction can be carried out as described in step (7) of
  • Reaction Scheme V ⁇ L The product can be isolated using conventional methods.
  • h step (5) of Reaction Scheme X a 7H-imidazo[4,5-c]tetrazolo[l,5- ⁇ ]pyridine of Formula LXVI is treated with N-hydroxyphthalimide to provide a compound of Formula LXV ⁇ , which contains a N-phthalimide-protected hydroxylamine.
  • the reaction is conveniently carried out as described in step (4) of Reaction Scheme I.
  • the product or a pharmaceutically acceptable salt thereof can be isolated using conventional methods.
  • step (6) of Reaction Scheme X the N-phthalimide-protected hydroxylamine of Formula LXV ⁇ is treated with hydrazine in a suitable solvent such as ethanol to provide a hydroxylamine of Formula LXV ⁇ I.
  • a suitable solvent such as ethanol
  • the reaction can be carried out at ambient temperature and the product can be isolated from the reaction mixture using conventional methods.
  • step (7) Reaction Scheme X the hydroxylamine group in a 7H-imidazo[4,5- c]tetrazolo[l,5-fl]pyridine of Formula LXV ⁇ I reacts with an aldehyde or ketone of Formula R 2 'C(O)R 2 M to provide an oxime of Formula LXIX.
  • the reaction can be carried out using the conditions described above in step (6) of Reaction Scheme I and the product can be isolated from the reaction mixture using conventional methods.
  • step (8) of Reaction Scheme X the tetrazolo ring is removed from a 7H- imidazo[4,5-c]tetrazolo[l,5- ⁇ ]pyridine of Formula LXIX by reaction with triphenylphosphine to form an N-triphenylphosphinyl intermediate of Formula LXX.
  • the reaction with triphenylphosphine can be run in a suitable solvent such as toluene or 1,2- dichlorobenzene under an atmosphere of nitrogen with heating, for example at the reflux temperature.
  • an N-triphenylphosphinyl intermediate of Formula LXX is hydrolyzed to provide an oxime-substituted lH-imidazo[4,5-c]pyridin-4- amine of Formula LXXI.
  • the hydrolysis can be carried out by general methods well known to those skilled in the art, for example, by heating in a lower alkanol or an alkanol/water solution in the presence of an acid such as trifluoroacetic acid, acetic acid, or hydrochloric acid.
  • the product can be isolated from the reaction mixture using conventional methods as the compound of Formula LXXI or as a pharmaceutically acceptable salt thereof.
  • a compound of the Formula LXXI may also be obtained through an alternative two-step route from a compound of Formula LXV ⁇ .
  • step (6a) of Reaction Scheme X a compound of Formula LXV ⁇ is treated sequentially according to the reaction conditions described in steps (8) and (9) of Reaction Scheme X using hydrochloric acid as the acid in step (9). Under these reaction conditions, the N-phthalimide is removed to provide the hydroxylamine-substituted lH-imidazo[4,5-c]pyridin-4-amine of Formula LXX ⁇ .
  • the product can be isolated and purified using conventional methods.
  • step (7a) of Reaction Scheme X a hydroxylamine-substituted lH-imidazo[4,5- c]pyridin-4-amine of Formula LXX ⁇ reacts with an aldehyde or ketone of Formula R 2 'C(O)R 2 " to provide an oxime of Formula LXXI.
  • the reaction can be earned out using the conditions described above in step (6) of Reaction Scheme I, and the product or the pharmaceutically acceptable salt thereof can be isolated from the reaction mixture using conventional methods.
  • step (10) of Reaction Scheme X the oxime of Formula LXXI is reduced using the conditions described in step (7) of Reaction Scheme I to afford a compound of Formula LXXIH, a subgenus of Formulas I, H, and VI.
  • the product or pharmaceutically acceptable salt thereof can be isolated by conventional methods.
  • step (11) of Reaction Scheme X a hydroxylamine of Formula LXXIH is converted into a compound of Formula LXXIV, a subgenus of Formulas I, H, and VI, using the reagents and conditions described in Reaction Scheme V or step (2) of Reaction Scheme VI.
  • the product or pharmaceutically acceptable salt thereof can be isolated by conventional methods.
  • steps (10a) and (Ila) of Reaction Scheme X a hydroxylamine of Formula LXXH is converted into a compound of Formula LXXIV using the reagents and methods described in steps (12a) and (13a), respectively, of Reaction Scheme VHL
  • the product or pharmaceutically acceptable salt thereof can be isolated by conventional methods.
  • amines of Formula R ⁇ -NH 2 used in step (1) of Reaction Scheme X, may contain a protected functional group, such as a tert-butoxycarbonyl-protected amino group.
  • the protecting group may be removed later in Reaction Scheme X after step (4) to reveal, for example, an amine on the Ri group of a compound of Formula LXVI.
  • compositions of the invention contain a therapeutically effective amount of a compound or salt of the invention as described above in combination with a pharmaceutically acceptable carrier.
  • a therapeutically effective amount and “effective amount” mean an amount of the compound or salt sufficient to induce a therapeutic or prophylactic effect, such as cytokine induction, immunomodulation, antitumor activity, and/or antiviral activity.
  • a therapeutic or prophylactic effect such as cytokine induction, immunomodulation, antitumor activity, and/or antiviral activity.
  • the exact amount of active compound or salt used in a pharmaceutical composition of the invention will vary according to factors known to those of skill in the art, such as the physical and chemical nature of the compound or salt, the nature of the carrier, and the intended dosing regimen, it is anticipated that the compositions of the invention will contain sufficient active ingredient to provide a dose of about 100 nanograms per kilogram (ng/kg) to about 50 milligrams per kilogram (mg/kg), preferably about 10 micrograms per kilogram ( ⁇ g/kg) to about 5 mg/kg, of the compound or salt to the subject.
  • a variety of dosage forms maybe used, such as tablets, lozenges, capsules
  • the compounds or salts of the invention can be administered as the single therapeutic agent in the treatment regimen, or the compounds or salts of the invention may be administered in combination with one another or with other active agents, including additional immune response modifiers, antivirals, antibiotics, antibodies, proteins, peptides, oligonucleotides, etc.
  • Cytokines whose production may be induced by the administration of compounds or salts of the invention generally include interferon- ⁇ (IFN- ⁇ ) and/or tumor necrosis factor- ⁇ (TNF- ⁇ ) as well as certain interleukins (TL). Cytokines whose biosynthesis may be induced by compounds or salts of the invention include IFN- ⁇ , TNF- ⁇ , IL-1, TL-6, EL- 10 and H-12, and a variety of other cytokines. Among other effects, these and other cytokines can inhibit virus production and tumor cell growth, making the compounds or salts useful in the treatment of viral diseases and neoplastic diseases.
  • IFN- ⁇ interferon- ⁇
  • TNF- ⁇ tumor necrosis factor- ⁇
  • TL-6 interleukins
  • the invention provides a method of inducing cytokine biosynthesis in an animal comprising administering an effective amount of a compound or salt or composition of the invention to the animal.
  • the animal to which the compound or salt or composition is administered for induction of cytokine biosynthesis may have a disease as described infra, for example a viral disease or a neoplastic disease, and administration of the compound or salt may provide therapeutic treatment.
  • the compound or salt may be administered to the animal prior to the animal acquiring the disease so that administration of the compound or salt may provide a prophylactic treatment.
  • compounds or salts of the invention can affect other aspects of the innate immune response. For example, natural killer cell activity may be stimulated, an effect that may be due to cytokine induction.
  • the compounds or salts may also activate macrophages, which in turn stimulate secretion of nitric oxide and the production of additional cytokines. Further, the compounds or salts may cause proliferation and differentiation of B-lymphocytes.
  • T helper type 1 T R T
  • T helper type 2 T H 2
  • H-5 and H-13 maybe inhibited upon administration of the compounds or salts.
  • TNF- ⁇ tumor necrosis factor- ⁇
  • the invention provides a method of inhibiting TNF- ⁇ biosynthesis in an animal comprising administering an effective amount of a compound or salt or composition of the invention to the animal.
  • the animal to which the compound or salt or composition is administered for inhibition of TNF- ⁇ biosynthesis may have a disease as described infra, for example an autoimmune disease, and administration of the compound or salt may provide therapeutic treatment.
  • the compound or salt may be administered to the animal prior to the animal acquiring the disease so that administration of the compound or salt may provide a prophylactic treatment.
  • the compound or salt or composition may be administered alone or in combination with one or more active components as in, for example, a vaccine adjuvant.
  • the compound or salt and other component or components may be administered separately; together but independently such as in a solution; or together and associated with one another such as (a) covalently linked or (b) non-covalently associated, e.g., in a colloidal suspension.
  • Conditions for which IRMs identified herein may be used as treatments include, but are not limited to:
  • viral diseases such as, for example, diseases resulting from infection by an adenovirus, a herpesvirus (e.g., HSV-I, HSV-H, CMV, or VZV), a poxvirus (e.g., an orthopoxvirus such as variola or vaccinia, or molluscum contagiosum), a picornavirus
  • a herpesvirus e.g., HSV-I, HSV-H, CMV, or VZV
  • a poxvirus e.g., an orthopoxvirus such as variola or vaccinia, or molluscum contagiosum
  • a picornavirus e.g., an orthopoxvirus such as variola or vaccinia, or molluscum contagiosum
  • a coronavims e.g., SARS
  • a papovaviras e.g., papillomaviruses, such as those that cause genital warts, common warts, or plantar warts
  • a hepadnavirus e.g., hepatitis B virus
  • a flavivirus e.g., hepatitis C virus or Dengue virus
  • a retrovirus e.g., a lentivirus such as HIV
  • bacterial diseases such as, for example, diseases resulting from infection by bacteria of, for example, the genus Escherichia, Enterobacter, Salmonella, Staphylococcus, Shigella, Listeria, Aerobacter, Helicobacter, Klebsiella, Proteus, Pseudomonas, Streptococcus, Chlamydia, Mycoplasma, Pneumococcus, Neisseria, Clostridium, Bacillus,
  • infectious diseases such as chlamydia, fungal diseases including but not limited to candidiasis, aspergillosis, histoplasmosis, cryptococcal meningitis, or parasitic diseases including but not limited to malaria, pneumocystis carnii pneumonia, leishmaniasis, cryptosporidiosis, toxoplasmosis, and trypanosome infection;
  • neoplastic diseases such as intraepithelial neoplasias, cervical dysplasia, actinic keratosis, basal cell carcinoma, squamous cell carcinoma, renal cell carcinoma, Kaposi's sarcoma, melanoma, leukemias including but not limited to myelogeous leukemia, chronic lymphocytic leukemia, multiple myeloma, non-Hodgkin's lymphoma, cutaneous T-cell lymphoma, B-cell lymphoma, and hairy cell leukemia, and other cancers; (e) T ⁇ 2-mediated, atopic diseases, such as atopic dermatitis or eczema, eosinophilia, asthma, allergy, allergic rhinitis, and Ommen's syndrome;
  • atopic diseases such as atopic dermatitis or eczema, eosinophilia, asthma, allergy, allergic rhinitis, and Ommen
  • autoimmune diseases such as systemic lupus erythernatosus, essential thrombocythaemia, multiple sclerosis, discoid lupus, alopecia areata; and (g) diseases associated with wound repair such as, for example, inhibition of keloid formation and other types of scarring (e.g., enhancing wound healing, including chronic wounds).
  • an IRM compound or salt of the present invention maybe useful as a vaccine adjuvant for use in conjunction with any material that raises either humoral and/or cell mediated immune response, such as, for example, live viral, bacterial, or parasitic immunogens; inactivated viral, tumor-derived, protozoal, organism-derived, fungal, or bacterial immunogens, toxoids, toxins; self-antigens; polysaccharides; proteins; glycoproteins; peptides; cellular vaccines; DNA vaccines; autologous vaccines; recombinant proteins; and the like, for use in connection with, for example, BCG, cholera, plague, typhoid, hepatitis A, hepatitis B, hepatitis C, influenza A, influenza B, parainfluenza, polio, rabies, measles, mumps, rubella, yellow fever, tetanus, diphtheria, hemophilus influenza b, tuberculosis, mening
  • Certain IRM compounds or salts of the present invention maybe particularly helpful in individuals having compromised immune function.
  • certain compounds or salts may be used for treating the opportunistic infections and tumors that occur after suppression of cell mediated immunity in, for example, transplant patients, cancer patients and HTV patients.
  • one or more of the above diseases or types of diseases may be treated in an animal in need thereof (having the disease) by administering a therapeutically effective amount of a compound or salt of the invention to the animal.
  • An amount of a compound or salt effective to induce or inhibit cytokine biosynthesis is an amount sufficient to cause one or more cell types, such as monocytes, macrophages, dendritic cells and B-cells to produce an amount of one or more cytokines such as, for example, IFN- ⁇ , TNF- ⁇ , IL-1, T -6, TL-10 and H-12 that is increased (induced) or decreased (inhibited) over a background level of such cytokines.
  • the precise amount will vary according to factors known in the art but is expected to be a dose of about 100 ng/kg to about 50 mg/kg, preferably about 10 ⁇ g/kg to about 5 mg/kg.
  • the invention also provides a method of treating a viral infection in an animal and a method of treating a neoplastic disease in an animal comprising administering an effective amount of a compound or salt or composition of the invention to the animal.
  • An amount effective to treat or inhibit a viral infection is an amount that will cause a reduction in one or more of the manifestations of viral infection, such as viral lesions, viral load, rate of virus production, and mortality as compared to untreated control animals.
  • an amount of a compound or salt effective to treat a neoplastic condition is an amount that will cause a reduction in tumor size or in the number of tumor foci.
  • the precise amount will vary according to factors known in the art but is expected to be a dose of about 100 ng/kg to about 50 mg/kg, preferably about 10 ⁇ g/kg to about 5 mg/kg.
  • N 4 -(2-Methylpropyl)quinoline-3,4-diamine 41 g
  • dichloromethane 550 mL
  • triethylamine 40 mL, 1.5 eq
  • chloroacetyl chloride 16.7 mL, 1.1 eq.
  • the reaction mixture was diluted with 1,2-dichloroethane (75 mL) and then washed with saturated aqueous sodium bicarbonate (3 x 400 mL).
  • the reaction mixture was stirred at ambient temperature for 1 hour and then filtered to remove a precipitate.
  • the filtrate was transfened to a separatory funnel and the layers were separated.
  • the aqueous layer was extracted with dichloromethane (2 x 100 mL).
  • the combined organics were dried over magnesium sulfate, filtered through a layer of CELITE filter aid, and then concentrated under reduced pressure to provide 16 g of crade product as a yellow foam.
  • the foam was dissolved in 10% methanol in dichloromethane (20 mL).
  • the solution was divided and loaded onto two FLASH 40+M silica cartridges (90 g), (available from Biotage, Inc, Charlottesville, Virginia, USA).
  • the cartridges were eluted sequentially with IL 1 :1 ethyl acetate:hexanes, 2% methanol in 1:1 ethyl acetate :hexanes, and 5% methanol in 1:1 ethyl acetate:hexanes.
  • the fractions containing product were combined and then concentrated under reduced pressure to provide 6.4 g of 2-chloromethyl-l -(2-methylpropyl)- 1H- imidazo[4,5-c]quinolin-4-amine as an orange foam.
  • Triethylamine (536 mg, 5.19 mmol) was added to a solution of N- hydroxyphthalimide (678 mg, 4.16 mmol) in N,N-dimethylformamide (DMF); after 5 minutes a solution of 2-chloromethyl-l-(2-methylpropyl)-lH-imidazo[4,5-c]quinolin-4- amine (1 g) in DMF (10 mL) was added. The reaction mixture was stined at ambient temperature for 2 hours. The reaction mixture was diluted with dichloromethane (50 mL) and then washed with water (1 x 100 mL).
  • aqueous layer was extracted with dichloromethane (2 x 50 mL) and ethyl acetate (1 x 50 mL).
  • the combined organics were dried over magnesium sulfate, filtered through a layer of CELITE filter aid, and then concentrated under reduced pressure to provide 1.8 g of crade product as a yellow solid.
  • the solid was dissolved in 5% methanol in chloroform (10 mL) and loaded onto a FLASH 40+M silica cartridge (90 g).
  • the cartridge was eluted sequentially with IL 1% methanol in chloroform and 3% methanol in chloroform.
  • the fractions containing the desired product were combined and then concentrated under reduced pressure to provide 950 mg of a yellow solid.
  • the filter cake was washed with several portions of dichloromethane.
  • the filtrate was concentrated under reduced pressure to provide 40 g of crude product as a brown semi- solid.
  • the solid was partitioned between IM aqueous hydrochloric acid (300 mL) and dichloromethane (100 mL). The layers were separated.
  • the aqueous layer was extracted with dichloromethane (2 x 100 mL). Analysis by liquid chromatography/mass spectroscopy (LCMS) showed that the organics did not contain product.
  • the aqueous layer was made basic (pH -10) with solid sodium carbonate and then extracted with dichloromethane (3 x 100 mL).
  • the resulting precipitate was isolated by filtration and then partitioned between dichloromethane (50 mL) and saturated aqueous sodium bicarbonate (50 mL). The aqueous layer was extracted with dichloromethane (3 x 50 mL). The combined organics were concentrated under reduced pressure to provide 500 mg of a foam. This material was dissolved in dichloromethane (50 mL) and then combined with 4M hydrochloric acid in dioxane (30 mL). A precipitate formed. The mixture was concentrated and then dissolved in hot ethanol. The solution was allowed to cool to ambient temperature, chilled (-10 °C) in a freezer overnight, and then allowed to warm to ambient temperature.
  • Triethylamine (1.47 mL, 10.5 mmol) was added to a solution of O- ⁇ [4-amino-l-(2- methylpropyl)-lH-imidazo[4,5-c]quinolin-2-yl]methyl ⁇ hydroxylamine (1.5 g, 5.3 mmol) in dichloromethane (50 mL). Methanesulfonyl chloride (0.448 mL, 5.78 mmol) was added and the reaction mixture was stined at ambient temperature for 2 hours.
  • the reaction mixture was washed with saturated aqueous sodium bicarbonate (1 x 30 mL) and brine (1 x 30 mL), dried over magnesium sulfate, filtered, and then concentrated under reduced pressure to provide 2.16 g of crade product as a brown foam.
  • This material was dissolved in dichloromethane (10 mL) and then loaded onto a FLASH 40+S silica cartridge (4O g). The cartridge was eluted sequentially with 500 mL ethyl acetate, 2%, 3%, and 5% methanol in ethyl acetate. The fractions containing product were combined and then concentrated under reduced pressure to provide 850 mg of a yellow solid.
  • the cartridge was eluted sequentially with 500 mL 2%, 4%, 6%, and 8% methanol in ethyl acetate. The fractions containing product were combined and then concentrated under reduced pressure to provide 880 mg of a yellow solid. This solid was recrystallized from acetonitrile, isolated by filtration, washed with acetonitrile and diethyl ether, and then dried under high vacuum to provide 365 mg of N- ⁇ [4-amino-l-(2-methylpropyl)-lH-imidazo[4,5-c]quinolin-2- yl]methoxy ⁇ -N '-isopropylurea as a light yellow crystalline solid, mp 218-219 °C.
  • the cartridges were eluted sequentially with 1 L 1:1 ethyl acetate :hexanes, 5% methanol in 1:1 ethyl acetate :hexanes, and 10% methanol in 1:1 ethyl acetate :hexanes.
  • the fractions containing product were combined and concentrated under reduced pressure to provide 8.96 g of tert-butyl [3-(2-chloromethyl-lH-imidazo[4,5- c] quinolin- 1 -yl)propyl] carbamate as a light brown foam.
  • the reaction mixture was stined at ambient temperature for 2 hours; an additional 1 g of para- toluensulfonyl chloride was added and the reaction mixture was stined for another hour.
  • the reaction mixture was filtered to remove solids. The filtrate was transfened to a separatory funnel and the layers were separated.
  • the organic layer was washed with 1:1 water: saturated aqueous sodium bicarbonate (2 x 150 mL).
  • the combined aqueous was extracted with dichloromethane (2 x 150 mL) and ethyl acetate (1 x 100 mL).
  • the combined organic extracts were concentrated under reduced pressure to provide 13.6 g of crade product as a brown foam.
  • the foam was dissolved in dichloromethane (20 mL).
  • the solution was divided and loaded onto two FLASH 40+M silica cartridges (90 g).
  • the first cartridge was eluted sequentially with IL 1 :1 ethyl acetate :hexanes, 5% methanol in 1:1 ethyl acetate :hexanes, and 10% methanol in 1:1 ethyl acetate:hexanes.
  • the second cartridge was eluted sequentially with IL 1:1 ethyl acetate :hexanes, 7% methanol in 1:1 ethyl acetate :hexanes, and 7% methanol in 1:1 ethyl acetate:hexanes.
  • Trifluoroacetic acid (7 mL) was added to a suspension of tert-butyl [3-(4-amino-2- isopropylideneaminoxymethyl-lH-imidazo[4,5-c]quinolin-l-yl)propyl]carbamate (4.12 g) in dichloromethane (70 mL). The reaction became homogeneous and was stined at ambient temperature for 2.5 hours. More trifluoroacetic acid (10 mL) was added and the reaction was stined for another hour.
  • the table below shows the acid chloride, sulfonyl chloride, sulfamoyl chloride, carbamoyl chloride or isocyanate used for each example, the structure of the resulting compound, and the observed accurate mass for the isolated trifluoroacetate salt.
  • Acetone 25 mL was added to a suspension of the crude material from Part D in methanol (100 mL). The resulting solution was stined at ambient temperature for 3 hours and then concentrated under reduced pressure. The residue was azeotroped once with toluene, slurried with ethanol (100 mL) and then filtered. The filter cake was washed with additional ethanol. The filtrate was concentrated under reduced pressure to provide 3.9 g of product as a yellow solid. Additional product (0.9 g) was obtained by extracting the filter cake with dichloromethane.
  • Trifluoroacetic acid (10 mL) was added to a suspension of tert-butyl [2-(4-amino- 2-isopropylideneaminooxymethyl-lH-imidazo[4,5-c]quinolin-l-yl)ethyl]carbamate (4.8 g) in dichloromethane (100 mL). The reaction became homogeneous and was stined at ambient temperature. At 2.5 hours and 3.5 hours more trifluoroacetic acid (10 mL and 5 mL respectively) was added. After a total reaction time of 4 hours the reaction mixture was concentrated under reduced pressure.
  • Part ⁇ A portion (1 mL) of the solution from Part G was transfened to a fresh test tube and then the solvent was removed by vacuum centrifugation. Methanol (1 mL), glacial acetic acid (1 mL), and 300 ⁇ L of a 1.0 M solution of sodium cyanoborohydride in tetrahydrofuran were added to the test tube. The test tube was capped and placed on a shaker at ambient temperature overnight (approximately 18 hours). The solvent was removed by vacuum centrifugation. The compounds were purified by preparative high performance liquid chromatography (prep ⁇ PLC) using a Waters Fraction Lynx automated purification system using the method described above for Examples 4 - 42.
  • prep ⁇ PLC preparative high performance liquid chromatography
  • the crade product was purified by flash chromatography (silica gel, elution with 33% ethyl acetate in hexanes followed by 66% ethyl acetate in hexanes) to afford 9.2 g of tert-butyl 4-[(2-chloro-5,6- dimethyl-3-nitropyridin-4-yl)amino]butylcarbamate.
  • Ethyl 2-chloroethanimidoate hydrochloride (ethyl chloroacetimidate hydrochloride) (2.58 g, 16.4 mmol) was added to a solution of tert-butyl 4-[(8-amino-5,6- dimethyltetraazolo[l,5- ]pyridin-7-yl)amino]butylcarbamate (3.80 g, 10.9 mmol) in chloroform (75 mL). The solution was stined for 3 days, then saturated aqueous sodium bicarbonate (40 mL) was added. The aqueous phase was extracted with chloroform (3 x
  • Benzoic anhydride (3.1 g, 13.8 mmol) was added to a flask containing 4-[8- (chloromethyl)-5,6-dimethyl-7H-imidazo[4,5-c]tetraazolo[l,5- ⁇ ]pyridin-7-yl]butan-l- amine hydrochloride (4.30 g, 12.5 mmol), triethylamine (3.70 mL, 26.3 mmol), and dichloromethane (100 mL) at 0 °C. The reaction mixture was stined at room temperature for 1 day and additional triethylamine (0.5 mL) and benzoic anhydride (0.8 g) were added.
  • reaction mixture was stined for 6 hours at room temperature.
  • the volatiles were removed under reduced pressure and water (50 mL) followed by ethyl acetate (50 mL) were added to the solid residue.
  • the mixture was sonicated for 1 minute, then the solid was isolated by filtration, washed with water and ethyl acetate, and dried under vacuum to afford 4.7 g of N- ⁇ 4-[8-(chloromethyl)-5,6-dimethyl-7H-imidazo[4,5-c]tetraazolo[l,5- ⁇ ]pyridin-7-yl]butyl ⁇ benzamide.
  • N- ⁇ ydroxyphthalimide (2.60 g, 16.0 mmol) and triethylamine (2.20 mL, 16.0 mmmol) were added to a suspension of N- ⁇ 4-[8-(chloromethyl)-5,6-dimethyl-7H- imidazo[4,5-c]tetraazolo[l,5- ⁇ ]pyridin-7-yl]butyl ⁇ benzamide (4.70 g, 11.4 mmol) in DMF (285 mL).
  • the reaction mixture was allowed to stir for 3 days, then was concentrated under reduced pressure to a white slurry. Methanol was added and a white solid was isolated by filtration, washed with methanol, and dried under vacuum to afford 5.70 g of
  • the solid was purified by chromatography using a HORIZON HPFC system (an automated, modular high- performance flash purification product available from Biotage, ie, Charlottesville, Virginia, USA) (silica gel, gradient elution with 10-35% CM A in chloroform, where CM A is 80:18:2 chloroform/methanol/concentrated ammonium hydroxide). The appropriate fractions were combined and concentrated under reduced pressure.
  • HORIZON HPFC system an automated, modular high- performance flash purification product available from Biotage, ie, Charlottesville, Virginia, USA
  • CM A is 80:18:2 chloroform/methanol/concentrated ammonium hydroxide
  • the foam was purified by chromatography on a HORIZON HPFC system (silica gel, gradient elution with 3-35%) CM A in chloroform) followed by crystallization from acetonitrile. The crystals were isolated by filtration and dried under vacuum at 70 °C to yield 80 mg of N-
  • the crade material was not purified by chromatography, rather by trituration with acetonitrile.
  • the purified product was isolated by filtration and was dried under vacuum to afford N-[4-(4-amino-2- ⁇ [(isopropylamino)oxy]methyl ⁇ -6,7-dimethyl-lH-imidazo[4,5- cjpyridin- 1 -yl)butyl]-2-methylpropanamide as a white powder, mp 156.0-157.0 °C.
  • Triethylamine (50.0 mL, 360 mmol) was added to a suspension of 4-chloro-3- nitroquinoline (50.0 g, 240 mmol) in DMF (200 mL), followed by dropwise addition of a solution of l-amino-2-methyl-propan-2-ol (23.5 g, 264 mmol) in DMF (50 mL). The reaction mixture was stined overnight at room temperature, then water (500 mL) was added and stirring was continued for 30 minutes.
  • Part B A mixture of 2-methyl-l-[(3-nitroquinolin-4-yl)amino]propan-2-ol (60.9 g, 233 mmol), 5% platinum on carbon (6.1 g), and ethanol (500 mL) was hydrogenated on a Parr apparatus at 30 psi (2.1 x 10 5 Pa) for 3 hours. The mixture was filtered through CELITE filter agent, which was subsequently rinsed with methanol and dichloromethane. The filtrate was concentrated under reduced pressure to yield an oil that was concentrated twice from toluene to afford 56.6 g of a brown oil that was used directly in the next step.
  • Triethylamine (49.0 mL, 350 mmol) was added to a stined suspension of the material from Part B in dichloromethane (450 mL).
  • the reaction mixture was stined for approximately 3 days at room temperature.
  • the solution was concentrated under reduced pressure.
  • the residue was partitioned between ethyl acetate (500 mL) and 1:1 saturated aqueous sodium bicarbonate/water (500 mL).
  • the aqueous layer was extracted with ethyl acetate (3 x 250 mL) and chloroform (250 mL).
  • the organic layers were combined, dried over magnesium sulfate, filtered, and concentrated under reduced pressure.
  • Part D mCPBA (77% pure, 36.5 g, 163 mmol) was added over 10 minutes to a stined suspension of l-[2-(chloromethyl)-lH-imidazo[4,5-c]quinolin-l-yl]-2-methylpropan-2-ol (23.6 g, 81.4 mmol) in chloroform (500 mL). The resulting solution was stined at room temperature for 1.5 hours. Concentrated ammonium hydroxide (200 mL) was added.
  • the crade product was purified in portions by chromatography on a HORIZON HPFC system (silica gel, elution with 5% methanol in chloroform followed by gradient elution with 5-15%) methanol in chloroform) to yield 9.42 g of l-[4-amino-2-(chloromethyl)-lH- imidazo[4,5-c]quinolin-l-yl]-2-methylpropan-2-ol as a pale yellow solid.
  • the flask containing the solution of l-[4-amirio-2-(chloromethyl)-lH- imidazo[4,5-c]quinolin-l-yl]-2-methylpropan-2-ol was rinsed with DMF (3.0 mL), wliich was added to the reaction solution.
  • the solution was stined at room temperature for 3 hours and a solid formed.
  • the solid was isolated by filtration, washed with dichloromethane, and dried.
  • the off-white solid was dissolved in hot DMF (20 mL). Acetonitrile (50 mL) was added to the solution, which was then placed in a freezer.
  • Methyl isocyanate (0.148 mL, 2.39 mmol) was added to a stined solution of 1 - ⁇ 4- amino-2- [(aminooxy)methyl] - lH-imidazo [4,5 -c] quinolin- 1 -yl ⁇ -2-methylpropan-2-ol (prepared as described in Example 100, 600 mg, 1.99 mmol) in DMF (5 mL). A solid formed immediately. The mixture was stined for 2 hours at room temperature, then was heated to form a solution to which acetonitrile (10 mL) was added. Crystals formed that were isolated by filtration and purified by chromatography using a HORIZON HPFC
  • the aqueous layer was extracted with dichloromethane (2 x 30 mL). The organic layers were combined and allowed to stand overnight at room temperature. Crystals formed and were isolated by filtration to provide 40 mg of N- ⁇ [4-amino-l-(2-hydroxy-2- methylpropyl)-lH-imidazo[4,5-c]quinolin-2-yl]methoxy ⁇ methanesulfonamide. Additional crystals were isolated from the mother liquor after a seed crystal was added.
  • Triethylamine (0.634 mL, 4.55 mmol) and cyclopropanecarbonyl chloride (0.248 mL, 2.73 mmol) were added to a solution of l- ⁇ 4-amino-2-[(aminooxy)methyl]-lH- imidazo[4,5-c]quinolin-l-yl ⁇ -2-methylpropan-2-ol (prepared as described in Example 100, 685 mg, 2.27 mmol) in DMF (5 mL).
  • the cloudy mixture was stined for 2 hours at room temperature, then was partitioned between water (20 mL) and dichloromethane (30 mL). The aqueous layer was extracted with dichloromethane (2 x 30 mL).
  • Examples 105-122 A reagent from the table below (1.1 equivalents, 0.10 mmol) was added to a test tube containing a solution of 1- ⁇ 4-amino-2-[(aminooxy)methyl]-lH-imidazo[4,5- c]quinolin-l-yl ⁇ -2-methylpropan-2-ol (prepared as described in Example 100, 29 mg, 0.09 mmol) and triethylamine (26 ⁇ L, 0.20 mmol) in DMF (1 mL). The test tubes were capped and placed on a shaker at ambient temperature overnight (approximately 18 hours). The solvent was removed from the test tubes by vacuum centrifugation.
  • the compounds were purified by preparative high perfonnance liquid chromatography (prep HPLC) using a Waters FractionLynx automated purification system.
  • the prep HPLC fractions were analyzed using a Waters LC/TOF-MS, and the appropriate fractions were centrifuge evaporated to provide the trifluoroacetate salt of the desired compound.
  • Reversed phase preparative liquid cliromatography was performed with non-linear gradient elution from 5- 95%) B where A is 0.05% trifluoroacetic acid/water and B is 0.05% trifluoroacetic acid/acetonitrile.
  • Fractions were collected by mass-selective triggering.
  • the table below shows the reagent used for each example, the stracture of the resulting compound, and the observed accurate mass for the isolated trifluoroacetate salt.
  • a reagent from the table below (1.1 equivalents, 0.11 mmol) was added to a test tube containing a solution of 2-[(aminooxy)methyl]-l-(2-methylpropyl)-6,7,8,9-tetrahydro- lH-imidazo[4,5-c]quinolin-4-amine (prepared as described in Example 123, 29 mg, 0.10 mmol) and NN-diisopropylethylamine (36 ⁇ L, 0.20 mmol) in chloroform (1 mL).
  • the test tubes were capped and placed on a shaker at ambient temperature for 4 hours. Water (two drops) was added to each test tube and the volatiles were removed from the test tubes by vacuum centrifugation.
  • the compounds were purified as described in Examples 105-122.
  • the table below shows the reagent used for each example, the structure of the resulting compound, and the observed accurate mass for the isolated trifluoroacetate salt.
  • Part C The general method described in Part C of Example 92 was used to convert N 4 - ⁇ - methyl ⁇ ropyl)[l,5]naphthyridine-3,4-diamine (from Part B) into 2-chloro-N- ⁇ 4-[(2- methylpropyl)amino][l,5]naphthyridin-3-yl ⁇ acetamide hydrochloride, which was isolated as a pale yellow solid that was used directly in the next step without purification.
  • Part F The material from Part E was dissolved in methanol (70 mL) and the solution was cooled to 0 °C. Concentrated ammonium hydroxide (6.7 mL) was added, followed by dropwise addition of benzenesulfonyl chloride (5.25 mL, 42.0 mmol). The reaction mixture was stined at 0 °C for 1 hour. The volatiles were removed under reduced pressure and the residue was partitioned between dichloromethane (150 mL) and saturated aqueous sodium bicarbonate (75 mL). The aqueous layer was extracted with dichloromethane (50 mL). The organic layers were combined, dried over magnesium sulfate, filtered, and concentrated.
  • dichloromethane 150 mL
  • saturated aqueous sodium bicarbonate 75 mL
  • the aqueous layer was extracted with dichloromethane (50 mL).
  • the crade product was purified by chromatography using a HORIZON HPFC system (silica gel, gradient elution with 0-25 % CMA in chloroform) to afford 4.14 g of approximately 85% pure 2-(chloromethyl)-l-(2-methylpropyl)-lH-imidazo[4,5- c] [ 1 ,5]naphthyridin-4-amine, wliich was used in the next step without further purification.
  • HORIZON HPFC system sica gel, gradient elution with 0-25 % CMA in chloroform
  • a reagent from the table below (1.1 equivalents, 0.11 mmol) was added to a test tube containing a solution of 2-[(aminooxy)methyl]-l-(2-methylpropyl)-lH-imidazo[4,5- c][l,5]naphthyridin-4-amine (prepared as described in Example 136, 29 mg, 0.10 mmol) and N,N-diisopropylethylamine (35 ⁇ L, 0.20 mmol) in chloroform (1 mL).
  • the test tubes were capped and placed on a shaker at ambient temperature for 4 hours. The solvent was removed from the test tubes by vacuum centrifugation.
  • the compounds were purified as described in Examples 105-122.
  • the table below shows the reagent used for each example, the structure of the resulting compound, and the observed accurate mass for the isolated trifluoroacetate salt.
  • Part D 7-Bromo-3-nitroquinolin-4-ol (42 g, 156 mmol) was suspended in POCl 3 (130 mL) and brought to 102 °C under an atmosphere of N 2 . After 45 min, all of the solids had dissolved, so the reaction was cooled to room temperature. The resulting solids were collected by filtration, washed with H 2 O, and then partitioned with CH C1 2 (3 L) and 2M

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
PCT/US2004/038033 2003-11-14 2004-11-12 Hydroxylamine substituted imidazo ring compounds WO2005048945A2 (en)

Priority Applications (5)

Application Number Priority Date Filing Date Title
CA002545825A CA2545825A1 (en) 2003-11-14 2004-11-12 Hydroxylamine substituted imidazo ring compounds
US10/595,790 US8598192B2 (en) 2003-11-14 2004-11-12 Hydroxylamine substituted imidazoquinolines
AU2004291122A AU2004291122A1 (en) 2003-11-14 2004-11-12 Hydroxylamine substituted imidazo ring compounds
EP04810969A EP1682544A4 (en) 2003-11-14 2004-11-12 HYDROXYLAMINE SUBSTITUTED IMIDAZO RING COMPOUNDS
JP2006539957A JP2007511535A (ja) 2003-11-14 2004-11-12 ヒドロキシルアミン置換イミダゾ環化合物

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US52021503P 2003-11-14 2003-11-14
US60/520,215 2003-11-14

Publications (2)

Publication Number Publication Date
WO2005048945A2 true WO2005048945A2 (en) 2005-06-02
WO2005048945A3 WO2005048945A3 (en) 2006-03-23

Family

ID=34619446

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2004/038033 WO2005048945A2 (en) 2003-11-14 2004-11-12 Hydroxylamine substituted imidazo ring compounds

Country Status (7)

Country Link
US (1) US8598192B2 (enGo)
EP (1) EP1682544A4 (enGo)
JP (1) JP2007511535A (enGo)
CN (1) CN1906192A (enGo)
AU (1) AU2004291122A1 (enGo)
CA (1) CA2545825A1 (enGo)
WO (1) WO2005048945A2 (enGo)

Cited By (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006080043A3 (en) * 2005-01-27 2006-09-08 Univ Bologna Alma Mater Organic compounds useful for the treatment of alzheimer's disease, their use and method of preparation
WO2006086634A3 (en) * 2005-02-11 2007-08-09 3M Innovative Properties Co Oxime and hydroxylamine substituted imidazo[4,5-c] ring compounds and methods
EP1685129A4 (en) * 2003-11-14 2008-10-22 3M Innovative Properties Co OXIMSUBSTITUTED IMIDAZORING CONNECTIONS
WO2009118296A3 (en) * 2008-03-24 2009-12-03 4Sc Ag Novel substituted imidazoquinolines
US7879849B2 (en) 2003-10-03 2011-02-01 3M Innovative Properties Company Pyrazolopyridines and analogs thereof
US7906506B2 (en) 2006-07-12 2011-03-15 3M Innovative Properties Company Substituted chiral fused [1,2] imidazo [4,5-c] ring compounds and methods
US7915281B2 (en) 2004-06-18 2011-03-29 3M Innovative Properties Company Isoxazole, dihydroisoxazole, and oxadiazole substituted imidazo ring compounds and method
US7923429B2 (en) 2003-09-05 2011-04-12 3M Innovative Properties Company Treatment for CD5+ B cell lymphoma
US7943609B2 (en) 2004-12-30 2011-05-17 3M Innovative Proprerties Company Chiral fused [1,2]imidazo[4,5-C] ring compounds
US7943636B2 (en) 2005-04-01 2011-05-17 3M Innovative Properties Company 1-substituted pyrazolo (3,4-C) ring compounds as modulators of cytokine biosynthesis for the treatment of viral infections and neoplastic diseases
US7943610B2 (en) 2005-04-01 2011-05-17 3M Innovative Properties Company Pyrazolopyridine-1,4-diamines and analogs thereof
US8034938B2 (en) 2004-12-30 2011-10-11 3M Innovative Properties Company Substituted chiral fused [1,2]imidazo[4,5-c] ring compounds
EP2394650A1 (en) 2004-12-30 2011-12-14 3M Innovative Properties Co. Use of resiquimod for the treatment of cutaneous metastases
CN103435524A (zh) * 2006-03-17 2013-12-11 约翰斯·霍普金斯大学医学院 作为有生理学价值的硝酰氧基供体的n-羟基磺酰胺衍生物
WO2014107663A2 (en) 2013-01-07 2014-07-10 The Trustees Of The University Of Pennsylvania Compositions and methods for treating cutaneous t cell lymphoma
US8871782B2 (en) 2003-10-03 2014-10-28 3M Innovative Properties Company Alkoxy substituted imidazoquinolines
US8951528B2 (en) 2006-02-22 2015-02-10 3M Innovative Properties Company Immune response modifier conjugates
US9248127B2 (en) 2005-02-04 2016-02-02 3M Innovative Properties Company Aqueous gel formulations containing immune response modifiers
EP3153180A1 (en) 2011-06-03 2017-04-12 3M Innovative Properties Company Heterobifunctional linkers with polyethylene glycol segments and immune response modifier conjugates made therefrom
US9932303B2 (en) 2014-01-17 2018-04-03 Cardioxyl Pharmaceuticals, Inc. N-hydroxymethanesulfonamide nitroxyl donors
US9962453B2 (en) 2013-12-02 2018-05-08 Altimmune Uk Limited Immunogenic compound
US10144735B2 (en) 2006-12-22 2018-12-04 3M Innovative Properties Company Immune response modifier compositions and methods
WO2019166946A1 (en) 2018-02-28 2019-09-06 Pfizer Inc. Il-15 variants and uses thereof
WO2019224716A2 (en) 2018-05-23 2019-11-28 Pfizer Inc. Antibodies specific for gucy2c and uses thereof
WO2019224715A1 (en) 2018-05-23 2019-11-28 Pfizer Inc. Antibodies specific for cd3 and uses thereof
WO2020128893A1 (en) 2018-12-21 2020-06-25 Pfizer Inc. Combination treatments of cancer comprising a tlr agonist
WO2021124073A1 (en) 2019-12-17 2021-06-24 Pfizer Inc. Antibodies specific for cd47, pd-l1, and uses thereof
WO2022013775A1 (en) 2020-07-17 2022-01-20 Pfizer Inc. Therapeutic antibodies and their uses
WO2025104289A1 (en) 2023-11-17 2025-05-22 Medincell S.A. Antineoplastic combinations

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003103584A2 (en) 2002-06-07 2003-12-18 3M Innovative Properties Company Ether substituted imidazopyridines
US20040265351A1 (en) 2003-04-10 2004-12-30 Miller Richard L. Methods and compositions for enhancing immune response
BRPI0413558A (pt) 2003-08-12 2006-10-17 3M Innovative Properties Co compostos contendo imidazo substituìdo por hidroxilamina
RU2006105101A (ru) * 2003-08-27 2007-10-10 3М Инновейтив Пропертиз Компани (US) Арилокси и арилалкиленокси замещенные имидазохинолины
AU2004315876B2 (en) 2003-10-03 2011-05-26 3M Innovative Properties Company Pyrazolopyridines and analogs thereof
NZ547467A (en) 2003-11-25 2010-06-25 3M Innovative Properties Co Substituted imidazo ring system and methods
WO2005066170A1 (en) 2003-12-29 2005-07-21 3M Innovative Properties Company Arylalkenyl and arylalkynyl substituted imidazoquinolines
JP2007517044A (ja) 2003-12-30 2007-06-28 スリーエム イノベイティブ プロパティズ カンパニー イミダゾキノリニル、イミダゾピリジニル、およびイミダゾナフチリジニルスルホンアミド
TW200612932A (en) 2004-03-24 2006-05-01 3M Innovative Properties Co Amide substituted imidazopyridines, imidazoquinolines, and imidazonaphthyridines
WO2005123080A2 (en) 2004-06-15 2005-12-29 3M Innovative Properties Company Nitrogen-containing heterocyclyl substituted imidazoquinolines and imidazonaphthyridines
WO2006009826A1 (en) 2004-06-18 2006-01-26 3M Innovative Properties Company Aryloxy and arylalkyleneoxy substituted thiazoloquinolines and thiazolonaphthyridines
US8541438B2 (en) * 2004-06-18 2013-09-24 3M Innovative Properties Company Substituted imidazoquinolines, imidazopyridines, and imidazonaphthyridines
WO2006038923A2 (en) 2004-06-18 2006-04-13 3M Innovative Properties Company Aryl substituted imidazonaphthyridines
WO2006028962A2 (en) 2004-09-02 2006-03-16 3M Innovative Properties Company 1-alkoxy 1h-imidazo ring systems and methods
EP1846419B1 (en) 2005-02-09 2014-04-16 3M Innovative Properties Company Alkoxy-substituted thiazoloquinolines and thiazolonaphthyridines
AU2006338521A1 (en) 2005-02-09 2007-10-11 Coley Pharmaceutical Group, Inc. Oxime and hydroxylamine substituted thiazolo(4,5-c) ring compounds and methods
WO2006091394A2 (en) 2005-02-11 2006-08-31 Coley Pharmaceutical Group, Inc. Substituted imidazoquinolines and imidazonaphthyridines
CA2598695A1 (en) * 2005-02-23 2006-09-21 Coley Pharmaceutical Group, Inc. Hydroxyalkyl substituted imidazoquinolines
JP2008531567A (ja) * 2005-02-23 2008-08-14 コーリー ファーマシューティカル グループ，インコーポレイテッド ヒドロキシアルキル置換イミダゾキノリン化合物および方法
WO2006091647A2 (en) * 2005-02-23 2006-08-31 Coley Pharmaceutical Group, Inc. Method of preferentially inducing the biosynthesis of interferon
ZA200803029B (en) 2005-09-09 2009-02-25 Coley Pharm Group Inc Amide and carbamate derivatives of alkyl substituted /V-[4-(4-amino-1H-imidazo[4,5-c] quinolin-1-yl)butyl] methane-sulfonamides and methods
BRPI0615788A2 (pt) 2005-09-09 2011-05-24 Coley Pharm Group Inc derivados de amida e carbamato de n-{2-[4-amino (etoximetil)-1h-imidazo [4,5-c] quinolin-1-il]-1,1-dimetiletil} metanossulfonamida, composição farmacêutica destes e seus usos
WO2007056112A2 (en) * 2005-11-04 2007-05-18 Coley Pharmaceutical Group, Inc. Hydroxy and alkoxy substituted 1h-imidazoquinolines and methods
WO2007106854A2 (en) 2006-03-15 2007-09-20 Coley Pharmaceutical Group, Inc. Hydroxy and alkoxy substituted 1h-imidazonaphthyridines and methods
WO2008030511A2 (en) * 2006-09-06 2008-03-13 Coley Pharmaceuticial Group, Inc. Substituted 3,4,6,7-tetrahydro-5h, 1,2a,4a,8-tetraazacyclopenta[cd]phenalenes
CA2707308C (en) * 2007-11-30 2016-08-02 Newlink Genetics Corporation Ido inhibitors
BRPI1009842B8 (pt) 2009-03-25 2021-05-25 Univ Texas uso de agonista de tlr9 e agonista de tlr2/6 na preparação de uma composição farmacêutica para tratamento, inibição ou atenuação de uma infecção microbiana, bem como composição farmaceuticamente aceitável compreendendo os referidos agonistas
EP2507237A1 (en) * 2009-12-03 2012-10-10 Dainippon Sumitomo Pharma Co., Ltd. Imidazoquinolines which act via toll - like receptors (tlr)
US8461328B2 (en) * 2010-01-12 2013-06-11 Genentech, Inc. Tricyclic heterocyclic compounds, compositions and methods of use thereof
PT2606047T (pt) 2010-08-17 2017-04-07 3M Innovative Properties Co Composições, formulações e métodos de um composto lipidado modificador da resposta imunitária
EP2717919B1 (en) 2011-06-03 2016-08-03 3M Innovative Properties Company Heterobifunctional linkers with polyethylene glycol segments and immune response modifier conjugates made therefrom
CN102516244B (zh) * 2011-12-02 2013-08-28 山东大学 六元芳杂环并咪唑巯乙酰胺类衍生物及其制备方法与应用
PT106142B (pt) 2012-02-10 2014-07-18 Hovione Farmaci Ncia S A Processo para a preparação de brometo de tiotrópio
WO2016044839A2 (en) 2014-09-19 2016-03-24 The Board Of Regents Of The University Of Texas System Compositions and methods for treating viral infections through stimulated innate immunity in combination with antiviral compounds
WO2016057931A1 (en) 2014-10-10 2016-04-14 The Research Foundation For The State University Of New York Trifluoromethoxylation of arenes via intramolecular trifluoromethoxy group migration
MA41614A (fr) * 2015-02-25 2018-01-02 Alios Biopharma Inc Composés antiviraux
CN108137586B (zh) * 2015-09-14 2021-04-13 辉瑞大药厂 作为LRRK2抑制剂的新颖咪唑并[4,5-c]喹啉和咪唑并[4,5-c][1,5]萘啶衍生物
JP7197244B2 (ja) 2017-12-20 2022-12-27 スリーエム イノベイティブ プロパティズ カンパニー 免疫応答調節剤として使用するための分岐鎖連結基を有するアミド置換イミダゾ［４，５－ｃ］キノリン化合物

Family Cites Families (298)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3314941A (en) 1964-06-23 1967-04-18 American Cyanamid Co Novel substituted pyridodiazepins
DE1645976A1 (de) 1966-06-18 1971-01-21 Ajinomoto Kk Verfahren zur Herstellung von Adenosin und 2',3'-O-Isopropylidenadenosin
ZA704419B (en) 1969-07-21 1971-04-28 Ici Australia Ltd Injectable aqueous solutions of tetramisole
US3692907A (en) 1970-10-27 1972-09-19 Richardson Merrell Inc Treating viral infections with bis-basic ethers and thioethers of fluorenone and fluorene and pharmaceutical compositons of the same
US3917624A (en) 1972-09-27 1975-11-04 Pfizer Process for producing 2-amino-nicotinonitrile intermediates
US4006237A (en) 1973-10-11 1977-02-01 Beecham Group Limited Tetrahydrocarbostyril derivatives for the prophylaxis of asthma, hayfever and rhinitis
US3891660A (en) 1974-02-07 1975-06-24 Squibb & Sons Inc Derivatives of 1H-imidazo{8 4,5-c{9 pyridine-7-carboxylic acids and esters
US3899508A (en) 1974-04-12 1975-08-12 Lilly Co Eli 5-(2-Aminophenyl)pyrazole-3-carboxylic acids and esters thereof
DE2423389A1 (de) 1974-05-14 1975-12-04 Hoechst Ag Arzneimittel mit psychotroper wirkung und verfahren zu ihrer herstellung
US4381344A (en) 1980-04-25 1983-04-26 Burroughs Wellcome Co. Process for producing deoxyribosides using bacterial phosphorylase
DE3204126A1 (de) 1982-02-06 1983-08-11 Bayer Ag, 5090 Leverkusen Pyrazoloxazine, -thiazine, -chinoline, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel
US4758574A (en) 1982-05-03 1988-07-19 Eli Lilly And Company 2-phenylimidazio (4,5-c) pyridines
US4563525A (en) 1983-05-31 1986-01-07 Ici Americas Inc. Process for preparing pyrazolopyridine compounds
CA1271477A (en) 1983-11-18 1990-07-10 John F. Gerster 1h-imidazo[4,5-c]quinolin-4-amines
IL73534A (en) 1983-11-18 1990-12-23 Riker Laboratories Inc 1h-imidazo(4,5-c)quinoline-4-amines,their preparation and pharmaceutical compositions containing certain such compounds
ZA848968B (en) 1983-11-18 1986-06-25 Riker Laboratories Inc 1h-imidazo(4,5-c)quinolines and 1h-imidazo(4,5-c)quinolin-4-amines
JPS61112075A (ja) 1984-11-05 1986-05-30 Shionogi & Co Ltd チエニルピラゾロキノリン誘導体
US4668686A (en) 1985-04-25 1987-05-26 Bristol-Myers Company Imidazoquinoline antithrombrogenic cardiotonic agents
US4593821A (en) 1985-04-25 1986-06-10 Laros Equipment Company, Inc. Belt separator for blow molding parts
US4698346A (en) 1985-05-08 1987-10-06 Usv Pharmaceutical Corporation Thiazolo[5,4-h]quinoline compounds useful as anti-allergy agents
US4826830A (en) 1985-07-31 1989-05-02 Jui Han Topical application of glyciphosphoramide
CA1306260C (en) 1985-10-18 1992-08-11 Shionogi & Co., Ltd. Condensed imidazopyridine derivatives
HU197019B (en) 1985-11-12 1989-02-28 Egyt Gyogyszervegyeszeti Gyar Process for producing thiqzolo (4,5-c) quinoline derivatives and pharmaceuticals comprising same
US4837378A (en) 1986-01-15 1989-06-06 Curatek Pharmaceuticals, Inc. Topical metronidazole formulations and therapeutic uses thereof
US4775674A (en) 1986-05-23 1988-10-04 Bristol-Myers Company Imidazoquinolinylether derivatives useful as phosphodiesterase and blood aggregation inhibitors
CA1287061C (en) 1986-06-27 1991-07-30 Roche Holding Ltd. Pyridine ethanolamine derivatives
US5500228A (en) 1987-05-26 1996-03-19 American Cyanamid Company Phase separation-microencapsulated pharmaceuticals compositions useful for alleviating dental disease
US4880779A (en) 1987-07-31 1989-11-14 Research Corporation Technologies, Inc. Method of prevention or treatment of AIDS by inhibition of human immunodeficiency virus
US4774339A (en) 1987-08-10 1988-09-27 Molecular Probes, Inc. Chemically reactive dipyrrometheneboron difluoride dyes
US5536743A (en) 1988-01-15 1996-07-16 Curatek Pharmaceuticals Limited Partnership Intravaginal treatment of vaginal infections with buffered metronidazole compositions
US5225183A (en) 1988-12-06 1993-07-06 Riker Laboratories, Inc. Medicinal aerosol formulations
US5736553A (en) 1988-12-15 1998-04-07 Riker Laboratories, Inc. Topical formulations and transdermal delivery systems containing 1-isobutyl-1H-imidazo 4,5-C!quinolin-4-amine
US5238944A (en) 1988-12-15 1993-08-24 Riker Laboratories, Inc. Topical formulations and transdermal delivery systems containing 1-isobutyl-1H-imidazo[4,5-c]quinolin-4-amine
DK0385630T3 (da) 1989-02-27 1997-05-12 Riker Laboratories Inc 1H-imidazo(4,5-c)quinolin-4-aminer som antivirale midler
US5756747A (en) 1989-02-27 1998-05-26 Riker Laboratories, Inc. 1H-imidazo 4,5-c!quinolin-4-amines
US5457183A (en) 1989-03-06 1995-10-10 Board Of Regents, The University Of Texas System Hydroxylated texaphyrins
US5037986A (en) 1989-03-23 1991-08-06 Minnesota Mining And Manufacturing Company Olefinic 1H-imidazo[4,5-c]quinolin-4-amines
US4929624A (en) 1989-03-23 1990-05-29 Minnesota Mining And Manufacturing Company Olefinic 1H-imidazo(4,5-c)quinolin-4-amines
NZ232740A (en) 1989-04-20 1992-06-25 Riker Laboratories Inc Solution for parenteral administration comprising a 1h-imidazo(4,5-c) quinolin-4-amine derivative, an acid and a tonicity adjuster
US4988815A (en) 1989-10-26 1991-01-29 Riker Laboratories, Inc. 3-Amino or 3-nitro quinoline compounds which are intermediates in preparing 1H-imidazo[4,5-c]quinolines
US5750134A (en) 1989-11-03 1998-05-12 Riker Laboratories, Inc. Bioadhesive composition and patch
CA2071897A1 (en) 1989-12-28 1991-06-29 Richard A. Glennon Sigma receptor ligands and the use thereof
US5274113A (en) 1991-11-01 1993-12-28 Molecular Probes, Inc. Long wavelength chemically reactive dipyrrometheneboron difluoride dyes and conjugates
US5530114A (en) 1990-04-30 1996-06-25 Isis Pharmaceuticals, Inc. Oligonucleotide modulation of arachidonic acid metabolism
JPH04235974A (ja) 1990-06-08 1992-08-25 Roussel Uclaf 新規なイミダゾール誘導体、それらの製造法、得られる新規な中間体、それらの薬剤としての使用及びそれらを含有する製薬組成物
DK0553202T3 (da) 1990-10-05 1995-07-03 Minnesota Mining & Mfg Fremgangsmåde til fremstilling af imidazo(4,5-c)quinolin-4-aminer
MX9203481A (es) 1990-10-18 1992-07-01 Minnesota Mining & Mfg Formulaciones.
US5248782A (en) 1990-12-18 1993-09-28 Molecular Probes, Inc. Long wavelength heteroaryl-substituted dipyrrometheneboron difluoride dyes
US5389640A (en) 1991-03-01 1995-02-14 Minnesota Mining And Manufacturing Company 1-substituted, 2-substituted 1H-imidazo[4,5-c]quinolin-4-amines
US5175296A (en) 1991-03-01 1992-12-29 Minnesota Mining And Manufacturing Company Imidazo[4,5-c]quinolin-4-amines and processes for their preparation
US5342784A (en) 1991-04-12 1994-08-30 Mitsubishi Paper Mills Limited Electrophotographic lithographic printing plate
JPH04327587A (ja) 1991-04-26 1992-11-17 Asahi Chem Ind Co Ltd ６’−ｃ−アルキル−３−デアザネプラノシンａ誘導体、その製造法およびその用途
US5187288A (en) 1991-05-22 1993-02-16 Molecular Probes, Inc. Ethenyl-substituted dipyrrometheneboron difluoride dyes and their synthesis
US5268376A (en) 1991-09-04 1993-12-07 Minnesota Mining And Manufacturing Company 1-substituted 1H-imidazo[4,5-c]quinolin-4-amines
TW300219B (enGo) 1991-09-14 1997-03-11 Hoechst Ag
PH31245A (en) 1991-10-30 1998-06-18 Janssen Pharmaceutica Nv 1,3-Dihydro-2H-imidazoÄ4,5-BÜ-quinolin-2-one derivatives.
US5266575A (en) 1991-11-06 1993-11-30 Minnesota Mining And Manufacturing Company 2-ethyl 1H-imidazo[4,5-ciquinolin-4-amines
US5378848A (en) 1992-02-12 1995-01-03 Shionogi & Co., Ltd. Condensed imidazopyridine derivatives
IL105325A (en) 1992-04-16 1996-11-14 Minnesota Mining & Mfg Immunogen/vaccine adjuvant composition
WO1993023011A1 (en) 1992-05-18 1993-11-25 Minnesota Mining And Manufacturing Company Transmucosal drug delivery device
US5352680A (en) 1992-07-15 1994-10-04 Regents Of The University Of Minnesota Delta opioid receptor antagonists to block opioid agonist tolerance and dependence
US6608201B2 (en) 1992-08-28 2003-08-19 3M Innovative Properties Company Process for preparing 1-substituted, 2-substituted 1H-imidazo[4,5-c]quinolin-4-amines
US5395937A (en) 1993-01-29 1995-03-07 Minnesota Mining And Manufacturing Company Process for preparing quinoline amines
KR100321649B1 (ko) 1993-03-17 2002-07-22 미네소타 마이닝 앤드 매뉴팩춰링 캄파니 에스테르,아미드또는머캅토에스테르로부터유도된분산보조제를함유하는에어로졸제제
DE4309969A1 (de) 1993-03-26 1994-09-29 Bayer Ag Substituierte heteroanellierte Imidazole
DE69314318T2 (de) 1993-04-27 1998-04-09 Agfa Gevaert Nv Verfahren zum Einfügen von einer Wasserumlöslichen Verbindung in eine hydrophile Schicht
CA2167042A1 (en) 1993-07-15 1995-01-26 Kyle J. Lindstrom Imidazo[4,5-c]pyridin-4-amines
US5352784A (en) 1993-07-15 1994-10-04 Minnesota Mining And Manufacturing Company Fused cycloalkylimidazopyridines
US5648516A (en) 1994-07-20 1997-07-15 Minnesota Mining And Manufacturing Company Fused cycloalkylimidazopyridines
CA2131680C (en) 1993-09-17 2006-11-07 Gerhard Stucky Process for preparing imidazopyridine derivatives
US5837809A (en) 1995-08-11 1998-11-17 Oregon Health Sciences University Mammalian opioid receptor ligand and uses
JPH07163368A (ja) 1993-12-15 1995-06-27 Hayashibara Biochem Lab Inc 組換えｄｎａとその組換えｄｎａを含む形質転換体
TW574214B (en) 1994-06-08 2004-02-01 Pfizer Corticotropin releasing factor antagonists
US6239116B1 (en) 1994-07-15 2001-05-29 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
AU713040B2 (en) 1994-07-15 1999-11-18 University Of Iowa Research Foundation, The Immunomodulatory oligonucleotides
US6207646B1 (en) 1994-07-15 2001-03-27 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US5612377A (en) 1994-08-04 1997-03-18 Minnesota Mining And Manufacturing Company Method of inhibiting leukotriene biosynthesis
US5644063A (en) 1994-09-08 1997-07-01 Minnesota Mining And Manufacturing Company Imidazo[4,5-c]pyridin-4-amine intermediates
GB9420168D0 (en) 1994-10-06 1994-11-23 Boots Co Plc Therapeutic agents
US5571819A (en) 1994-11-22 1996-11-05 Sabb; Annmarie L. Imidazopyridines as muscarinic agents
US5482936A (en) 1995-01-12 1996-01-09 Minnesota Mining And Manufacturing Company Imidazo[4,5-C]quinoline amines
US6071949A (en) 1995-03-14 2000-06-06 The United States Of America As Represented By The Department Of Health And Human Services Use of lipoxygenase inhibitors as anti-cancer therapeutic and intervention agents
US5585612A (en) 1995-03-20 1996-12-17 Harp Enterprises, Inc. Method and apparatus for voting
FR2732605B1 (fr) 1995-04-07 1997-05-16 Pasteur Merieux Serums Vacc Composition destinee a l'induction d'une reponse immunitaire mucosale
US5766789A (en) 1995-09-29 1998-06-16 Energetics Systems Corporation Electrical energy devices
EP0778277B1 (en) 1995-12-08 2003-06-25 Pfizer Inc. Substituted heterocyclic derivatives as CRF antagonists
US5939047A (en) 1996-04-16 1999-08-17 Jernberg; Gary R. Local delivery of chemotherapeutic agents for treatment of periodontal disease
US5861268A (en) 1996-05-23 1999-01-19 Biomide Investment Limited Partnership Method for induction of tumor cell apoptosis with chemical inhibitors targeted to 12-lipoxygenase
US5741908A (en) 1996-06-21 1998-04-21 Minnesota Mining And Manufacturing Company Process for reparing imidazoquinolinamines
US5693811A (en) 1996-06-21 1997-12-02 Minnesota Mining And Manufacturing Company Process for preparing tetrahdroimidazoquinolinamines
EP0882727B9 (en) 1996-07-03 2005-06-15 Sumitomo Pharmaceuticals Company, Limited Novel purine derivatives
US6387938B1 (en) 1996-07-05 2002-05-14 Mochida Pharmaceutical Co., Ltd. Benzimidazole derivatives
ES2290969T3 (es) 1996-10-25 2008-02-16 Minnesota Mining And Manufacturing Company Compuestos modificadores de la respuesta inmune para el tratamiento de enfermedades mediadas por th2 y relacionadas.
US5939090A (en) 1996-12-03 1999-08-17 3M Innovative Properties Company Gel formulations for topical drug delivery
US6069149A (en) 1997-01-09 2000-05-30 Terumo Kabushiki Kaisha Amide derivatives and intermediates for the synthesis thereof
US6406705B1 (en) 1997-03-10 2002-06-18 University Of Iowa Research Foundation Use of nucleic acids containing unmethylated CpG dinucleotide as an adjuvant
US6426334B1 (en) 1997-04-30 2002-07-30 Hybridon, Inc. Oligonucleotide mediated specific cytokine induction and reduction of tumor growth in a mammal
US6303347B1 (en) 1997-05-08 2001-10-16 Corixa Corporation Aminoalkyl glucosaminide phosphate compounds and their use as adjuvants and immunoeffectors
US6113918A (en) 1997-05-08 2000-09-05 Ribi Immunochem Research, Inc. Aminoalkyl glucosamine phosphate compounds and their use as adjuvants and immunoeffectors
EP1003531B1 (en) 1997-05-20 2007-08-22 Ottawa Health Research Institute Processes for preparing nucleic acid constructs
US6123957A (en) 1997-07-16 2000-09-26 Jernberg; Gary R. Delivery of agents and method for regeneration of periodontal tissues
US6077349A (en) 1997-08-20 2000-06-20 Sony Corporation Method and apparatus for manufacturing disc-shaped recording medium
US6309623B1 (en) 1997-09-29 2001-10-30 Inhale Therapeutic Systems, Inc. Stabilized preparations for use in metered dose inhalers
ATE247654T1 (de) 1997-11-28 2003-09-15 Sumitomo Pharma Neue heterozyklische verbindungen
US6121323A (en) 1997-12-03 2000-09-19 3M Innovative Properties Company Bishydroxyureas
UA67760C2 (uk) 1997-12-11 2004-07-15 Міннесота Майнінг Енд Мануфакчурінг Компані Імідазонафтиридин та тетрагідроімідазонафтиридин, фармацевтична композиція, спосіб індукування біосинтезу цитокінів та спосіб лікування вірусної інфекції, проміжні сполуки
TW572758B (en) 1997-12-22 2004-01-21 Sumitomo Pharma Type 2 helper T cell-selective immune response inhibitors comprising purine derivatives
US6114058A (en) 1998-05-26 2000-09-05 Siemens Westinghouse Power Corporation Iron aluminide alloy container for solid oxide fuel cells
US6110929A (en) 1998-07-28 2000-08-29 3M Innovative Properties Company Oxazolo, thiazolo and selenazolo [4,5-c]-quinolin-4-amines and analogs thereof
JP2000119271A (ja) 1998-08-12 2000-04-25 Hokuriku Seiyaku Co Ltd １ｈ―イミダゾピリジン誘導体
US5962636A (en) 1998-08-12 1999-10-05 Amgen Canada Inc. Peptides capable of modulating inflammatory heart disease
US6518280B2 (en) 1998-12-11 2003-02-11 3M Innovative Properties Company Imidazonaphthyridines
US6486168B1 (en) 1999-01-08 2002-11-26 3M Innovative Properties Company Formulations and methods for treatment of mucosal associated conditions with an immune response modifier
ATE304852T1 (de) 1999-01-08 2005-10-15 3M Innovative Properties Co Zubereitungen, umfassend imiquimod oder andere immunantwort modifizierenden verbindungen, zur behandlung von zervikaler dysplasie
EP1495758A3 (en) 1999-01-08 2005-04-13 3M Innovative Properties Company Formulations and methods for treatment of mucosal associated conditions with an immune response modifier
US20020058674A1 (en) 1999-01-08 2002-05-16 Hedenstrom John C. Systems and methods for treating a mucosal surface
US6558951B1 (en) 1999-02-11 2003-05-06 3M Innovative Properties Company Maturation of dendritic cells with immune response modifying compounds
US6294271B1 (en) 1999-02-12 2001-09-25 Shin-Etsu Chemical Co., Ltd. Flip-chip type semiconductor device sealing material and flip-chip type semiconductor device
JP2000247884A (ja) 1999-03-01 2000-09-12 Sumitomo Pharmaceut Co Ltd アラキドン酸誘発皮膚疾患治療剤
EP1171609B1 (en) 1999-04-12 2008-06-25 Lexicon Pharmaceuticals, Inc. Lipoxygenase proteins and polynucleotides encoding the same
US6756382B2 (en) 1999-06-10 2004-06-29 3M Innovative Properties Company Amide substituted imidazoquinolines
US6331539B1 (en) 1999-06-10 2001-12-18 3M Innovative Properties Company Sulfonamide and sulfamide substituted imidazoquinolines
US6451810B1 (en) 1999-06-10 2002-09-17 3M Innovative Properties Company Amide substituted imidazoquinolines
US6541485B1 (en) 1999-06-10 2003-04-01 3M Innovative Properties Company Urea substituted imidazoquinolines
US6573273B1 (en) 1999-06-10 2003-06-03 3M Innovative Properties Company Urea substituted imidazoquinolines
US6315985B1 (en) 1999-06-18 2001-11-13 3M Innovative Properties Company C-17/21 OH 20-ketosteroid solution aerosol products with enhanced chemical stability
CA2784789A1 (en) 1999-08-13 2001-02-22 Idera Pharmaceuticals, Inc. Modulation of oligonucleotide cpg-mediated immune stimulation by positional modification of nucleosides
US6432989B1 (en) 1999-08-27 2002-08-13 Pfizer Inc Use of CRF antagonists to treat circadian rhythm disorders
KR100702878B1 (ko) 1999-10-29 2007-04-04 넥타르 테라퓨틱스 개선된 분산성을 갖는 건조 분말 조성물
IL139197A0 (en) 1999-10-29 2001-11-25 Pfizer Prod Inc Use of corticotropin releasing factor antagonists and related compositions
US6376669B1 (en) 1999-11-05 2002-04-23 3M Innovative Properties Company Dye labeled imidazoquinoline compounds
US6916925B1 (en) 1999-11-05 2005-07-12 3M Innovative Properties Co. Dye labeled imidazoquinoline compounds
US6313156B1 (en) 1999-12-23 2001-11-06 Icos Corporation Thiazole compounds as cyclic-AMP-specific phosphodiesterase inhibitors
US20040023870A1 (en) 2000-01-21 2004-02-05 Douglas Dedera Methods of therapy and diagnosis using targeting of cells that express toll-like receptor proteins
GB0001704D0 (en) 2000-01-25 2000-03-15 Glaxo Group Ltd Protein
BR0108303A (pt) 2000-02-09 2003-03-05 Hokuriku Pharmaceutical Derivados do 1h-imidazopiridina
AU2001245823A1 (en) 2000-03-17 2001-10-03 Corixa Corporation Novel amphipathic aldehydes and their use as adjuvants and immunoeffectors
US20010046968A1 (en) 2000-03-23 2001-11-29 Zagon Ian S. Opioid growth factor modulates angiogenesis
EP1270578A4 (en) 2000-03-30 2004-11-03 Shionogi & Co NOVEL PROCESS FOR PRODUCING MOLTEN IMIDAZOPYRIDINE DERIVATIVE AND NOVEL CRYSTALLINE FORM
US6894060B2 (en) 2000-03-30 2005-05-17 3M Innovative Properties Company Method for the treatment of dermal lesions caused by envenomation
DE10020465A1 (de) 2000-04-26 2001-11-08 Osram Opto Semiconductors Gmbh Strahlungsemittierendes Halbleiterbauelement mit Lumineszenzkonversionselement
AU2001264753A1 (en) 2000-05-19 2001-12-03 Millennium Pharmaceuticals, Inc. 46638, a putative family member of human lipoxygenase
DE10029580C1 (de) 2000-06-15 2002-01-10 Ferton Holding Sa Vorrichtung zum Entfernen von Körpersteinen mit einem intrakorporalen Lithotripter
US6387383B1 (en) 2000-08-03 2002-05-14 Dow Pharmaceutical Sciences Topical low-viscosity gel composition
US6900016B1 (en) 2000-09-08 2005-05-31 Applera Corporation Polymorphisms in known genes associated with inflammatory autoimmune disease, methods of detection and uses thereof
US20020055517A1 (en) 2000-09-15 2002-05-09 3M Innovative Properties Company Methods for delaying recurrence of herpes virus symptoms
EP1366077B1 (en) 2000-09-15 2011-05-25 Coley Pharmaceutical GmbH PROCESS FOR HIGH THROUGHPUT SCREENING OF CpG-BASED IMMUNO-AGONIST/ANTAGONIST
GB0023008D0 (en) 2000-09-20 2000-11-01 Glaxo Group Ltd Improvements in vaccination
DE60126136T8 (de) 2000-12-07 2008-04-10 Aoyama Seisakusho Co., Ltd., Nagoya Verfahren zum durcherhitzen von stahlteilen
US6545016B1 (en) 2000-12-08 2003-04-08 3M Innovative Properties Company Amide substituted imidazopyridines
US6525064B1 (en) 2000-12-08 2003-02-25 3M Innovative Properties Company Sulfonamido substituted imidazopyridines
US6664264B2 (en) 2000-12-08 2003-12-16 3M Innovative Properties Company Thioether substituted imidazoquinolines
UA74852C2 (en) 2000-12-08 2006-02-15 3M Innovative Properties Co Urea-substituted imidazoquinoline ethers
AU3249802A (en) 2000-12-08 2002-06-18 3M Innovative Properties Co Screening method for identifying compounds that selectively induce interferon alpha
US6677348B2 (en) 2000-12-08 2004-01-13 3M Innovative Properties Company Aryl ether substituted imidazoquinolines
UA74593C2 (en) 2000-12-08 2006-01-16 3M Innovative Properties Co Substituted imidazopyridines
US6664260B2 (en) 2000-12-08 2003-12-16 3M Innovative Properties Company Heterocyclic ether substituted imidazoquinolines
US6664265B2 (en) 2000-12-08 2003-12-16 3M Innovative Properties Company Amido ether substituted imidazoquinolines
US6677347B2 (en) 2000-12-08 2004-01-13 3M Innovative Properties Company Sulfonamido ether substituted imidazoquinolines
US6545017B1 (en) 2000-12-08 2003-04-08 3M Innovative Properties Company Urea substituted imidazopyridines
US6667312B2 (en) 2000-12-08 2003-12-23 3M Innovative Properties Company Thioether substituted imidazoquinolines
US6660747B2 (en) 2000-12-08 2003-12-09 3M Innovative Properties Company Amido ether substituted imidazoquinolines
US20020107262A1 (en) 2000-12-08 2002-08-08 3M Innovative Properties Company Substituted imidazopyridines
US6660735B2 (en) 2000-12-08 2003-12-09 3M Innovative Properties Company Urea substituted imidazoquinoline ethers
US20020182274A1 (en) 2001-03-21 2002-12-05 Kung-Ming Lu Methods for inhibiting cancer growth, reducing infection and promoting general health with a fermented soy extract
US7157465B2 (en) 2001-04-17 2007-01-02 Dainippon Simitomo Pharma Co., Ltd. Adenine derivatives
US20020193729A1 (en) 2001-04-20 2002-12-19 Cormier Michel J.N. Microprojection array immunization patch and method
WO2002085933A1 (en) 2001-04-20 2002-10-31 The Institute For Systems Biology Toll-like receptor 5 ligands and methods of use
US6627639B2 (en) 2001-04-26 2003-09-30 Wyeth Uses for indoletetrahydropyridine derivatives of 2,3-dihydro-7H-[1,4]dioxino-[2,3-e]indole
US7226928B2 (en) 2001-06-15 2007-06-05 3M Innovative Properties Company Methods for the treatment of periodontal disease
US6756399B2 (en) 2001-06-29 2004-06-29 The United States Of America As Represented By The Department Of Health And Human Services Use of lipoxygenase inhibitors and PPAR ligands as anti-cancer therapeutic and intervention agents
CA2453664A1 (en) 2001-07-16 2003-01-30 Takayuki Kasai Process for preparation of amidine derivatives
MXPA04001972A (es) 2001-08-30 2005-02-17 3M Innovative Properties Co Metodos para hacer madurar celulas dendricas plasmacitoide utilizando moleculas modificadoras de respuesta enmune.
EP1434579B1 (en) 2001-10-09 2011-06-08 Amgen Inc. Imidazole derivatives as antiinflammatory agents
EP1478371A4 (en) 2001-10-12 2007-11-07 Univ Iowa Res Found METHOD AND PRODUCTS FOR IMPROVING IMMUNE RESPONSES WITH IMIDAZOCHINOLINE COMPOUNDS
DE60230340D1 (de) 2001-11-16 2009-01-22 3M Innovative Properties Co N-Ä4-(4-Amino-2-ethyl-1H-imidazoÄ4,5-cÜchinolin-1-yl)butylÜmethanesulfonamide, diese enthaltende pharmazeutische Zusammensetzung und deren Verwendung
AU2002364897A1 (en) 2001-11-17 2003-06-10 Maria Martinez-Colon Imiquimod therapies
BR0214407A (pt) 2001-11-27 2004-10-19 Anadys Pharmaceuticals Inc Compostos, composições farmacêuticas e método de modulação das imunoatividades da citocina
IL161786A0 (en) 2001-11-29 2005-11-20 3M Innovative Properties Co Pharmaceutical formulations comprising an immune
US6677349B1 (en) 2001-12-21 2004-01-13 3M Innovative Properties Company Sulfonamide and sulfamide substituted imidazoquinolines
US6775514B2 (en) 2002-01-11 2004-08-10 Xerox Corporation Substrate size monitoring system for use in copier/printers
US6525028B1 (en) 2002-02-04 2003-02-25 Corixa Corporation Immunoeffector compounds
US20050281813A1 (en) 2002-02-14 2005-12-22 Nuvelo, Inc. Methods of therapy and diagnosis using targeting of cells that express toll-like receptor proteins
NZ534566A (en) 2002-02-22 2007-02-23 3M Innovative Properties Co Method of reducing and treating UVB-induced immunosuppression
US20030185835A1 (en) 2002-03-19 2003-10-02 Braun Ralph P. Adjuvant for vaccines
ES2734652T3 (es) 2002-04-04 2019-12-11 Zoetis Belgium S A Oligorribonucleótidos inmunoestimulantes que contienen G y U
RU2379031C2 (ru) 2002-04-30 2010-01-20 Юниджен Фармасьютиклз, Инк. Приготовление смеси флавоноидов со свободным в-кольцом и флаванов как терапевтического агента
GB0211649D0 (en) 2002-05-21 2002-07-03 Novartis Ag Organic compounds
WO2003101949A2 (en) 2002-05-29 2003-12-11 3M Innovative Properties Company Process for imidazo[4,5-c]pyridin-4-amines
WO2003103584A2 (en) 2002-06-07 2003-12-18 3M Innovative Properties Company Ether substituted imidazopyridines
KR20050028047A (ko) 2002-07-23 2005-03-21 비오갈 기오기스제르갸르 알티. 1ｈ-이미다조[4,5-ｃ]퀴놀린-4-프탈이미드 중간체를 통한1ｈ-이미다조[4,5-ｃ]퀴놀린-4-아민의 제조
SI1539752T1 (sl) 2002-07-26 2007-08-31 Teva Gyogyszergyar Zartkoruen Mukodo Reszvenytarsasag Priprava 1H-imidazo(4,5-c)kinolin-4-aminov preko novih imidazo(4,5-c)kinolin-4-ciano in 1H-imidazo(4,5-c)kinolin-4- karboksamidnih intermediatov
PT1545597E (pt) 2002-08-15 2010-12-29 3M Innovative Properties Co Composições imunoestimulantes e métodos de estimulação de uma resposta imunológica
WO2004028539A2 (en) 2002-09-26 2004-04-08 3M Innovative Properties Company 1h-imidazo dimers
JP2006512313A (ja) 2002-10-31 2006-04-13 アムジェン インコーポレイテッド 抗炎症剤
US20040166137A1 (en) 2002-11-08 2004-08-26 Lackey John William Hetero-substituted benzimidazole compounds and antiviral uses thereof
AU2003287316A1 (en) 2002-12-11 2004-06-30 3M Innovative Properties Company Assays relating to toll-like receptor activity
AU2003287324A1 (en) 2002-12-11 2004-06-30 3M Innovative Properties Company Gene expression systems and recombinant cell lines
CA2510375A1 (en) 2002-12-20 2004-07-15 3M Innovative Properties Company Aryl / hetaryl substituted imidazoquinolines
EP2572715A1 (en) 2002-12-30 2013-03-27 3M Innovative Properties Company Immunostimulatory Combinations
US7375180B2 (en) 2003-02-13 2008-05-20 3M Innovative Properties Company Methods and compositions related to IRM compounds and Toll-like receptor 8
US7485432B2 (en) 2003-02-27 2009-02-03 3M Innovative Properties Company Selective modulation of TLR-mediated biological activity
US8110582B2 (en) 2003-03-04 2012-02-07 3M Innovative Properties Company Prophylactic treatment of UV-induced epidermal neoplasia
BRPI0408125A (pt) 2003-03-07 2006-03-01 3M Innovative Properties Co 1-amino 1h-imidazoquinolinas
US7163947B2 (en) 2003-03-07 2007-01-16 3M Innovative Properties Company 1-Amino 1H-imidazoquinolines
KR20050109562A (ko) 2003-03-13 2005-11-21 쓰리엠 이노베이티브 프로퍼티즈 컴파니 피부의 질을 개선시키는 방법
CA2518445A1 (en) 2003-03-13 2004-09-23 3M Innovative Properties Company Method of tattoo removal
EP1608282A4 (en) 2003-03-13 2010-12-08 3M Innovative Properties Co METHODS OF DIAGNOSING SKIN LESIONS
US20040192585A1 (en) 2003-03-25 2004-09-30 3M Innovative Properties Company Treatment for basal cell carcinoma
US20040191833A1 (en) 2003-03-25 2004-09-30 3M Innovative Properties Company Selective activation of cellular activities mediated through a common toll-like receptor
EP1608369B1 (en) 2003-03-28 2013-06-26 Novartis Vaccines and Diagnostics, Inc. Use of organic compounds for immunopotentiation
US20040265351A1 (en) 2003-04-10 2004-12-30 Miller Richard L. Methods and compositions for enhancing immune response
JP2006522823A (ja) 2003-04-10 2006-10-05 スリーエム イノベイティブ プロパティズ カンパニー 免疫反応調節物質化合物の送達
EP1617845A4 (en) 2003-04-28 2006-09-20 3M Innovative Properties Co COMPOSITIONS AND METHODS FOR INDUCING OPOID RECEPTORS
WO2004110992A2 (en) 2003-06-06 2004-12-23 3M Innovative Properties Company Process for imidazo[4,5-c] pyridin-4-amines
WO2004110991A2 (en) 2003-06-06 2004-12-23 3M Innovative Properties Company PROCESS FOR IMIDAZO[4,5-c]PYRIDIN-4-AMINES
EP1635846A4 (en) 2003-06-20 2009-01-28 Coley Pharm Gmbh SMALL MOLECULAR TLR (TOLL-LIKE RECEPTOR) ANTAGONISTS
MY157827A (en) 2003-06-27 2016-07-29 3M Innovative Properties Co Sulfonamide substituted imidazoquinolines
US20050106300A1 (en) 2003-06-30 2005-05-19 Purdue Research Foundation Method for producing a material having an increased solubility in alcohol
US8221771B2 (en) 2003-08-05 2012-07-17 3M Innovative Properties Company Formulations containing an immune response modifier
BRPI0413558A (pt) 2003-08-12 2006-10-17 3M Innovative Properties Co compostos contendo imidazo substituìdo por hidroxilamina
EP1660122A4 (en) 2003-08-25 2007-10-24 3M Innovative Properties Co IMMUNOSTIMULATORY COMBINATIONS AND TREATMENTS
RU2006105101A (ru) 2003-08-27 2007-10-10 3М Инновейтив Пропертиз Компани (US) Арилокси и арилалкиленокси замещенные имидазохинолины
CA2537763A1 (en) 2003-09-05 2005-03-17 3M Innovative Properties Company Treatment for cd5+ b cell lymphoma
JP2007504232A (ja) 2003-09-05 2007-03-01 アナディス ファーマシューティカルズ インク Ｃ型肝炎ウイルス感染治療用のｔｌｒ７リガンド及びそのプロドラッグの投与
GB0321615D0 (en) 2003-09-15 2003-10-15 Glaxo Group Ltd Improvements in vaccination
EP1664342A4 (en) 2003-09-17 2007-12-26 3M Innovative Properties Co SELECTIVE MODULATION OF TLR GENE EXPRESSION
US7687628B2 (en) 2003-10-01 2010-03-30 Taro Pharmaceuticals U.S.A., Inc. Method of preparing 4-amino-1H-imidazo(4,5-c)quinolines and acid addition salts thereof
JP5043435B2 (ja) 2003-10-03 2012-10-10 スリーエム イノベイティブ プロパティズ カンパニー アルコキシ置換イミダゾキノリン
US7544697B2 (en) 2003-10-03 2009-06-09 Coley Pharmaceutical Group, Inc. Pyrazolopyridines and analogs thereof
US20090075980A1 (en) 2003-10-03 2009-03-19 Coley Pharmaceutical Group, Inc. Pyrazolopyridines and Analogs Thereof
US20050096259A1 (en) 2003-10-31 2005-05-05 3M Innovative Properties Company Neutrophil activation by immune response modifier compounds
US20050239733A1 (en) 2003-10-31 2005-10-27 Coley Pharmaceutical Gmbh Sequence requirements for inhibitory oligonucleotides
ITMI20032121A1 (it) 2003-11-04 2005-05-05 Dinamite Dipharma Spa In Forma Abbr Eviata Dipharm Procedimento per la preparazione di imiquimod e suoi intermedi
JP2007511527A (ja) 2003-11-14 2007-05-10 スリーエム イノベイティブ プロパティズ カンパニー オキシム置換イミダゾ環化合物
CU23404A1 (es) 2003-11-19 2009-08-04 Ct Ingenieria Genetica Biotech Polisacáridos capsulares de neisseria meningitidis como inmunopotenciadores mucosales y formulaciones resultantes
NZ547467A (en) 2003-11-25 2010-06-25 3M Innovative Properties Co Substituted imidazo ring system and methods
US8778963B2 (en) 2003-11-25 2014-07-15 3M Innovative Properties Company Hydroxylamine and oxime substituted imidazoquinolines, imidazopyridines, and imidazonaphthyridines
US20050226878A1 (en) 2003-12-02 2005-10-13 3M Innovative Properties Company Therapeutic combinations and methods including IRM compounds
EP1689361A4 (en) 2003-12-02 2009-06-17 3M Innovative Properties Co THERAPEUTIC COMBINATIONS AND PROCESSES WITH IRM COMPOUNDS
AR048289A1 (es) 2003-12-04 2006-04-19 3M Innovative Properties Co Eteres de anillos imidazo sulfona sustituidos.
WO2005066172A1 (en) 2003-12-29 2005-07-21 3M Innovative Properties Company Piperazine, [1,4]diazepane, [1,4]diazocane, and [1,5]diazocane fused imidazo ring compounds
WO2005066170A1 (en) 2003-12-29 2005-07-21 3M Innovative Properties Company Arylalkenyl and arylalkynyl substituted imidazoquinolines
JP2007517044A (ja) 2003-12-30 2007-06-28 スリーエム イノベイティブ プロパティズ カンパニー イミダゾキノリニル、イミダゾピリジニル、およびイミダゾナフチリジニルスルホンアミド
EP1699398A4 (en) 2003-12-30 2007-10-17 3M Innovative Properties Co IMPROVING THE IMMUNE RESPONSE
US20050158325A1 (en) 2003-12-30 2005-07-21 3M Innovative Properties Company Immunomodulatory combinations
TW200612932A (en) 2004-03-24 2006-05-01 3M Innovative Properties Co Amide substituted imidazopyridines, imidazoquinolines, and imidazonaphthyridines
WO2005110013A2 (en) 2004-04-09 2005-11-24 3M Innovative Properties Company Methods, compositions, and preparations for delivery of immune response modifiers
US20050267145A1 (en) 2004-05-28 2005-12-01 Merrill Bryon A Treatment for lung cancer
WO2005123079A2 (en) 2004-06-14 2005-12-29 3M Innovative Properties Company Urea substituted imidazopyridines, imidazoquinolines, and imidazonaphthyridines
WO2005123080A2 (en) 2004-06-15 2005-12-29 3M Innovative Properties Company Nitrogen-containing heterocyclyl substituted imidazoquinolines and imidazonaphthyridines
WO2006009832A1 (en) 2004-06-18 2006-01-26 3M Innovative Properties Company Substituted imidazo ring systems and methods
WO2006038923A2 (en) 2004-06-18 2006-04-13 3M Innovative Properties Company Aryl substituted imidazonaphthyridines
WO2006093514A2 (en) 2004-06-18 2006-09-08 3M Innovative Properties Company Aryl and arylalkylenyl substituted thiazoloquinolines and thiazolonaphthyridines
WO2006065280A2 (en) 2004-06-18 2006-06-22 3M Innovative Properties Company Isoxazole, dihydroisoxazole, and oxadiazole substituted imidazo ring compounds and methods
WO2006009826A1 (en) 2004-06-18 2006-01-26 3M Innovative Properties Company Aryloxy and arylalkyleneoxy substituted thiazoloquinolines and thiazolonaphthyridines
WO2006026760A2 (en) 2004-09-02 2006-03-09 3M Innovative Properties Company 1-amino imidazo-containing compounds and methods
EP1819364A4 (en) 2004-12-08 2010-12-29 3M Innovative Properties Co COMPOSITIONS, IMMUNOMODULATORY COMBINATIONS AND ASSOCIATED METHODS
EP1819226A4 (en) 2004-12-08 2010-12-29 3M Innovative Properties Co COMBINATIONS AND METHODS OF IMMUNOSTIMULATION
CA2592904C (en) 2004-12-30 2015-04-07 3M Innovative Properties Company Chiral fused [1,2]imidazo[4,5-c] ring compounds
US20080207674A1 (en) 2004-12-30 2008-08-28 Coley Pharmaceutical Group, Inc. Immune Response Modifier Formulations And Methods
JP5313502B2 (ja) 2004-12-30 2013-10-09 スリーエム イノベイティブ プロパティズ カンパニー 置換キラル縮合［１，２］イミダゾ［４，５−ｃ］環状化合物
AU2006210392A1 (en) 2005-02-04 2006-08-10 Coley Pharmaceutical Group, Inc. Aqueous gel formulations containing immune response modifiers
EP1846419B1 (en) 2005-02-09 2014-04-16 3M Innovative Properties Company Alkoxy-substituted thiazoloquinolines and thiazolonaphthyridines
AU2006338521A1 (en) 2005-02-09 2007-10-11 Coley Pharmaceutical Group, Inc. Oxime and hydroxylamine substituted thiazolo(4,5-c) ring compounds and methods
WO2006091394A2 (en) 2005-02-11 2006-08-31 Coley Pharmaceutical Group, Inc. Substituted imidazoquinolines and imidazonaphthyridines
US7968563B2 (en) 2005-02-11 2011-06-28 3M Innovative Properties Company Oxime and hydroxylamine substituted imidazo[4,5-c] ring compounds and methods
CA2597595A1 (en) 2005-02-11 2006-08-17 Coley Pharmaceutical Group, Inc. Substituted fused [1,2]imidazo[4,5-c] ring compounds and methods
AU2006216799A1 (en) 2005-02-23 2006-08-31 Coley Pharmaceutical Group, Inc. Hydroxyalkyl substituted imidazonaphthyridines
CA2598695A1 (en) 2005-02-23 2006-09-21 Coley Pharmaceutical Group, Inc. Hydroxyalkyl substituted imidazoquinolines
JP2008531567A (ja) 2005-02-23 2008-08-14 コーリー ファーマシューティカル グループ，インコーポレイテッド ヒドロキシアルキル置換イミダゾキノリン化合物および方法
WO2006091647A2 (en) 2005-02-23 2006-08-31 Coley Pharmaceutical Group, Inc. Method of preferentially inducing the biosynthesis of interferon
EP1863770A4 (en) 2005-04-01 2010-05-05 Coley Pharm Group Inc RING CLOSURE AND CORRESPONDING METHODS AND INTERMEDIATE PRODUCTS
WO2006107771A2 (en) 2005-04-01 2006-10-12 Coley Pharmaceutical Group, Inc. PYRAZOLO[3,4-c]QUINOLINES, PYRAZOLO[3,4-c]NAPHTHYRIDINES, ANALOGS THEREOF, AND METHODS
EP1863814A1 (en) 2005-04-01 2007-12-12 Coley Pharmaceutical Group, Inc. 1-substituted pyrazolo (3,4-c) ring compounds as modulators of cytokine biosynthesis for the treatment of viral infections and neoplastic diseases
JP2008535832A (ja) 2005-04-01 2008-09-04 コーリー ファーマシューティカル グループ，インコーポレイテッド ピラゾロピリジン−１，４−ジアミン、およびそのアナログ
GB0510390D0 (en) 2005-05-20 2005-06-29 Novartis Ag Organic compounds
US20100152230A1 (en) 2005-09-02 2010-06-17 Pfizer Inc. Hydroxy substituted 1h-imidazopyridines and methods
BRPI0615788A2 (pt) 2005-09-09 2011-05-24 Coley Pharm Group Inc derivados de amida e carbamato de n-{2-[4-amino (etoximetil)-1h-imidazo [4,5-c] quinolin-1-il]-1,1-dimetiletil} metanossulfonamida, composição farmacêutica destes e seus usos
ZA200803029B (en) 2005-09-09 2009-02-25 Coley Pharm Group Inc Amide and carbamate derivatives of alkyl substituted /V-[4-(4-amino-1H-imidazo[4,5-c] quinolin-1-yl)butyl] methane-sulfonamides and methods
KR20080048551A (ko) 2005-09-23 2008-06-02 콜레이 파마시티컬 그룹, 인코포레이티드 1Ｈ-이미다조[4,5-ｃ]피리딘 및 그의 유사체의 제조법
WO2007056112A2 (en) 2005-11-04 2007-05-18 Coley Pharmaceutical Group, Inc. Hydroxy and alkoxy substituted 1h-imidazoquinolines and methods
WO2007062043A1 (en) 2005-11-23 2007-05-31 Coley Pharmaceutical Group Inc. Method of activating murine toll-like receptor 8
EP1968587A1 (en) 2005-12-16 2008-09-17 Coley Pharmaceutical, Inc. Substituted imidazoquinolines, imidazonaphthyridines, and imidazopyridines, compositions, and methods
WO2007079146A1 (en) 2005-12-28 2007-07-12 Coley Pharmaceutical Group, Inc Treatment for non-hodgkin's lymphoma
WO2007079086A1 (en) 2005-12-28 2007-07-12 Coley Pharmaceutical Group, Inc. Pyrazoloalkyl substituted imidazo ring compounds and methods
WO2007079169A2 (en) 2005-12-28 2007-07-12 Coley Pharmaceutical Group, Inc. Treatment for acute myeloid leukemia
WO2007079202A2 (en) 2005-12-28 2007-07-12 Coley Pharmaceutical Group, Inc. Treatment for acute lymhoblastic leukemia
EP1968582A4 (en) 2005-12-28 2011-02-16 3M Innovative Properties Co TREATMENT OF CUTTAN T CELL LYMPHOMA
WO2007079171A2 (en) 2005-12-28 2007-07-12 Coley Pharmaceutical Group, Inc. Treatment for hodgkin's lymphoma
US20090306388A1 (en) 2006-02-10 2009-12-10 Pfizer Inc. Method for substituted ih-imidazo[4,5-c] pyridines
US8088788B2 (en) 2006-03-15 2012-01-03 3M Innovative Properties Company Substituted fused[1,2] imidazo[4,5-c] ring compounds and methods
WO2007106854A2 (en) 2006-03-15 2007-09-20 Coley Pharmaceutical Group, Inc. Hydroxy and alkoxy substituted 1h-imidazonaphthyridines and methods
WO2007143526A2 (en) 2006-06-05 2007-12-13 Coley Pharmaceutical Group, Inc. Substituted tetrahydroimidazonaphthyridines and methods
US7906506B2 (en) 2006-07-12 2011-03-15 3M Innovative Properties Company Substituted chiral fused [1,2] imidazo [4,5-c] ring compounds and methods
WO2008030511A2 (en) 2006-09-06 2008-03-13 Coley Pharmaceuticial Group, Inc. Substituted 3,4,6,7-tetrahydro-5h, 1,2a,4a,8-tetraazacyclopenta[cd]phenalenes
WO2008036312A1 (en) 2006-09-19 2008-03-27 Coley Pharmaceutical Group, Inc. Fungicidal methods using immune response modifier compounds
WO2008045543A1 (en) 2006-10-13 2008-04-17 Coley Pharmaceutical Group, Inc. Substituted 4h-imidazo [4, 5, 1-ij] [1, 6] naphthyridine-9-amines and their pharmaceutical use

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of EP1682544A4 *

Cited By (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7923429B2 (en) 2003-09-05 2011-04-12 3M Innovative Properties Company Treatment for CD5+ B cell lymphoma
US8871782B2 (en) 2003-10-03 2014-10-28 3M Innovative Properties Company Alkoxy substituted imidazoquinolines
US7879849B2 (en) 2003-10-03 2011-02-01 3M Innovative Properties Company Pyrazolopyridines and analogs thereof
EP1685129A4 (en) * 2003-11-14 2008-10-22 3M Innovative Properties Co OXIMSUBSTITUTED IMIDAZORING CONNECTIONS
US7915281B2 (en) 2004-06-18 2011-03-29 3M Innovative Properties Company Isoxazole, dihydroisoxazole, and oxadiazole substituted imidazo ring compounds and method
US8034938B2 (en) 2004-12-30 2011-10-11 3M Innovative Properties Company Substituted chiral fused [1,2]imidazo[4,5-c] ring compounds
EP2394650A1 (en) 2004-12-30 2011-12-14 3M Innovative Properties Co. Use of resiquimod for the treatment of cutaneous metastases
US7943609B2 (en) 2004-12-30 2011-05-17 3M Innovative Proprerties Company Chiral fused [1,2]imidazo[4,5-C] ring compounds
US7307083B2 (en) 2005-01-27 2007-12-11 Alma Mater Studiorum-Universita'di Bologna Tetrahydro-acridine and dithiolane derivatives
WO2006080043A3 (en) * 2005-01-27 2006-09-08 Univ Bologna Alma Mater Organic compounds useful for the treatment of alzheimer's disease, their use and method of preparation
US10071156B2 (en) 2005-02-04 2018-09-11 3M Innovative Properties Company Aqueous gel formulations containing immune response modifiers
US9248127B2 (en) 2005-02-04 2016-02-02 3M Innovative Properties Company Aqueous gel formulations containing immune response modifiers
US7968563B2 (en) 2005-02-11 2011-06-28 3M Innovative Properties Company Oxime and hydroxylamine substituted imidazo[4,5-c] ring compounds and methods
WO2006086634A3 (en) * 2005-02-11 2007-08-09 3M Innovative Properties Co Oxime and hydroxylamine substituted imidazo[4,5-c] ring compounds and methods
US7943610B2 (en) 2005-04-01 2011-05-17 3M Innovative Properties Company Pyrazolopyridine-1,4-diamines and analogs thereof
US7943636B2 (en) 2005-04-01 2011-05-17 3M Innovative Properties Company 1-substituted pyrazolo (3,4-C) ring compounds as modulators of cytokine biosynthesis for the treatment of viral infections and neoplastic diseases
US8951528B2 (en) 2006-02-22 2015-02-10 3M Innovative Properties Company Immune response modifier conjugates
EP3085373A1 (en) 2006-02-22 2016-10-26 3M Innovative Properties Company Immune response modifier conjugates
US9487498B2 (en) 2006-03-17 2016-11-08 The Johns Hopkins University N-hydroxylsulfonamide derivatives as new physiologically useful nitroxyl donors
US10829445B2 (en) 2006-03-17 2020-11-10 Cardioxyl Pharmaceuticals, Inc. N-hydroxylsulfonamide derivatives as new physiologically useful nitroxyl donors
US9221780B2 (en) 2006-03-17 2015-12-29 The Johns Hopkins University N-hydroxylsulfonamide derivatives as new physiologically useful nitroxyl donors
US11306056B2 (en) 2006-03-17 2022-04-19 Cardioxyl Pharmaceuticals, Inc. N-hydroxylsulfonamide derivatives as new physiologically useful nitroxyl donors
US10179765B2 (en) 2006-03-17 2019-01-15 Cardioxyl Pharmaceuticals, Inc. N-hydroxylsulfonamide derivatives as new physiologically useful nitroxyl donors
CN103435524A (zh) * 2006-03-17 2013-12-11 约翰斯·霍普金斯大学医学院 作为有生理学价值的硝酰氧基供体的n-羟基磺酰胺衍生物
US9969684B2 (en) 2006-03-17 2018-05-15 Cardioxyl Pharmaceuticals, Inc. N-hydroxylsulfonamide derivatives as new physiologically useful nitroxyl donors
US9725410B2 (en) 2006-03-17 2017-08-08 The Johns Hopkins University N-hydroxylsulfonamide derivatives as new physiologically useful nitroxyl donors
US10487049B2 (en) 2006-03-17 2019-11-26 Cardioxyl Pharmaceuticals, Inc. N-hydroxylsulfonamide derivatives as new physiologically useful nitroxyl donors
US7906506B2 (en) 2006-07-12 2011-03-15 3M Innovative Properties Company Substituted chiral fused [1,2] imidazo [4,5-c] ring compounds and methods
US10144735B2 (en) 2006-12-22 2018-12-04 3M Innovative Properties Company Immune response modifier compositions and methods
EA023556B1 (ru) * 2008-03-24 2016-06-30 4ЭсЦэ АГ 1,2-дизамещенные-4-аминоимидазохинолины
US9908880B2 (en) 2008-03-24 2018-03-06 4Sc Ag Substituted imidazoquinolines
US9073913B2 (en) 2008-03-24 2015-07-07 4Sc Ag Substituted imidazoquinolines
WO2009118296A3 (en) * 2008-03-24 2009-12-03 4Sc Ag Novel substituted imidazoquinolines
US9446040B2 (en) 2008-03-24 2016-09-20 4Sc Ag Substituted imidazoquinolines
EP3153180A1 (en) 2011-06-03 2017-04-12 3M Innovative Properties Company Heterobifunctional linkers with polyethylene glycol segments and immune response modifier conjugates made therefrom
WO2014107663A2 (en) 2013-01-07 2014-07-10 The Trustees Of The University Of Pennsylvania Compositions and methods for treating cutaneous t cell lymphoma
EP3756669A1 (en) 2013-01-07 2020-12-30 The Trustees of the University of Pennsylvania Compositions for use for treating cutaneous t cell lymphoma
US10849984B2 (en) 2013-12-02 2020-12-01 Altimmune Uk Limited Immunogenic compound
US10434183B2 (en) 2013-12-02 2019-10-08 Altimmune UK Ltd. Immunogenic compound
US9962453B2 (en) 2013-12-02 2018-05-08 Altimmune Uk Limited Immunogenic compound
US9932303B2 (en) 2014-01-17 2018-04-03 Cardioxyl Pharmaceuticals, Inc. N-hydroxymethanesulfonamide nitroxyl donors
WO2019166946A1 (en) 2018-02-28 2019-09-06 Pfizer Inc. Il-15 variants and uses thereof
WO2019224716A2 (en) 2018-05-23 2019-11-28 Pfizer Inc. Antibodies specific for gucy2c and uses thereof
WO2019224715A1 (en) 2018-05-23 2019-11-28 Pfizer Inc. Antibodies specific for cd3 and uses thereof
US11434292B2 (en) 2018-05-23 2022-09-06 Pfizer Inc. Antibodies specific for CD3 and uses thereof
EP4414034A2 (en) 2018-05-23 2024-08-14 Pfizer Inc. Antibodies specific for cd3 and uses thereof
WO2020128893A1 (en) 2018-12-21 2020-06-25 Pfizer Inc. Combination treatments of cancer comprising a tlr agonist
WO2021124073A1 (en) 2019-12-17 2021-06-24 Pfizer Inc. Antibodies specific for cd47, pd-l1, and uses thereof
WO2022013775A1 (en) 2020-07-17 2022-01-20 Pfizer Inc. Therapeutic antibodies and their uses
WO2025104289A1 (en) 2023-11-17 2025-05-22 Medincell S.A. Antineoplastic combinations

Also Published As

Publication number Publication date
WO2005048945A3 (en) 2006-03-23
CN1906192A (zh) 2007-01-31
US8598192B2 (en) 2013-12-03
EP1682544A2 (en) 2006-07-26
JP2007511535A (ja) 2007-05-10
AU2004291122A1 (en) 2005-06-02
CA2545825A1 (en) 2005-06-02
US20090105295A1 (en) 2009-04-23
EP1682544A4 (en) 2009-05-06

Similar Documents

Publication Publication Date Title
US8598192B2 (en) Hydroxylamine substituted imidazoquinolines
US7897767B2 (en) Oxime substituted imidazoquinolines
US8735421B2 (en) Imidazoquinolinyl sulfonamides
US8802853B2 (en) Arylalkenyl and arylalkynyl substituted imidazoquinolines
US7939526B2 (en) Sulfone substituted imidazo ring ethers
US8778963B2 (en) Hydroxylamine and oxime substituted imidazoquinolines, imidazopyridines, and imidazonaphthyridines
US20090270443A1 (en) 1-amino imidazo-containing compounds and methods
MXPA06001669A (es) Compuestos que contienen imidazo-oxima sustituidos.
EP1699792A1 (en) Piperazine, 1,4¨diazepane, 1,4¨diazocane, and 1,5¨diazocane fused imidazo ring compounds
EP1687307A2 (en) Substituted imidazo ring systems and methods
US9550773B2 (en) Substituted imidazoquinolines, imidazopyridines, and imidazonaphthyridines

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 10595790

Country of ref document: US

WWE Wipo information: entry into national phase

Ref document number: 2006539957

Country of ref document: JP

Ref document number: 2545825

Country of ref document: CA

Ref document number: 1680/CHENP/2006

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 2004291122

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2004810969

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2004291122

Country of ref document: AU

Date of ref document: 20041112

Kind code of ref document: A

WWP Wipo information: published in national office

Ref document number: 2004291122

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 200480040435.3

Country of ref document: CN

WWP Wipo information: published in national office

Ref document number: 2004810969

Country of ref document: EP